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Abstract 
Saturated ether rings of various sizes are part of the structure of a variety of natural substances, 
as well as of non-natural substances characterized by important biological properties. In particular, 
2,5-disubstituted tetrahydrofurans are structural fragments commonly found in natural substances 
such as polyether antibiotics, e.g. monensin A,
1
 squalene-derived metabolites such as glabrescol,
2
 
and annonaceous acetogenins such as goniocin and mucocin,
 3
 just to mention some representative 
categories. Interest toward isolation, synthesis and structural modification of the basic backbone of 
these substances is still very keen as witnessed by the numerous researches devoted to these targets. 
Indeed, a variety of methods have been developed to produce or modify the oxacycle portions of 
these molecules, in order to obtain substances belonging to the above mentioned classes, but also to 
synthesize new analogues of these molecules to be used in biological assay or in structure activity 
relationship (SAR) studies. In the past years the laboratory where this PhD thesis has been carried 
out has focused on the synthesis of new THF-containing compounds using transition metal oxo-
species such as RuO4, PCC, MeReO3 and OsO4. In this regard this PhD thesis focuses on the 
development of new oxidative processes mediated by transition metal oxo-species. In particular, 
new types of useful oxidative transformations involving the THF ring have been disclosed. 
In the first year of my PhD programme four novel C30 polyether bis-spiroketals, displaying 
selective cell killing effect on BT474 breast-derived cancer cell line, have been obtained from 
squalene through an unprecedented one-step, RuO4-catalysed, cascade process characterised by a 
tandem oxidative pentacyclization/double oxidative spiroketalization sequence.
4
 Preliminary studies 
indicate that the Ru-mediated spiroketalization steps proceed with retention of configuration at the 
forming spirocentres. A similarity with the oxidative behaviour of PCC has also been disclosed.
5
 
Moreover a novel bis-iodurated polyether compound, based on an unprecedented tetra-THF 
backbone, has been isolated as a trace by-product of the oxidation of squalene.
6
 The double erythro 
configuration of the central portion of the molecule furnishes the first indirect support of the 
previously postulated pathway operating in the oxidative pentacyclization of the isoprenoid 
substrate.
7
 A bidirectional double oxidative bis-cyclization is invoked to explain the formation of 
this compound. The isolated substance was also successfully subjected to a double rearrangement-
ring expansion to give a novel bis-THF-bis-THP compound. 
As part of our efforts toward the understanding of the oxidizing behavior of transition metal oxo-
species, in the second year of my PhD programme PCC and the catalytic system PCC(cat.)/H5IO6 
Abstract 
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have been employed to oxidize mono- and poly-tetrahydrofuran compounds.
8
 Novel oxidative 
pathways have been disclosed. 2,2,5-trisubstituted THF rings lead to dicarbonyl compounds via 
oxidative cleavage of the C2-C3 bond. Cyclic enolethers appear to be intermediate species in this 
process. Oxidation of 2,2,5-trisubstituted -keto-THF compounds proceeds with the oxidative 
cleavage of the C2(THF)-C=O bond to give 1,4-diketones possessing a degraded carbon backbone. 
Attack of the oxidant to 2,5-disubstituted THF rings leads to 1,4-diketones possessing the intact 
THF carbon framework. Oxidation of complex poly-THF substrates, embodying up to five THF 
rings, allows the access to novel poly-THF compounds via diastereoselective THF oxidation along 
the poly-THF backbone. The collected results provide a deeper comprehension of the reactivity of 
the PCC and also suggest a new mechanistic hypothesis of the PCC-mediated oxidative cleavage of 
-hydroxy-THF compounds to -lactones. The proposed mechanism well agrees with that reported 
for the oxidative cleavage of 8-hydroxy-neoisocedranol oxide by RuO4 
9 
and is in line with the 
similar oxidizing behaviour shown by these two oxo-species. The synthesis of racemic 
umbelactone,
10
 an antiviral natural butenolide metabolite, has also been carried out by using the 
developed chemistry. 
8b
 
On the basis of this results, in the third year of my PhD programme, the first general synthesis of 
bis--acyloxy 1,4- and 1,5-diketones has been accomplished by CCP catalytic oxidative opening of 
bis acylated THF and THP diols, in turn synthesized by osmium- or ruthenium-catalyzed oxidative 
cyclization of 1,5- and 1,6-dienes.
11
 The overall sequence corresponds to the regioselective double 
ketoacyloxylation of the starting diene. To test the breadth of our methodology acylated cis-
reticulatacin,
12
 a representative mono-THF Annonaceous acetogenin,
13
 has also been successfully 
oxidized with our procedure, thus opening the way to the preparation of new non-THF analogues of 
these active substances, to be used in biological assays. Moreover, among the conceivable synthetic 
uses the bis--acyloxy-1,5-dicarbonyl compounds obtained have been transformed into pyridine-
based oxido pincer ligands or pyrazine dimethanol substances, leading to the discovery of 
unprecedented aromatization routes. 
In the frame of a project joined in collaboration with the group of prof. L. Mayol from the 
“Dipartimento di Chimica delle Sostanze Naturali”, oxidative processes have been applied to the 
synthesis of new nucleoside analogues possessing different base modifications. The first general 
approach that allows either the synthesis of ring-expanded nucleosides (RENs), containing the 
unprecedented bis-alkylated imidazo[4,5-d][1,2, 6]oxadiazepine heterocyclic ring system,
14
 or the 
2,6-dialkyl(aril)purine moiety has been developed. This method entails first of all the formation of a 
purine N1-oxide by treatment of the purine nucleoside with MeReO3 followed by addition of a 
Abstract 
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Grignard reagent to the electrophilic C-6 carbon of the substrate.
15
 The reactivity of the C-6-
substituted purine nucleosides towards a second Grignard reagent afforded new 4,5-disubstituted 
imidazo-nucleosides from which we obtained imidazo[4,5-d][1,2,6]oxadiazepine nucleosides, if 
treated with t-BuOOH, or 2,6-disubstituted purine nucleosides by treatment with Ac2O in pyridine. 
Using this procedure a small collection of ring-expanded nucleosides (RENs) has been synthesized 
and subjected to preliminary cytotoxicity tests on breast (MCF-7) and lung (A549) cancer cell lines. 
We are also synthesizing a collection of 2,6-disubstituted purine nucleosides to be subjected to 
biological assay. 
Eventually, some preliminary experiments have been done to develop RuO4 conditions for the 
synthesis of bis--acyloxy 1,4-diketones, in order to extend the procedure to acid- or PCC- 
sensitive molecules. As part of our efforts working toward the synthesis of poly-THF compounds 
some experiments have been carried out to assess the osmium ability to mediate the bis-cyclization 
of polyenes with a repetitive 1,5-diene structural motif. These finding deserve further studies. 
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Riassunto 
Eteri ciclici di varie dimensioni fanno parte della struttura di numerose sostanze naturali sia di 
origine terrestre che marina, come anche di sostanze non naturali. Uno o più anelli tetraidrofuranici 
(THF) 2,5-disostituiti ed anelli tetraidropiranici sono comunemente presenti in molecole naturali 
dotate di importanti attività biologiche. Fra queste sono da ricordare gli antibiotici polieterei come 
la monensina A
1
, alcuni metaboliti derivanti dallo squalene, come il glabrescolo
2
, e le acetogenine 
da Annonaceae come la goniocina e la mucocina
3
 (Figura 1). 
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Figura 1. Alcuni esempi di molecole naturali contenenti anelli THF e THP. 
Negli ultimi anni numerosi gruppi di ricerca, impegnati nella sintesi totale di molecole naturali, 
hanno indirizzato i loro sforzi verso la messa a punto di metodi stereoselettivi per la costruzione 
della porzione ossaciclica di tali tipi di sostanze e di loro analoghi non naturali. 
Accanto a metodi classici è stato sviluppato, soprattutto nell’ultimo decennio, un approccio 
totalmente diverso che coinvolge la reazione di osso-specie di metalli di transizione come RuO4, 
OsO4, MnO4
-
 e RuO4
-
 con 1,5- 1,6- e 1,7-dieni o di alcoli bis-omoallilici con ossidi del renio (VII) 
(Schema 1 e Schema 2).
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Schema 1. Monociclizzazione ossidativa di dieni mediata da osso-specie di metalli di transizione.
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OH O HH OH
Re2O7 o 
CF3CO2ReO3
trans-THF alcoolAlcool bis-omoallilico  
Schema 2. Ciclizzazione ossidativa di alcoli bis-omoallilici mediata da renio (VII). 
Il laboratorio di ricerca presso il quale è stato condotto questo lavoro di tesi, nell’ambito di studi 
su polieni isoprenoidici e lineari, caratterizzati da un’unità 1,5-dienica ripetuta, come il farnesil 
acetato, il geranilgeranil acetato e lo squalene, ha messo a punto un processo di policiclizzazione 
ossidativa a cascata, catalizzato dal tetrossido di rutenio,
17
 che consente la sintesi in un unico step di 
prodotti poli-tetraidrofuranici complessi, del tipo mostrato nello Schema 3. La potenzialità del 
metodo è stata inoltre saggiata nella sintesi del “core” bis-THF diolico di due acetogenine da 
Annonaceae molto attive: la rollimembrina e la rollinastatina-1.
17
 
 
OOOOOOH OHH H H H H H
Squalene
cis cis transtrans trans
RuO4(cat.)/NaIO4
 
Schema 3. Policiclizzazione ossidativa dello squalene mediata da RuO4. 
Studi recenti condotti dallo stesso gruppo di ricerca, rivolti alla degradazione ossidativa del 
prodotto penta-THF 1 in presenza di piridinio clorocromato (PCC) (schema 4), hanno portato alla 
scoperta di un nuovo processo di spirochetalizzazione ossidativa mediato da PCC
5
 che conduce alla 
formazione di un nuovo tipo di sostanze poli-THF (2 e 3) caratterizzate da una porzione terminale 
spirochetalica mai sintetizzata in precedenza. Studi preliminari hanno mostrato che tali sostanze, ed 
alcuni loro derivati (3 e 4), sintetizzati per degradazione mediata da PCC, posseggono attività 
antitumorale su linee cellulari del cancro delle ovaie (HEY) e del seno (BT474) a concentrazioni 
M. 
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Schema 4. Scissione ossidativa del penta-THF 1 con PCC e degradazione dei prodotti spirochetalici 
ottenuti. 
Nel corso del I anno di dottorato è stato affrontato lo studio della policiclizzazione ossidativa 
dello squalene catalizzata da RuO4 in nuove condizioni sperimentali. L’esigenza di ottenere tale 
sostanza in maggiori quantità per studi sintetici correlati, ci ha spinto ad effettuare il processo su 
quantità più elevate del substrato (50 g). Tali quantità di squalene avrebbero però richiesto un 
volume troppo elevato di solvente per la completa dissoluzione del co-ossidante necessario al 
processo, che è stato pertanto effettuato in condizioni più concentrate. Il nuovo processo ha 
condotto alla formazione, in un unico step, di quattro nuovi prodotti polieterei isomerici (Schema 
5), caratterizzati da porzioni spirochetaliche terminali strutturalmente simili, attraverso una 
complessa sequenza di reazioni di ciclizzazione.
4
 In particolare, si ritiene che inizialmente si 
formino prodotti penta-THF isomerici del tipo 1, i quali sottostanno ad una doppia 
spirochetalizzazione ossidativa, che coinvolge i terminali bis-THF, generando le porzioni 
spirochetaliche terminali.  
La determinazione della struttura dei nuovi prodotti è stata effettuata mediante studi 2D-NMR su 
Riassunto 
 
ix 
 
spettrometri ad alto campo ed infine confermata mediante esperimenti di diffrazione dei raggi X. E’ 
stato, inoltre, dimostrato che gli step di spirochetalizzazione ossidativa avvengono con ritenzione di 
configurazione. Alcuni dei prodotti hanno mostrato attività di inibizione selettiva della crescita di 
cellule derivanti da tumore al seno (BT474) e alle ovaie (HEY). 
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Schema 5. Formazione di quattro nuovi prodotti spirochetalici per ossidazione dello squalene con 
RuO4 nelle nuove condizioni sperimentali. 
Un’accurata analisi HPLC della miscela di reazione dell’ossidazione dello squalene nelle nuove 
condizioni sperimentali ha consentito l’isolamento di un nuovo prodotto tetra-THF bis-iodurato la 
cui stereostruttura è stata determinata mediante diffrazione dei raggi X su cristallo singolo. ottenuto 
per lenta evaporazione da una soluzione di cloroformio.
6
 La doppia configurazione eritro della 
porzione centrale della molecola fornisce supporto indiretto all’ipotesi meccanicistica 
precedentemente postulata per la pentaciclizzazione ossidativa dello squalene.
7
 Tale prodotto è 
stato, inoltre, sottoposto con successo ad un doppio riarrangiamento con espansione d’anello, 
ottenendo un nuovo composto bis-THF-bis-THP (Schema 6). Sebbene tale tipo di reazione fosse 
stata utilizzata nella sintesi di composti a struttura polieterea complessa come la salinomicina, la 
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reazione effettuata rappresenta il primo esempio di una doppia espansione di anello di tale tipo. 
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Schema 6: Prodotto minore poli-THF bis-iodurato dalla policiclizzazione ossidativa dello squalene 
catalizzata da RuO4 e suo doppio riarrangiamento ad un nuovo composto bis-THF-bis-
THP. 
Nel corso del II anno di dottorato di ricerca è stato affrontato lo studio dell’ossidazione di alcuni 
substrati mono- e poli-THF ad opera del sistema catalitico PCC(cat.)/H5IO6 (clorocromatoperiodato, 
CCP)
18 
scoprendo nuove utili trasformazioni ossidative.
8 
In particolare, è stato dimostrato, per la 
prima volta, che il CCP è in grado indurre la scissione ossidativa del legame C2-C3 di anelli THF 
2,2,5-trisostituiti, portando alla formazione di composti dicarbonilici (Schema 7). Si ritiene che 
prodotti enoleterei ciclici siano intermedi di tale processo. La presenza di una funzione chetonica 
adiacente all’anello THF 2,2,5-trisostituito conduce alla formazione di 1,4-dichetoni con scheletro 
carbonioso degradato, attraverso la scissione del legame C(THF)2-C=O. E’ stato inoltre osservato 
che quando l’anello THF è 2,5-disostituito si ottengono 1,4-dichetoni mediante l’apertura ossidativa 
del ciclo con ossidazione di entrambi i carboni angolari. Si ritiene che il primo evento in ciascun 
processo sia costituito dall’attacco del CCP al legame C-H angolare del THF coinvolto. Vi è da 
sottolineare che, fino ad ora, il PCC in forma catalitica è stato utilizzato solo in rari casi.  
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Schema 7: Reattività di anelli THF 2,2,5-trisostituiti e 2,5-disostituiti in presenza di CCP. 
E’ stata quindi ottimizzata la scissione dei mono-THF trisostituiti, scegliendo il composto 10 
come modello. Le migliori rese (80%) sono state ottenute conducendo il processo a t.a. con il 5 % 
mol di  PCC e 4 equiv. di H5IO6. Tali condizioni sono state poi applicate all’ossidazione di altri 
composti mono-THF trisostituiti, opportunamente sintetizzati, ottenendo i corrispondenti prodotti 
dicarbonilici con rese elevate (65-80%, Schema 7).  
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Schema 8: Esempi di ossidazione di substrati tetraidrofuranici 2,2,5-trisostituiti con CCP. 
Il nuovo processo è stato poi utilizzato nella sintesi dell’umbelattone (Schema 9), un prodotto 
naturale a struttura -butenolidica isolato dagli estratti etanolici del Memeycelon umbellatum 
Brum,
10
 che mostra diverse attività biologiche tra cui quella antivirale contro il virus responsabile 
del morbo di Ranikhet. 
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Schema 9 Sintesi dell’umbelattone. 
Nel corso del III anno di dottorato di ricerca è stata studiata la scissione ossidativa di mono-THF 
2,5-disostituiti e mono-THP 2,6-disostituiti ad opera del sistema catalitico PCC(cat.)/H5IO6 
(clorocromatoperiodato, CCP).
11
 Tale processo consente di ottenere bis -acilossi-1,4- ed 1,5-
dichetoni. E’ noto che -acilossi chetoni sono utili “buildings blocks” in sintesi organica. La 
presenza di due funzioni -acilossi-chetoniche nella stessa molecola amplia ulteriormente le 
potenzialità sintetiche di tali sostanze. In particolare, sono stati sintetizzati diversi substrati 
tetraidrofuranici e tetraidropiranici, mediante ciclizzazione ossidativa catalizzata da RuO4 o OsO4 di 
opportuni 1,5- ed 1,6-dieni,
16
 i quali sono stati sottoposti a scissione ossidativa con CCP (Schema 
10). 
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Schema 10. Sintesi di bis -acilossi-1,4- ed 1,5-dichetoni a partire da 1,5- ed 1,6-dieni. 
E’ stato, inoltre, sintetizzato il substrato morfolinico 14, che per reazione con il sistema catalitico 
PCC/H5IO6 ha dato il dichetone atteso 15, sebbene in basse rese (Schema 11). Ciò è probabilmente 
dovuto al carattere di doppio legame della funzione ammidica, che induce la formazione di un 
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intermedio morfolinico insaturo, il quale viene poi scisso dal CCP dando prodotti collaterali. 
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Schema 11. Scissione ossidativa di un derivato morfolinico con CCP. 
E’ stato dimostrato che il gruppo benzoilico, quello acetilico, il tosilato e la funzione ammidica 
resistono alle condizioni di scissione ossidativa dell’anello etereo. Dagli esperimenti effettuati è, 
inoltre, risultato che centri chirali adiacenti alle funzioni carboniliche generate non subiscono 
epimerizzazione. Ciò suggerisce che utilizzando il metodo sviluppato è possibile sintetizzare bis--
acilossi-1,4-dichetoni aciclici chirali.  
Per saggiare la nuova procedura su substrati strutturalmente più complessi è stata utilizzata la 
cis-reticulatacina,
12
 una molecola appartenente alla classe delle acetogenine da Annonaceae,
13
 un 
gruppo di metaboliti aventi un ampio spettro di proprietà biologiche. Tale molecola è stata protetta 
sia come acetato che benzoato (16 e 18, rispettivamente) e sottoposta a scissione ossidativa con 
CCP fornendo i dichetoni attesi (17 e 19, Schema 12). 
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Schema 12. Ossidazione della cis-reticulatacina bis-acilata. 
L’analisi 1H NMR dei prodotti minori di tali reazioni ha mostrato che la funzione lattonica 
insatura terminale è preservata (presenza di segnali caratteristici a circa 5 e 7 ppm) e che pertanto 
anche tale funzione tollera le condizione di reazione. I risultati ottenuti suggeriscono che la 
procedura messa a punto possa essere utilizzata per la scissione di anelli THF in molecole 
complesse per ottenere nuovi analoghi “non-tetraidrofuranici” di molecole biologicamente attive, da 
usare in saggi biologici e studi SAR. 
Dato che gruppi carbonilici -ossigenati sono suscettibili di varie trasformazioni, è stata 
esplorata la possibilità di convertire i composti 1,5-dicarbonilici ottenuti in eterocicli aromatici 
azotati (Schema 13). In particolare, utilizzando NH4OAc/AcOH per il dichetone 20 e le classiche 
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condizioni di Knoevenagel per i composti 23, 25 e 15, seguite da metanolisi dei gruppi protettori, è 
stato possibile ciclizzare gli 1,5-dichetoni sintetizzati ottenendo, rispettivamente, dimetanol-piridine 
(21b e 24b) appartenenti alla famiglia degli “oxido-pincer ligands”, sostanze caratterizzate dalle 
spiccate proprietà chelanti, una piridina N-ossido (26b) ed una dimetanol-pirazina (27). In 
particolare, la conversione di 25 in 26b rappresenta il primo caso di formazione diretta di una 
piridina N-ossido da un 1,5-dichetone, mentre la trasformazione di 15 in 27b potrebbe avere 
interesse non solo da un punto di vista sintetico, ma anche farmacologico, in quanto rappresenta nel 
complesso la conversione di un composto morfolinico in uno pirazinico (conversione di 14 in 27b). 
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Schema 13. Sintesi di piridine e pirazine dimetanoliche da bis –benzoilossi1,5-dichetoni. a) 
NH4OAc (7 eq.), AcOH (6.5 eq.), dry MeOH, 24 h t.a. 48 h 55°C; b) NH2OH·HCl (3.5 
eq.), EtOH anidro, 6 h-15 h, riflusso; c) 10 mol % K2CO3, MeOH, t.a., 30 min; d) 
MCPBA (1.2 eq.), CHCl3, t.a., 90 min. 
Un’ulteriore linea di ricerca ha riguardato lo sviluppo di processi ossidativi per la sintesi di nuovi 
analoghi nucleosidici modificati. Negli ultimi anni, infatti, molti gruppi di ricerca hanno indirizzato 
la loro attenzione alla preparazione di nuovi nucleosidi e nucleotidi modificati, sulla base e/o sullo 
zucchero, con lo scopo di ottenere nuove molecole con potenziali attività antineoplastiche, 
antiipertensive e antivirali. Basi puriniche e nucleosidi recanti un C- o N-sostituente al C-6 
rappresentano un’importante classe di composti che possiedono un ampio spettro di attività 
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biologiche.
14,15
 Di recente, nell’ambito di uno studio in collaborazione con il gruppo di ricerca del 
professor L. Mayol del Dipartimento di Chimica delle Sostanze Naturali della Federico II, è stata 
messa a punto una nuova via sintetica del tutto generale per la preparazione di nucleosidi C-6 C-
sostituiti. In particolare è stata studiata la reattività della porzione nitronica C6-N1-O
-
 della 9-
ribosil-purina (nebularina) N1-ossido nei confronti dei reattivi di Grignard (Schema 14).
15
 L’iniziale 
attacco di questi ultimi sulla posizione più reattiva C-6, fornisce l’addotto N1-idrossi C6-sostituito, 
che poi aromatizza per trattamento con anidride acetica in piridina. Contrariamente a quanto atteso, 
il trattamento dei nucleosidi C-6-sostituiti con MeReO3  non permette di ottenere nucleosidi purinici 
N1-ossido C-6-alchil (aril)-sostituiti 31 con rese soddisfacenti.
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Schema 14. Sintesi di nuovi nucleosidi modificati. 
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L’osservazione che il trattamento dell’addotto 29 con la sola piridina ad elevata temperatura 
porta alla formazione di nucleosidi purinici N1-ossido C-6-alchil (aril)-sostituiti voluti (31), ha 
aperto la strada allo studio di un’ulteriore funzionalizzazione della base purinica, in posizione C-2. 
Su tali basi, in collaborazione con il suddetto gruppo di ricerca, è stata realizzata una collezione di 
nucleosidi purinici C-6-alchil (aril)-sostituiti N1-ossido (31) da funzionalizzare al C-2. In 
particolare, gli studi effettuati hanno mostrato che il secondo attacco del reattivo di Grignard in 
posizione C-2 fornisce l’intermedio aperto 32 che può ciclizzare e aromatizzare fornendo nucleosidi 
2,6-disostituiti se trattato con anidride acetica in piridina, oppure può fornire “ring-expanded 
nucleosides” (RENs), contenenti il nuovo sistema biciclico imidazo[4,5-d][1,2,6]-ossadiazepinico, 
per trattamento con t-BuOOH (10 eq.) in CCl4 a riflusso.
6b
 Con tale procedura sono stati ottenuti 
diversi nucleosidi purinici 2,6-alchil (aril) sostituiti. Inoltre, i RENs sintetizzati hanno mostrato 
interessanti attività antitumorali nei confronti di cellule tumorali del seno (MCF-7) e del polmone 
(A549).
14 
Infine, nel corso dell’ultimo anno di ricerca sono stati condotti studi preliminari riguardo la 
scissione ossidativa di anelli tetraidrofuranici con il sistema catalitico RuO4/NaIO4 ed è stata 
saggiata la bis-ciclizzazione ossidativa mediata dall’OsO4 di substrati trienici tipo farnesil acetato 
(Schema 15). 
OAc
OO
OH
OAc
OHH H
cis cis 
OsO4 (cat.) 
 (E,E)-Farnesil  acetato NaIO4  
Schema 15. Bis-ciclizzazione ossidativa mediata da OsO4.
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Chapter 1 
The use of transition metal oxo-species  
in organic chemistry 
1.1. Introduction 
Oxidation is one of the most fundamental reactions in synthetic organic chemistry and there is 
always demand for selective and mild oxidation methods. Indeed, over the past few years, 
numerous research groups have directed their efforts toward the development of novel and useful 
oxidation processes. In particular significant progress has been achieved within the area of catalytic 
oxidations, which has led to a variety of selective and mild methods. These reactions may be based 
on organocatalysis, metal catalysis or biocatalysis. In this regard transition metal oxo-species are of 
particular interest since they can catalyze a wide spectra of oxidative reactions. This thesis is 
focused on the use of some of these species namely RuO4, PCC, MeReO3 and OsO4, with the aim of 
establishing new general and synthetically useful oxidation methods. 
1.2. RuO4-catalyzed oxidation of organic compounds 
Ruthenium (VIII) tetroxide, RuO4, is a tetrahedral 16-electron d
0
 species, which is isoelectronic 
to the well-known OsO4. It was introduced as an organic oxidant in 1953 by Djerassi,
1
 who 
oxidized several sulfides to sulfoxides and sulfones. Since then it has been used for a long time 
almost for the cleavage of C=C bonds and aromatic compounds leading to its reputation of being a 
reagent too reactive to be selective. RuO4 can be generated on treatment of catalytic amount of 
RuCl3 or RuO2 with a stoichiometric oxidant such as NaIO4, HIO4, NaOCl, or NaBrO3, or under 
electrochemical conditions (Figure 1).
2 
 
RuO
4
RuO
2
substrate (S)
product (SO)oxidant (XO)
(X)
 
Figure 1. RuO4 catalytic cycle.
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At the beginning the reactions were performed in a biphasic system made up of organic solvent 
and water, leading to sluggish suspensions that made reactions very slow and incomplete. These 
problems were due to inactivation of ruthenium catalysts because of the formation of low-valent 
ruthenium carboxylate complexes, which inhibit the catalyst activity by acting as strongly 
coordinating ligands.
3
 This trouble was overcome by Sharpless,
4
 who noticed that the addition of 
CH3CN as a co-solvent led to a more selective and faster oxidation even reducing the amount of 
catalyst. Thus, various oxidations with RuO4 are improved considerably by employing a solvent 
system consisting of CCl4-H2O-CH3CN. However, it was only in 1993, with the study made by the 
research group where this thesis have been carried out, that RuO4 was found to be a powerful and 
selective catalyst for the non-destructive oxidation of olefins.
5
 Indeed, they managed to get syn-
diols through a process similar to the reaction of the isoelectronic and less reactive OsO4 with 
alkenes. Next Shing at al.
6
 reported the dihydroxylation of a wide range of olefines with RuO4 
calling that process “flash dihydroxylation” because of the reduced reaction time. With subsequent 
studies, it was clear that RuO4 was able to give dihydroxylation even on substrates unreactive with 
OsO4 o MnO4
-
. 
The interest towards the oxidation not only of unsaturated substrates but also of a great variety of 
functional groups has grown over the time and now RuO4-mediated oxidations are an indispensable 
and irreplaceable tool for organic chemists (Scheme 1), as reported in a recent review.
2
 
Recently the dihydroxylation reaction has been further improved and conditions for -chetols 
have been developed.
7
 Lately our research group was interested in the oxidative cyclization of 1,n-
dienes showing that stereoselective synthesis of 2,5-THF-diols, 2,6-THP-diols, 2,7-oxepan-diols 
from 1,5-dienes, 1,6-dienes e 1,7-dienes, respectively, is possible.
8
 
Moreover the same group has also discovered the stereoselective oxidative polycyclization of 
polyenes characterized by a repetitive 1,5-diene structural motif.
8a
 This process allows access to 
adjacently linked polytetrahydrofuran products in a single step using catalytic amounts of RuO4 in 
the presence of NaIO4 as co-oxidant. Among the reported experiments, the pentacyclization of 
squalene is noteworthy, not only because it generates five THF rings in a single step with a 
remarkable yield of 40-50%, but also because ten new chiral centers are formed and the product is 
obtained as a single diastereoisomer (Scheme 2).
8a, b
 This process is useful in organic synthesis, 
since it can be used for the preparation of the THF portions of numerous natural and non-natural 
biological active substances, such as polyether antibiotics,
9
 squalene-derived metabolites
10
 and 
annonaceous acetogenins,
11
 containing one or more 2,5-disubstituted THF rings adjacently linked. 
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The ruthenium-mediated oxidative polycyclization process seems to be closely related to the 
oxidative polycyclization of polyenic bis-homoallylic alchohols carried out with rhenium(VII) oxo-
species that allows the formation of either bis- or tris-tetrahydrofuran compounds.
12 
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Scheme 1. RuO4 mediated transformations’overview. 
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RuO4(cat.)/NaIO4
1  
Scheme 2. RuO4 mediated pentacyclization of squalene. 
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In this thesis we have further explored the potential applications of RuO4 in the organic 
synthesis. In particular we have reinvestigated the pentacyclization reaction of squalene in new 
conditions, discovering new and unexpected results (see Chapter 4). Some preliminary experiments 
have been also carried out to find alternative conditions for the oxidation of 2,5-substitued THF 
ring, a PCC oxidative process developed during my PhD (see Chapters 3 and 6).  
1.3. From Pyridinium Chlorochromate (PCC) to Chlorochromatoperiodate (CCP) 
Pyridinium chlorochromate (PCC, also known as Corey's reagent) is a well known reagent 
employed in an array of oxidising processes.
13
 It is a red-orange solid salt with the formula 
C5H5NH[CrO3Cl].
 
PCC was synthesized for the first time in 1899 by Meyer,
14
 but only after the studies of Corey
15
 
and co-workers in 1975 organic chemists began to use it for the oxidation of primary and secondary 
alchools to aldehyde and chetones.  
For many years, researchers have worked to find a mild, versatile and selective reagent for the 
operationally simple oxidation of alcohols to carbonyl compounds. Many reagents containing the 
chromium (VI) ion have been studied, but a large portion of them may not be used in modern 
organic synthesis due to difficulties in their use, toxicity or because too poorly selective.
13 
PCC have almost replaced the Jones and Collins reagents in the oxidation of alcohols. Indeed, 
when compared with the Jones reagent, which is a solution of chromium trioxide in diluted sulfuric 
acid, PCC is milder, less acidic and does not promote the over-oxidation of obtained aldehydes to 
carboxylic acids. Both the Collins reagent, which is a chromium trioxide/pyridine complex, and 
PCC are able to stop primary alcohols oxidation at aldehyde level, but PCC is easier and safer to 
prepare (Collins reagent can inflame during preparation), self-stable, and more efficient, since up to 
a sixfold excess of Collins reagent may be required to effect a complete reaction.
16
 
PCC can be prepared easly and safely by addition of chromium trioxide to 6 N hydrochloric acid, 
then pyridine is added at 0 °C to the unstable chlorochromic acid formed and immediately PCC 
precipitates as a red-orange solid which is not appreciable hygroscopic.
 13
 
An improved procedure for PCC preparation has been described by Agarwal in 1990.
17 
In the 
same paper is reported that synthetic utility of the reagent increases in the presence of anhydrous 
acetic acid, used for the first time as catalyst, for the oxidation of alcohols.  
Though the most popular process mediated by PCC is the oxidation of primary and secondary 
alcohols, many other functional groups undergo PCC oxidation. As a continuation of the interest in 
oxidative processes mediated by transition metal oxo-species as well as in the synthesis and 
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derivatization of new THF-containing compounds,
8 
the research group where this thesis have been 
carried out recently focused on oxidation processes mediated by PCC.
18
 These studies led to the 
discovery of a new interesting oxidative spiroketalization process. In particular, it has been 
reported
18
 that penta-THF 1, obtained by the Ru(VIII)-catalysed oxidative pentacyclization of 
squalene (Scheme 2),
8b-d
 when treated with PCC furnishes four new compounds (2-5) representative 
of a novel class of cytotoxic antitumor poly-THF spiroketals, besides poly-THF -lactones 6-8, the 
main products of the process (Scheme 3). 
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Scheme 3. Spiroketal and degradation products obtained by PCC-mediated oxidation of a 
penta-THF compound 
Inspection of the structure of these substances reveals that compound 1 undergoes three types of 
oxidative processes all involving the interaction of the oxidant with different THF ether methine 
groups. In particular, lactones 2 and 4, the main oxidation products, are produced by oxidative 
removal of one or both the terminal three-carbon chains of 1. The spiroketal-containing compound 
5, possessing the intact carbon skeleton of 1, originates from an oxidative spiroketalization process 
formally involving the C(2)OH group and the C-7 carbon at the cis-cis bis-THF terminus of the 
poly-THF chain. The terminal lactone in the related spiro-compound 6 in turn arises from the 
further oxidative cleavage of the C22-C23 bond in 5 as it happens when compounds 2-4 are 
generated from 1. Finally, an inter-THF C-C bond cleavage in 5 and/or 6 is responsible of the 
formation of the degraded, minor, spiro-compounds 7 and 8. 
During my PhD programme this process has been further explored leading to the discovery of 
related novel oxidative pathways.  
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PCC is usually used in stoichiometric or in excess amounts to oxidise a variety of functional 
groups. In contrast, the use of PCC in catalytic amounts has received little attention to date,
19,20
 
though chromium(VI) species are known to be carcinogenic and environmentally hazardous and the 
use of substoichiometric amounts of such reagent would therefore be highly desirable. In this 
respect, the catalytic system PCC (cat.)/H5IO6 is particularly appealing. From previous studies
21
 it is 
thought that the combination of PCC and H5IO6 generates chlorochromatoperiodate (CCP, Scheme 
4), an oxidising agent more powerful than PCC itself. 
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Scheme 4. Chlorochromate periodate (CCP) formation. 
CCP has been employed in only a few cases so far, in particular in 2005 Hunsen described a 
pyridinium chlorochromate catalyzed (2 mol%) oxidation of alcohols to ketones and aldehydes 
using 1.05 equiv of H5IO6 in acetonitrile.
19a
 In 2008, Stark and Roth reported the catalytic cleavage 
of cyclic -hydroxy ethers, which were converted to the corresponding -butyrolactones and -
valerolactones within minutes and isolated in excellent yield.
20 
As a part of our ongoing interest in oxidative processes mediated by PCC a substantial part of 
my thesis work was devoted to the study of new oxidative processes mediated by catalytic amounts 
of PCC, testing the CCP's ability to interact with THF methane bonds and finding new useful 
oxidative transformation involving various THF ring systems (see Chapters 2 and 3).  
1.4. Methyltrioxorhenium, a versatile oxidant in organic synthesis 
Methyltrioxorhenium (MTO for short) is one of the most versatile oxidation catalyst known to 
date and its efficient synthesis and catalytic utility have made it one of the most studied 
organometallic compound. It has been widely studied expecially during the last 30 years as an 
oxygen transfer reagent.
22 
Actually it has been used for the oxidation of a number of functionalized 
compounds, including alkenes, alkynes, arenes, phenols, benzaldehydes, sulfides, anilines, amines, 
phosphines, as well as for insertion into C-H bonds.
 
MTO was synthesized for the first time in 1979 by Beattie and Jones.
23
 Later, in 1991, Herrmann 
developed a more simple synthesis featuring the reaction of dirhenium heptoxide with 
methyltributyltin.
24
 Herrmann was the first to demonstrate the ability of MTO to catalyze the 
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epoxidation of alkenes. In 1993 Espenson et al. began to study MTO from a mechanistic point of 
view so they have fully explained the mechanism of oxygen transfer in the MTO/H2O2 system.
25
 
H2O2 is usually used as the stoichiometric oxidant in reaction with MTO. MTO reacts with H2O2 to 
give equilibria with formation of monoperoxo- and diperoxo-rhenium(VII) species (Scheme 5). 
Both peroxorhenium complexes are able to react with oxygen-accepting substrates. However the 
latter confers a characteristic yellow color to the solution and it is the most reactive.  
 
Re
CH
3
O O
O
Re
CH
3
O
O
O
OH
2O
Re
CH
3
O
O
O
OH
2
O O
H
2
O
2
H
2
O
2
-H
2
O
2
XXOXXO
the most reactive
 
Scheme 5. General mechanism of oxygen transfer from hydrogen peroxide catalyzed by MTO. 
Until the discovery of the MTO/H2O2 system, epoxidation were performed almost exclusively 
using meta-chloroperoxybenzoic acid (m-CPBA). In contrast with the m-CPBA, MTO has many 
advantages: it is safer; it has greater scope and selectivity, as even acid sensitive substrates can be 
oxidized; it is more reactive, requires less solvent and involves easier product work up and 
isolation; water is the only byproduct. Moreover Sharpless and coworkers discovered that the 
addition of at least 3 mol % catalytic amounts of pyridine to the MTO/H2O2 system improves 
olefins epoxidation by increasing the rate, preventing epoxide hydrolysis and extending the catalyst 
lifetime (Scheme 6).
26 
 
OR
1
R2
R3
R4
R1
R2
R3
R4
30% acqueous H2O2 (2 eq)
MTO (0,3 mol %), CH2Cl2,
pyridine (3 mol %) r.t.  
Scheme 6. Alkenes epoxidation catalyzed by the MTO/H2O2 system. 
In 1998 as a continuation of the interest in oxidative processes mediated by transition metal oxo-
species, the research group where this thesis has been carried out tested the reactivity of some 
conjugated diene steroids with MTO, using H2O2 as a co-oxidant.
27 
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Another fundamental reaction catalyzed by MTO is the oxidation of secondary amines. This 
reaction is an important means to obtain nitrones, which are precious substrates in organic synthesis 
for the assembly of structurally complex nitrogen-containing molecules. The oxidation of amines 
can be performed either with MTO/H2O2 system or with urea-hydrogen peroxide complex (UHP) as 
the stoichiometric oxidant in reactions carried out in non-aqueous media.
28 
More recently a convenient method for the selective N-oxidation of purine catalyzed by the 
MTO/H2O2 system.
29
 Inspired by these findings, part of the current PhD project has also been 
devoted to the achievement of a novel approach to the synthesis of nucleoside analogues possessing 
new base modifications. The developed method is based on the formation of a C6-N1-O
- 
aldonitrone moiety of 9-ribosyl-purine (nebularine) N1-oxide in the presence of MTO which is then 
prone to be attacked at the electrophilic C-6 carbon by a Grignard (see Chapter 5). 
1.5. OsO4, a Nobel prize oxidant 
Among osmium compounds, OsO4 is the most important and easy to prepare. As well as 
ruthenium, osmium is octavalent (of all the elements, they are the only two that reach such a high 
oxidation state), but in contrast with the first, it is a more controllable and milder oxidizing agent 
and most of its applications derive from this property.
30 
One of the osmium tetroxide distinguishing feature is that the solid is volatile at room 
temperature. Its vapors are poisonous, but OsO4 carries its own warning system, a characteristic 
rather ozone-like smell, that makes accidents with it rare. However, despite its toxicity, an aqueous 
solutions of osmium tetroxide is used to treat refractory rheumatoid arthritis in humans by local 
administration.
31
 Overall OsO4 should be regarded as no more dangerous than many reagents daily 
used in laboratories. Osmium tetroxide is also expensive and this, together with the safety concerns, 
led to the development of catalytic methods.  
OsO4 was discovered in 1803 by Smithson Tennant, who also isolated metallic osmium from it.
32
 
Since then osmium tetroxide applications have increased over the time, both in the organic 
chemistry and in biochemistry. Osmium tetroxide capability of oxidizing olefins is known and 
applied since 1913,
30
 but the process has been widely studied from the 70s by Sharpless and many 
others chemists.
33
 However it was only during the 90s that the Sharpless’group developed the 
optimized conditions for the catalytic asymmetric dihydroxylation (AD) process (Scheme 7). They 
found that best ee were obtained using K2OsO4•2H2O, as source of OsO4, K3Fe(CN)6, as the 
stoichiometric oxidant, K2CO3 and methanesulfonamide (MeSO2NH2), to increase the rate of the 
reaction, and cinchona alkaloid derivatives as chiral ligands. Together, these reagents form a premix 
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which is now commercially available under the name of “AD-mix”. For his work on AD, Sharpless 
was awarded the Nobel Prize in 2001.  
Ph
Ph
Ph
Ph
OH
OH
Ph
Ph
OH
OH K2OsO42H2O, K3Fe(CN)6,
     K2CO3, MeSONH2
tBuOH, H2O, 0 °C
   DHQD2PHAL
tBuOH, H2O, 0 °C
     DHQ2PHAL
K2OsO42H2O, K3Fe(CN)6,
     K2CO3, MeSONH2
 
Scheme 7. Sharpless catalytic asymmetric dihydroxylation. DHQD and DHQ are the alkaloid 
ligands dihydroquinidine and dihydroquinine, respectively. PHAL is the phthalazine 
based group attached to the ligands. 
Another important OsO4-catalyzed reaction is the oxidative cleavage of olefins to aldeydes 
and/or ketones. The standard method for the direct oxidative cleavage of olefins is ozonolysis, but 
due to safety concerns alternative procedures have been developed. There are different methods 
employing OsO4, the most common are Johnson-Lemieux oxidation (NaIO4, OsO4 (cat.))
34
 and the 
more recent and popular Upjohn dihydroxylation/diol cleavage (NMO, OsO4 (cat).; NaIO4).
35
 Both 
methods are based on the olefins dihydroxylation by catalytic OsO4, followed by NaIO4 cleavage of 
the resulting 1,2-diol, but Johnson-Lemieux oxidation employed NaIO4 also as co-oxidant for 
osmium tetroxide, whereas in the Upjohn oxidation NMO is used. Borhan and co-workers have 
recently developed new procedures (an example is reported in scheme 8) involving the use of oxone 
(a triple salt containing two parts of KHSO5, one part of KHSO4, and one part of K2SO4)
36
 or of 
H2O2
37
 as the co-oxidant for oxidative cleavage of olefins with OsO4, proceeding without the 
intermediacy of 1,2-diols. 
R1 R2
OsO4 (0.01 eq)
Oxone (4 eq)
DMF, 3h, r.t.
R1CO2H    +     R
2CO2H
 
Scheme 8. Osmium tetroxide-promoted cleavage of olefins (Borhan’s procedure). 
At this point, we should mention another fundamental osmium tetroxide application that is the 
cyclization of dienes to THF compounds, that was first reported in 1998 by the research group 
where this thesis have been carried out.
38
 Indeed professor Piccialli found that using catalytic 
osmium tetroxide with sodium periodate as a reoxidant it was possible to cyclize geranyl acetate 
and neryl acetate into their corresponding THFs in moderate yields (see Scheme 9).
38 
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Scheme 9. The first example of OsO4–mediated cyclization of 1,5-dienes by V. Piccialli.
38 
Then Donohoe and co-workers have widely studied the osmium–mediated cyclization of 1,5-
dienes.
39
 They continuously developed the method until it has been transformed into an extremely 
efficient and powerful new catalytic reactions for the stereoselective formation of THFs and 
pyrrolidines (Scheme 10). In particular they found that by performing a regioselective asymmetric 
dihydroxylation of certain polyenes and treating the resulting enantioenriched diols (bearing a 
pendant alkene) with Os
VI
 rather than the more familiar Os
VIII
, more satisfactory results in terms of 
yields and stereoselectivity were obtained. All their efforts in this area are recorded in a recent 
perspective. 
39
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Scheme 10. Donohoe’s conditions for THFs and pyrrolidines synthesis. 
As a continuation of our efforts toward the synthesis and modification of THFs containing 
compounds, during the third year of my PhD programme some preliminary experiments have been 
carried out to evaluate the possibility of inducing the OsO4-catalized oxidative bis-cyclization of 
farnesol-like substrates (see Chapter 7). 
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Chapter 2 
Pyridinium chlorochromate-mediated oxidation of mono- and 
poly-tetrahydrofurans. Disclosure of novel oxidative pathways  
2.1. Introduction 
Tetrahydrofuran-containing compounds are widely distributed in nature. In particular 2,5-
disubstituted THF fragments are commonly found in a great variety of biologically active 
substances such as polyether antibiotics, e.g. monensin A,
1
 squalene-derived polycyclic polyether 
metabolites (oxasqualenoids) such as glabrescol,
2
 and annonaceous acetogenins, such as goniocin 
and mucocin (Figure 1).
3
 Interest toward isolation, synthesis and structural modification of the basic 
backbone of these substances is still very keen as witnessed by the numerous researches devoted to 
these targets. Synthesis of non-natural poly-THF or THF-containing substances represents a related 
area of research aimed at obtaining materials displaying new important biological properties.
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Figure 1. Some bio-active THF-containing natural compounds. 
As a part of our ongoing interest in oxidative processes mediated by transition metal oxo-
species
4
 and in particular in the synthesis and derivatization of mono and poly-THF compounds,
5
 
we report here the results of a study concerning the oxidation of some mono- and poly-THF 
compounds with pyridinium chlorochromate (PCC)
6
 as well as with the catalytic system PCC 
(cat.)/H5IO6 (Chlorocromatoperiodate, CCP)
7, 8, 9
 (for PCC and CCP see Chapter 1).The present 
investigation started from some observations made during the oxidation of a poly-THF compound 
with PCC. In particular, we have recently reported
10
 that compound 1, the penta-THF product 
obtained by the Ru(VIII)-catalysed oxidative pentacyclization of squalene,
5g, 5j
 when treated with 
PCC (Scheme 1, see also Chapter 1, paragraph 1.3) furnishes compounds 2-5, four representative of 
a novel class of cytotoxic poly-THF spiroketals, besides poly-THF -lactones 6-8, the main 
products of the process. 
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Scheme 1. Summary of the products obtained by PCC-mediated oxidative 
spiroketalization/oxidative cleavage of penta-THF compound 1. 
Whereas the PCC-mediated conversion of -hydroxy mono- and poly-THF compounds to -
lactones (see for example the conversion of 2 to 3 or 1 to 6-8, scheme 1) is well-documented,
11
 
PCC-mediated cleavage of inter-THF bonds is unprecedented. In order to collect further evidences 
on the oxidative routes leading to compounds 2-8, we preliminarily undertook a careful analysis of 
some persistent minor side-products formed during the oxidation of 1 with PCC. This survey 
allowed to confirm that PCC is indeed able to cleave the inter-THF bonds in 1 providing a deeper 
insights into the mode of action of PCC with THF-containing compounds. Prompted by these 
results we next examined the oxidation of some less structurally complex poly- and mono-THF 
substances with PCC, extending our investigation to the related PCC(cat.)-H5IO6 system as well. 
Overall, the acquired data leaded to disclose novel oxidative pathways on the oxidation of 
differently substituted and configurated tetrahydrofurans with PCC or allowed to confirm 
previously formulated mechanistic hypotheses on some PCC-mediated processes.
10
 A new plausible 
hypothesis on the PCC-mediated oxidative cleavage of THF rings bearing an  tertiary alcohol 
function,
5d, 5g, 11
 such as 1, 6, 7 or 2, to the corresponding -lactones, that well agrees with the 
mechanism proposed for the analogous process mediated by RuO4, has also been formulated. 
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2.2. Results and Discussion 
2.2.1 Identification of minor products arisen from the oxidation of penta-THF 1 with PCC 
C-8 oxygenated spiroketals 
Penta-THF 1 was synthesized from squalene according to a previously described procedure
5g 
 
and thoroughly purified by preparative direct and reversed-phase HPLC to exclude the presence of 
minor impurities. Its purity was further checked by 700 MHz 
1
H NMR analysis. The oxidation of 1 
in the presence of PCC was carried out in CH2Cl2 at reflux as previously described.
10
 The crude 
reaction mixture was subjected to a careful preparative and then, when required, analytical HPLC to 
give the new C-8 oxygenated spiroketals 9 and 10 (Scheme 2) as well as some dilactone compounds 
derived from the degradation of the carbon backbone of 1 (see later, Scheme 4), besides previously 
isolated compounds 2-8. 
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Scheme 2. Minor C-8 oxygenated spiroketals obtained by PCC-mediated oxidation of 1 
Determination of the stereostructure of the C-8 keto-compound 9 was accomplished by 
registration of a full set of high-field 2D-NMR spectra while the structure of the corresponding C-8 
alcohol 10 was inferred by chemical correlation with 9 and NMR evidence. In particular, the 
configuration of the C-7 spiro-centre belonging to the tricyclic spiroketal subunit in 9 was 
established to be the same found in related spiro-compounds 2-5 (Scheme 1) through unambiguous 
ROESY evidence. 
The structural relationship between 9 and the corresponding alcohol 10 was proven by sodium 
borohydride reduction of 9 that gave alcohol 10 (10%, Scheme 3) along with the corresponding triol 
11 (75%) derived from the further reduction of the -lactone function in 9 through attack of the 
reducing agent to the carbonyl plane from its upper face. Configuration at C-8 in 10 was established 
on the basis of 2D-NMR studies carried out on the corresponding triol 11, available in higher 
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amounts, having ascertained the streostructural relationship between the two compounds by 
borohydride reduction of the former to the latter. In particular, a significant ROESY correlation 
peak between Me-26 and H-8 (Figure 1) established the -orientation of the OH group in this 
compound and thus its cis relationship with the oxygen bridging C-2 and C-7 in the 1,4-dioxane 
ring, a fact having important mechanistic implications, as discussed later. 
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Scheme 3. Borohydride reduction of the C-8 keto-spirocompound 9. 
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Figure 1. A stereo-view of the spiroketal-containing portion of 11 showing significant ROESY 
correlations. 
Dilactones 
Dilactones 12-14 (Scheme 4), derived from the cleavage of the poly-THF backbone of 1 at 
different hydrogen-carrying angular positions, were also isolated as minor products (overall 2% 
yield) of the oxidation of 1 with PCC. The stereostructures of 12 and 13 was determined by 2D-
NMR studies. The trans configuration of both the THF rings in the most abundant among these 
substances (12, 1%) indicated that it came from the oxidative cleavage of 1 at the C6-C7 bond 
interconnecting A and B THF rings accompanied by the oxidative removal of the terminal 2-
hydroxypropyl moiety at the other end of the molecule (C22-C23 bond cleavage). Dilactone 13 (0.5 
%) is the threo-cis-threo-trans-threo isomer of 12 originating from the analogous oxidative 
cleavage of the C18-C19 bond connecting D and E THF rings and the oxidative cleavage of the C2-
C3 bond. Conflicting NMR evidences prevented assignment of the configuration for the remaining 
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tricyclic dilactone 14 (0.5%). Consequently, both a threo-trans-threo or threo-cis-threo 
configuration is possible for this substances according to the two cleavage patterns conducting to it 
(cleavage of C10-C11/C22-C23 or C2-C3/C14-C15 bond pairs). 
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Scheme 4. Minor polycyclic dilactone products from the PCC-mediated degradation of 1 and 
relevant cleavage patterns. 
2.2.2 A mechanistic rationalisation for the formation of spiroketals 9, 10 and dilactones 12-
14 
Isolation of the above products suggested intriguing new oxidative pathways. A plausible 
mechanistic rationalisation for the formation of above spiroketal and dilactone substances, that 
agrees with reported reactivity for PCC
6
 and previously developed chemistry by our own group
10
 is 
given in schemes 5 and 6. 
Thus, after the initial formation of a chromium ester 15 (Scheme 5) by interaction of PCC with 
the C(2)-OH, the oxo-chromium appendage tethered to C-2 may either attack the close-in-space C7-
H bond, causing the closure of the spiroketal function in 2 (route a), or generate a cyclic chromium 
diester intermediate 16 (route b) through a path involving the a [3+2] addition of a O=Cr=O portion 
to the same C7-H bond.  
Formation of chromate ester 15 is a reasonable assumption since there is evidence for the very 
rapid formation of such esters by reaction of PCC with primary, secondary and tertiary alcohols.
12
 
In addition, attack of transition metal oxo-species such as OsO4
13
 and RuO4
14
 to C-H bonds of 
alkanes has been suggested to proceed through a [3+2] addition of a C-H bond across an O=M=O 
unit through a mechanism analogous to the one now widely accepted for alkene bishydroxylation. 
Moreover, evidence is reported in the literature that RuO4 oxidation of neoisocedrane oxide,
15
 a 
sesquiterpene containing a THF ring, proceeds through the insertion of an oxoruthenium bond into 
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the angular C-H bond of the THF (see later Scheme 9), much in the same way postulated in the 
transformation of 15 to 16. On this ground the proposed [3+2] attack of the C-2 oxo-chromium 
portion to the CH-7 bond in 15 to give 16 seems a very logical event. 
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Scheme 5. A mechanistic explanation for the formation of compounds 2, 3, 9, 10 and 12 
As previously pointed out,
10
 the closure of the spiroketal (conversion of 15 to 2) is made possible 
by the cis-threo-cis configuration of the bis-THF terminus in 1, that resulted in the vicinity in the 
space of the C7-H bond and the oxochromium appendage tethered to C-2. In fact, closure of a 
similar spiroketal at the other end of 1 is not possible due to the trans-threo-trans configuration of 
the terminal bis-THF portion (Figure 2) and an alternative path, leading to the cleavage of the C22-
C23 bond, is observed (see conversion of 2 to 3). Formation of diester 16 appears essential to 
explain the generation of all the other isolated substances. Indeed, 16 can evolve through two paths 
(route c and d) both conducting to cyclic enolether products (17 and 18). In particular, route c 
would be responsible for the direct formation of dilactone 12 and enolether 17 via oxidative 
cleavage of the C6-C7 bond connecting A and B rings. It was anticipated that the C-C double bond 
in the latter would likely undergo oxidative cleavage to the dicarbonyl compound 19 based on 
previous evidence on the reactivity of enolethers with PCC.
16
 Evidence for the existence of such an 
intermediate was subsequently gained when the dibenzoate of 1 was oxidised in the same conditions 
(see later Schemes 10 and Figure 3) and we succeeded in the isolation of the benzoate of 19. A 
chromium diester intermediate strictly similar to 16 has been postulated in the oxidative ring fission 
of 2,5-dialkylfuranes with PCC to give -unsaturated 1,4-dicarbonyl compounds.17 Alternatively, 
diester 16 can generate the ring-B enolether intermediate 18 (route d), where the chromium-
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containing appendage is still linked to C-2 and the carbon backbone of 1 is preserved, via an 
elimination step. Formation of  spiroketal 10 would then follow via a cycloaddition step, possibly a 
[3+2] process involving the attack of the oxochromium appendage still tethered to C-2 on the 7 
double bond in 18. In this way the spiroketal system of 10 is formed with the simultaneous delivery 
of an hydroxyl group at C-8. 
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Figure 2. Intra-molecular versus inter-molecular attack of PCC to the terminal trans-trans bis-THF 
portion of 1. 
Conversion of 18 to 10 is a likely transformation because the PCC-mediated oxidative 
cyclization of bishomoallylic tertiary alcohols to THF-alcohols has previously been reported.
18
 It is 
worth noting that such a cycloaddition step also explains the observed cis relationship between the 
ring-F spiroketal oxygen and the hydroxyl on C-8 (see Figure 1 for derivative 11). Finally, keto-
spiroketal 9 would derive from the corresponding alcohol 10 by further PPC oxidation at C-8 in the 
reaction medium. It is to be noted that 9, 10 and 12 (Schemes 2 and 4) all possess ring-D terminal 
lactone moieties originating by a further oxidative cleavage step of the C22-C23 bond of the type 
involved in the conversion of 2 to 3 (Scheme 7 and 8) 
Our results on the conversion of 18 to 10 well agree with the Schlecht et al
18c
 and McDonald et 
al
18b
 mechanistic proposals. This transformation is strongly reminiscent of the oxidative 
spirocyclization of cyclic enolethers mediated by rhenium (VII) oxides
19
 reported by Boyce and 
Kennedy and represents the first example of the PCC-induced closure of a cyclic spiroketal 
involving an enolether double bond. It is to be noted that this transformation involves the chromium 
ester of a tertiary alcohol (C2-OH) while the rhenium-mediated process is reported to induce the 
sole spiroketalization of primary alcohols. This transformation is certainly worth of further 
experimentation using ad hoc devised substrates. 
Formation of dilactone 13, the threo-cis-threo-trans-threo isomer of 12, (not shown in Scheme 
5) would proceed in a way strictly analogous to that conducting to 12,  via cleavage of C2-C3 and 
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C18-C19 bonds, the former one once again generating fragment 17. However, in this case, an 
intermolecular attack of PCC to C18-H bond should be invoked because a C23-tethered 
oxochromium appendage and the C18-H bond cannot be brought near in the space due to the threo-
trans-threo configuration of the bis-THF terminus (Figure 2), as above pointed out for the 
spiroketalization at this terminus. 
Formation of dilactone 14 from 1 is depicted in Scheme 6. It requires the cleavage of one of the 
bonds adjacent to the central THF ring (C10-C11 or C14-C15) to take place (scheme 6 shows the 
attack at C11-H). An the inter-molecular attack of PCC is required in this case as well, to give the 
chromium ester intermediate 20. Lactone 21 would then originate from 20 through a route strictly 
similar to the one by which 16 is transformed into bis-lactone 12 (see route c, Scheme 5). A bis-
THF enolether-containing species (22) would also be produced in this step, the fate of which we 
were unable to follow further though it is presumable that its C-C double bond could underwent 
oxidative cleavage as hypothesised for 17 in scheme 5. Finally, PCC-mediated oxidative cleavage 
of the terminal side chain in 21 would give rise to the second lactone function of 14. 
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Scheme 6. Proposed mechanism for the formation of dilactone 14 
Summarising, the above results clearly established the ability of PCC to cleave inter-THF bonds 
in 1. The main oxidative routes, leading to -lactones 6-8,5g, 10 spiro-compounds 2 and 3 as well as 
minor C-8 oxygenated spiro-compounds 9 and 10 and bis-lactone 12, proceed through the 
preliminary formation of chromium esters by interaction of PCC with the two hydroxyl groups of 1. 
Secondary routes leading to truncated spirolactones 4 and 5 (Scheme 1) and dilactones 13 and 14, 
likely proceed through inter-molecular attack of PCC to the suitable THF CH bonds followed by 
inter-THF C-C cleavage. There is evidence indicating formation of cyclic enolethers. 
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2.2.3 On the oxidative cleavage of -hydroxy-THF compounds. Conversion of 1 to 6-8 
The PCC-mediated oxidative cleavage of -hydroxy mono- and poly-THF compounds to -
lactones (see for example conversion of 1 to 6-8 or 2 to 3 in Scheme 1) is a well-documented 
process
11
 interesting both from a mechanistic and applicative point of view. No definitive evidence 
on the real path of this transformation has been provided to date although plausible speculative 
reasoning have been put forward.
5g,11
 In the light of the above collected evidences a comment to this 
transformation, with reference to THF bearing -tertiary alcoholic moieties, seems appropriate. 
Reasoning for example for the transformation of 1 to 7 (Scheme 1), a summary of the reported 
routes, explaining the oxidative cleavage of the C2-C3 bond, is shown in Scheme 7. 
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Scheme 7. Oxidative cleavage of the -hydroxy-THF portion of 1 according to previously 
formulated mechanistic hypotheses.
11 
In particular, the great part of the reported hypotheses, including our own, supposes a 
preliminary coordination of PCC to the alcohol group  to the THF ring. Thus, the C-2 tethered 
oxochromium appendage in the first-formed species 15 may attack the C-3 carbon though route a, 
with formation of a C-3 chromium ester intermediate 23, that in a successive oxidation step would 
generate the lactone function in 7. Alternatively, a cation species 24 may be formed (route b) that is 
then further oxidised by PCC to give 7. Another reported route (route c)
11d
 supposes the 
involvement of an enolether species such as 25, formed by dehydration, that is then cleaved by 
PCC. However, such a type of substance could not be detected among the reaction products, as the 
authors pointed out.
11d
 In line with our reasoning on the conversion of 15 to 16 shown in Scheme 5.  
We believe that a fourth plausible path (Scheme 8) can be proposed where the C3-H bond is 
attacked by the close-in-space C-2 tethered oxidant, to give the cyclic chromium diester 26. 
Successive oxidative fragmentation of this intermediate, would proceed in the usual manner with 
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expulsion of acetone, generating the lactone function of 7. This route would compete with the one 
where the C7-H is attacked by the same C-2 tethered O-Cr=O portion to give 16 (Scheme 5). Cyclic 
esters such as 26 are thought to be involved into the oxidative cleavage of alkenes or vicinal diols 
with related oxo-species RuO4, OsO4, RuO4
-
 and MnO4
-
. Importantly, our path is strictly similar to 
the proposed route for the oxidative cleavage observed for 8-hydroxy-neoisocedranol oxide with 
RuO4 shown in Scheme 9
15
 and further supports our hypothesis on the similarity between the RuO4 
and PCC in such processes. On this ground it seems also conceivable that this route could work 
with related -hydroxy-THF substances.11 
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Scheme 8. Our proposed route for the oxidative cleavage of the -hydroxy-THF portion in 1. 
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Scheme 9. Reported oxidative cleavage of 8-hydroxy-neoisocedranol oxide with RuO4 and 
postulated mechanism.
15 
2.2.4 Minor oxidation products from the PCC-mediated oxidation of penta-THF dibenzoate 
27 
Intrigued by these results, we decided to collect further evidences on the oxidative pathways 
depicted in Schemes 5 and 6 by investigating the reactivity of the bis-benzoate of 1 (27, Scheme 10) 
in the same oxidative conditions. Based on the above mechanistic hypothesis, the absence of the C-
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2 and C-23 hydroxyl groups in 27 would depress the main oxidative route thus enhancing, in 
principle, the intermolecular attack of PCC to the differently substituted THF rings embodied in 1. 
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Scheme 10. Major products from the oxidation of penta-THF dibenzoate 27 with PCC/AcOH. 
Dibenzoate 27 was prepared from 1 under standard benzoylation conditions (BzCl, DMAP, 
CH2Cl2) and thoroughly purified by preparative direct and reversed-phase HPLC and then subjected 
to oxidation with PCC in CH2Cl2. After 16 h at reflux, a 60% conversion was reached and the 
process was stopped. Careful HPLC separation of the reaction mixture, both in a direct and reverse-
phase mode, gave as main products the two isomeric acids 28 and 29 in 25% and 7% yields, 
respectively (Scheme 10), characterised by strictly similar dicarbonyl moieties, clearly originating 
from the degradation of D or B rings in 27. Minor products (Figure 3) included ketol 30 (2%) 
embodying a ring-B oxygenated moiety, lactone 31 (2%) lacking one of the terminal rings of 27, 
two isomeric small-sized lactones 32 and 33 (major isomer 4%; minor isomer 2%), conceivably 
originating by cleavage of the central THF ring in 27, as well as the two isomeric unsaturated 
aldehydes 34 (1% each) and fragment 35 (2%), the benzoate derivative of previously hypothesised 
19 (Scheme 5). The latter embodies a dicarbonyl moiety analogous to that present in compounds 28 
and 29. The rest of material for mass balance was mostly made up of very polar substances likely 
originating by over-oxidation of some of the isolated substances or by other oxidation side 
processes. 
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Figure 3. Minor products from the oxidation of penta-THF dibenzoate 27 with PCC. 
The structure of 28-35 indicated that the D-ring was preferably attacked by PCC, furnishing acid 
28 as the main substance whereas attack at B and C rings took place to a less extent. B ring 
oxidation gives 29 and 30 whereas degradation products 32-34 originate from the oxidation of the C 
ring. Lactone 31, the configuration of which could not be determined, can result from oxidation of 
either B or D ring.  
The reactivity of 27 can be rationalised as shown in Schemes 11 and 12 following the lines 
traced in schemes 5 and 6 for the corresponding debenzoylated analogous. In particular, following a 
backward reasoning for the formation of 28, it seems clear that the dicarbonyl portion in this 
substance can be traced back to the oxidative cleavage of an enolether function embodied in the D 
ring of 27 (see intermediate 37, scheme 11) via formation of chromium diester 38 and its successive 
oxidative cleavage to aldehyde 39 that is eventually oxidised to acid 28. Enolether 37 is in turn 
formed through an elimination step involving the first-formed chromium ester 36 that originates 
from the attack of PCC to the C18-H bond, in a manner similar to that priviously shown in Scheme 
6 (see conversion of 1 to 22). A similar path would give rise to isomer 29 by attack of PCC to the 
C7-H bond in ring B via chromium diester 40 (Scheme 12, route a), analogous to 38. Corroboration 
for this path came from the isolation of ring-B ketol 30, likely formed by the competing oxidative 
opening (oxidation at C-8) of the chromium diester intermediate 40. Isolation of 30 furnishes the 
first indirect support to the previously hypothesised
16
 formation of a chromium diester intermediate 
in the oxidative cleavage of enolethers. 
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Scheme 11. An hypothesis for the formation of compounds 28 from 27. 
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Scheme 12. Formation of compounds 29 and 30 from 27. 
Whereas PCC is unable to cleave isolated (unactivated) carbon-carbon double bonds, the 
oxidative cleavage of both cyclic and acyclic enolethers to esters with PCC has been reported.
16
 In 
particular, the above reactivity (conversion of 37 to 39, scheme 11) well agrees with the previously 
observed oxidative cleavage of cyclic enolethers lacking  hydrogens.16a,16c 
Formation of degraded compounds 32-34 is rationalised through attack of PCC to both C11-H 
and C14-H in the central THF (Scheme 13). Reasoning for the attack at C14-H, in line with the 
previously developed hypothesis, lactones 32 and 33 would derive from the monoester intermediate 
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41 by oxidative cleavage of C14-C15  bond (route a) whereas an alternative path (route b) would 
conduct to the ring-C enolether 42, by elimination of a chromium species (see also conversion of 36 
to 37, Scheme 11). Oxidative cleavage of the enolether double bond in the latter, followed by the 
further elimination of the rings D/E-containing portion of the molecule, would give rise to the 
conjugated aldehydes 34a and 34b. 
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Scheme 13. Formation of 32-34 from 27. 
Finally, structurally complementary compounds 31 and 35 are formed from 27 (Scheme 14) 
through cleavage of the C18-C19 bond in the chromium ester 36 (shown in Scheme 11). 
Meanwhile, a cyclic enolether species (43) is once again delivered and it gives rise to the dicarbonyl 
compound 35 when its olefin function is oxidatively cleaved through formation and successive 
oxidative fragmentation of a cyclic chromium diester (44). This route is analogous to that 
conducting to structurally similar 12 and 17 when 1 was oxidised (Scheme 5). Since configuration 
of 27 remained undetermined its formation can either follow the depicted route, through attack at 
C18-H, or the analogous path where the symmetric B ring is oxidised by attack of C7-H. 
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Scheme 14. A mechanistic explanation for the formation of compounds 31 and 35 from 27. 
Thus, the oxidation of dibenzoate 27 provided confirmatory evidences on the reactivity of its 
debenzoylated counterpart 1 with PCC. The absence of free hydroxyl groups on terminal side 
chains eliminated both the spiroketalization and oxidative cleavage of terminal moieties, caused by 
the preliminary coordination of PCC to them. The ability of PCC to cleave inter-THF bonds was 
still observed as indicated by the isolation of terminal lactones 31-33. In the meantime, a new 
oxidative route, leading to the oxidative cleavage of the ,-bond of B and D THF rings, not 
observed during the oxidation of 1, was disclosed. This path, as well as isolation of ketol 30 and 
aldehydes 34, strongly support the involvement of cyclic enolether intermediates. Worth 
mentioning is also the sole formation of the B-ring ketol 30. The analogous, possible, ring-D ketol 
could not be detected even after careful HPLC analysis. As expected, due to the presence of five 
THF rings this process is scarcely selective though a propensity for the attack at B and D rings is 
observed. 
2.2.5 Oxidations of poly-THF compounds with PCC/H5IO6 
We next decided to test the reactivity of 27 in the presence of the catalytic system PCC (cat.)-
H5IO6 (Scheme 15; see also Chapter 1, pargraph 1.3).This oxidising combination has received to 
date little attention.
7-9
 Based on previous studies
9
 it is thought that the combination of the two 
reagents generates chlorochromatoperiodate (CCP), an oxidising agent more powerful than PCC. It 
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was hoped that the use of a more reactive and sterically demanding reagent such as this, might 
improve the regioselectivity of the attack of the oxidant to the poly-THF system of 27 and could 
also reduce reaction times and force the process to completion. The oxidation was initially carried 
out in CH3CN at 0°C using 1% of PCC and four equiv. of periodic acid (Scheme 12, conditions A). 
The process was indeed much cleaner under this conditions and overall improved yields of acids 28 
and 29 (28: 40%; 29 4%) were obtained in a shorter time (3h at 0°C). Importantly, the two isomers 
were now obtained in a ca. 10:1 ratio in favour of 28, indicating a preferred attack of the oxidant at 
the D ring. However, under these conditions the process was still incomplete and stopped at 80% 
conversion. Attack of the oxidant at the central THF ring was the second most important route 
giving isomeric lactones 32 and 33 in 6% overall yield (major isomer: 5%; minor isomer: 1%). 
Addition of a further 1% PCC and 1 equiv of H5IO6 (conditions B) forced the process to completion 
at the expense of a slight reduction in the yield of 28 whereas yields of acid 29 and lactones 32/33 
were scarcely affected. 
Cr
O
O I
O
O
OH
OH
OH
O
Cl
OOOO
H H H OBzH H
O
HBzO
Cr
O
O
Cl O
OH I
O
OH
OH
OH
OH
H
O
H OBz
O
O
H
OO
H HBzO
O
HO
2
C
O
O
CO
2
H
O
HBzO
O OO
H H OBzHH
BzO O
OOH OH H
A:PCC(1 mol-%)/H5IO6 
(4 equiv.), CH3CN, 0°C, 3h 
(80% conversion) 
B: PCC(2 mol-%)/H5IO6 
(5 equiv.), CH3CN, 0°C, 4h 
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+
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+
32 (A: 5%; B: 4%)
33 (A: 1%; B: 1%)  
Scheme 15. Oxidation of penta-THF dibenzoate 27 with PCC(cat.)-H5IO6. 
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Oxidation of tris-THF tetrabenzoate 45 (Scheme 16), a structurally “simplified” substrate, was 
then carried out. Compound 45 was obtained by benzoylation of the corresponding tetrol in turn 
prepared from penta-THF 1 through a short degradative sequence set up in a previous study 
conducted by our group.
5g
 For a comparative purpose, the process was conducted both with PCC-
AcOH and PCC(cat.)-H5IO6. This compound was obtained by benzoylation of the corresponding 
tetrol in turn prepared from penta-THF 1 through a short sequence set up in a previous study.
6e
 
Interestingly, in this case the three major products 46-47, two of them, acids 46 and 47, structurally 
related to compounds 28 and 29, and all originating from the attack of the oxidant at the central 
THF ring, were obtained. Once again better results were obtained with the PCC(cat.)-H5IO6 system 
though a 2% amount of PCC was required to force the process to completion (conditions B). A new 
interesting feature of the process was formation of the 1,4-diketone 48 through a third oxidative 
route featuring the oxidation of both the angular carbons of the central THF ring in 45. This route 
did not operate in previous instances. In addition, the oxidative route leading to the inter-THF bond 
cleavage seems not to operate with this substrate. Since 1,4-diketones are easily transformed into 
five-membered heterocycles, substances such as 48 may be synthetically useful to access new types 
of mixed poly-THF/heterocycle compounds. 
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Scheme 16. Oxidation of tris-THF tetrabenzoate 45. 
The parent penta-THF 1 can be obtained in a single step in multi-gram amounts from cheap and 
commercially available squalene, so the oxidative degradation of its penta-THF backbone can allow 
the facile access to stereochemically definite and functionalised cis-cis-trans and trans-trans-cis 
tris-THF compounds by hydrolysis of the inter-THF ester function in either 28 or 29 (Scheme 17). 
Likewise, new functionalised cis or trans mono-THF can originate from 46 and 47 by hydrolysis 
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(Scheme 5). Given literature precedents, it can be presumed that at least some of these substances 
may be useful for further citotoxic activity studies and also for synthetic purposes.
20
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Scheme 17. Functionalised new all-threo mono- and tris-THF systems accessible trough hydrolysis 
of poly-THF compounds 28, 29, 46 and 47. 
A further simplification of the poly-THF substrate was achieved by conversion of the tetrol 
corresponding to 45 to bis-lactone 49 (Scheme 18) through a previously set up sequence.
5g
 This 
compound proved unreactive with PCC under standard conditions while gave 1,4-diketone 50 in an 
interesting 45% yield with PCC(cat.)-H5IO6. This behaviour can be tentatively explained assuming 
that an electron density deprivation of the angular CH bonds in the THF would result due to the 
withdrawing effect of the two lactone moieties. As a result the weakly electrophilic PCC was no 
longer able to attack these bonds. In accord with this reasoning, the strongly Lewis-acidic 
chromium species CCP was capable of attacking the THF ring of this compound, even though a 
longer reaction time is required compared to the oxidation of tris-THF 45 with the same reactive. 
OOO OO
HH
OO OO O O
49
50 (45%)
PCC(2%)-
H5IO6(4 eq.)
CH3CN, 0°C, 
3.5 h 
PCC-HOAc, 
CH2Cl2, 
reflux, 9 h
No reaction
 
Scheme 18. Oxidation of dilactone 49. 
2.2.6 Oxidation of mono-THF compounds with PCC/H5IO6 
The above collected results indicated that the oxidation of complex poly-THF compounds 
containing both di- and trisubstituted THF rings, proceeds through two main routes. Oxidative 
cleavage of the C2-C3 bond is preferred when a 2,2,5-trisubstituted THF ring is involved as in the 
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oxidation of 27. A second route leads to 1,4-diketones, such as 48 and 50, through the attack of the 
oxidant at a 2,5-disubstituted THF ring and oxidation of both its angular carbons, as in the oxidation 
of 45 and 49. 
With the aim of rendering the above process synthetically useful, the oxidation of some mono-
THF compounds, based on the di- and trisubstituted THF motifs present in previously studied poly-
THF compounds, was tested. cis-THF 51 (Table 1), obtained by benzoylation of the corresponding 
diol, in turn synthesized by RuO4-catalyzed oxidative cyclization of geranyl benzoate,
21
 was 
initially chosen as a model compound to find the best conditions for the oxidative process. 
Oxidation of 51 under previously employed conditions (PCC 2 mol %, H5IO6 4 eq., 0 °C) gave acid 
52, analogous to compounds 28/29 and 46/47, obtained from more complex substrates, in a 54% 
yield (Table 1, entry 1) although longer reaction times were required. The process was then carried 
out at room temp. with the same amounts of catalysts and co-oxidant, leading to 51 with a similar 
55% yield in only 3 h (entry 2). Improved yields (80%) and further reduced reaction times (45 min.) 
were achieved by increasing the catalyst amount to 5% (entry 3). Increasing of the catalyst amount 
to 10% resulted in a similar yield and further reduced times (78%, 30 min., entry 4). Further 
increasing of the catalyst up to stoichiometric amounts (50-100%) only resulted in diminished 
yields (entries 5 and 6). Finally, the effect of addition of water to the process was tested. Although 
the related system CrO3(cat.)/H5IO6 has been successfully used to oxidise alcohols cleanly in wet 
CH3CN (0.75 vol-% water)
22
 in our case we have observed that addition of water (2-5 vol-%) is 
detrimental, causing the process to stop at 10-20% conversion. 
Table 1. Optimization of the process on a model 2,2,5-trisubstituted THF compound. 
O
H OBzBzO
OBz
OBz
OBz
BzO
O
O
CO
2
H
OO OBz
OBz
51 
PCC (cat)- 
H5IO6 (4 eq.)
    CH3CN
52 (Major product) 
+
53 (Minor product) 
Oxidative 
cleavage
 
Entry PCC 
(mol-%) 
H5IO6 
(equiv.) 
Time Yield of 
12
[a]
 (%) 
1
[b]
 2 4 19 h 54 
2 2 4 3 h 55 
3 5 4 45 min. 80
[c]
 
4 10 4 30 min. 78 
5 50 4 30 min. 62 
6 100 4 30 min. 37 
[a] Estimated by 
1
H-NMR of the crude mixture. [b] Carried out at 
0° C. [c] Isolated yield. 
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Oxidation of mono-THF compounds structurally related to 51 under optimized conditions was 
then carried out (Scheme 19). cis-THF 54, 56 and 64 were synthesized by benzoylation of the 
corresponding THF diols, in turn obtained by RuO4-catalysed oxidative cyclization of trans trans-
2,6-dimethyl-2,6-octadiene-1,8-diol diacetate,
5k
 methyl geranate
5k
 and hexa-1,5-diene,
21
 
respectively, as reported. trans-THF 59 was obtained by benzoylation of the corresponding THF 
diol, a minor product from the oxidative cyclization of geranyl benzoate.
23
 THF 60 was synthesized 
from 51 through a short sequence. In particular, selective removal of both the primary and 
secondary benzoates in 51 with K2CO3 in MeOH, proceeded cleanly to give the corresponding diol. 
Oxidative cleavage of the diol system by treatment with silica-supported NaIO4
24
 in CH2Cl2, 
followed by borohydride reduction and benzoylation, afforded dibenzoate 60 in 43% yield (over 
four steps). Ketone 62 was obtained by TPAP-catalysed oxidative cyclization of geranyl acetate
5h
 
followed by benzoylation. 
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Scheme 19. Oxidation of functionalised 2,2,5-trisubstituted and 2,5-disubstituted THF compounds. 
i) PCC (5 mol-%), H5IO6 (4 equiv.), CH3CN, r.t., 1h; ii) PCC (2 mol-%), H5IO6 (4 
equiv.), CH3CN, r.t., 40 min. 
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CCP oxidation of cis-THF diacetate 54 and trans-THF 59 gave acids 55 and 52, respectively, in 
65-70% yields. The methoxycarbonyl derivative 56 unexpectedly afforded the corresponding acid 
in a diminished 30% yield, the major product of the process being lactone 58, analogous to 53, 
derived from the oxidative removal of the dimethylated left-hand side chain. This side process is 
unusual and is reminiscent of the oxidative cleavage of a similar substrate.
8
 This type of lactone is 
also the main side-product of the process carried out on all the other substrates. Similarly, the THF 
derivative 60 gave acid 61 in 65 % yield. 
In another experiment, -keto THF 62 was oxidised. In this case the presence of a keto group 
adjacent to the THF ring induced removal of the side chain through the oxidative cleavage of the 
C(THF)2-C bond to give 1,4-diketones 63 in good yields. 
Finally, the reactivity of the 2,5-disubstituted cis mono-THF 64, was tested. Pleasingly, 1,4-
diketone 65 was obtained in a nearly quantitative yield (98%) even when the amount of PCC was 
reduced to 2 mol-% amount, This process is particularly appealing because it allows, when coupled 
with the oxidative cyclization of 1,5-dienes, the transformation of the latter into bis-ketols in a 
regioselective manner. This experiment and the oxidation of the more complex disubstituted mono-
THF 49 demonstrated that for substrates containing only a 2,5-disubstituted THF ring the preferred 
route is the one leading to 1,4-diketones. 
2.2.7 Mechanistic considerations on the oxidation of mono-THFs compounds 
Based on the known reactivity of PCC, a rational mechanistic route explaining the formation of 
the above compounds was hypothesised. In particular, a path leading to compound 52, but that also 
applies to the formation of the analogous compounds 55 and 57, is shown in scheme 20. It is similar 
to that postulated for the formation of the compounds 28/29 and 46/47. It is likely that the process 
begins with the attack of CCP, formed by elimination of water from PCC and periodic acid, to the 
angular C-H bond of the THF ring to give the mixed chromium ester intermediate 66. This step is 
conceivably a [3+2] addition of the O=Cr=O portion of the oxidant to the angular C-H bond of the 
THF ring as seen before in Scheme 5.  
In the next step chromium ester 66 would give rise to cyclic enolether 67 through an elimination 
step delivering a low-valent chromium species that was then reoxidised to CCP by H5IO6. 
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Scheme 20. A plausible catalytic cycle explaining formation of acid 52. 
The conversion of 67 to the final dicarbonyl compound 52 is thought to proceed through the 
formation of the chromium diester intermediate 68, via a second [3+2] addition step in a manner 
similar to that seen before for conversion of 37 to 39 in Scheme 11. Oxidative cleavage to aldehyde 
69, followed by oxidation of the latter eventually generates acid 12. Finally, formation of lactone 
53, the main side-product of the oxidation of 51, can be seen to originate from the oxidative 
removal of the dimethyl benzoate side-chain. It has previously been observed that THF rings 
flanked by a tertiary (free) alcohol function undergo a similar oxidative cleavage with CCP to give 
-lactones8 such as 13, via a C-2 chromium ester intermediate. It is conceivable that a similar route 
could be responsible of the C2-C3 oxidative cleavage in a chromium ester intermediate possibly 
formed by further evolution of 66 (Scheme 21). This interaction is supported by the complete 
absence of hydrolysis of primary and secondary benzoate functions co-existing in the same 
molecule. 
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Scheme 21. Formation of lactone 53 by side-chain removal in intermediate 66. 
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Along the same line of reasoning, formation of diketone 63 from 62 (Scheme 22) can be 
explained assuming that the first-formed chromium ester 70 collapses to the dicarbonyl species 71 
the -ketol portion of which undergoes oxidative cleavage to give 63 through a known process. 
O
H
BzO
OAc
O
Cr
O
O
Cl
X
OAc
Cr O
O
X
O
Cl
OBzO
H
OAc
OH OBzO O BzO OO
Cr
OH
O
X
Cl
62
63
70
71
Ring
opening
CCP
+
H5IO6
H5IO6
X= OIO5H3 PyH  
+-
 
Scheme 22. A catalytic cycle for the formation of diketone 63. 
Formation of 1,4-diketone 65 from 64 is shown in Scheme 23. In particular, CCP would attack 
one of the angular CH bonds in 64 in the usual way to give chromium ester 72. Opening of the latter 
would then follow to give ketol 73 (route a) with simultaneous delivery of a chromium species the 
oxidation of which would regenerate CCP closing the catalytic cycle. CCP oxidation of the alcohol 
function in 73
7a
 would eventually give 1,4-diketone 63. Formation of related 1,4-diketones 48 
(Scheme 16) and 50 (Scheme 18) can be explained in a similar manner. It is to be noted that the 
possible competing path giving rise to an enolether species (74, Scheme 23, route b) from 72 is 
completely suppressed in this case. It is worth noting that the chemical behaviour of PCC in this 
transformation parallels the one displayed by RuO4. In fact, in a similar transformation, 2,5-
dimethyl-tetrahydrofuran is reported to give the oxidative opening to 2,5-hexanedione by the 
RuO2(cat.)/NaIO4 system.
25 
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Scheme 23. A catalytic cycle for the formation of 1,4-diketone 65. 
2.2.8 Synthesis of umbelactone 
As an application of the developed oxidative procedure, a short synthesis of racemic 
umbelactone was carried out. Umbelactone is a -butenolide natural product isolated from the 
ethanolic extracts of Memecylon umbellatum Brum,
26
 that exhibited antiviral activity against the 
Ranikhet disease virus as well as spasmolytic and antiamphetamine activity. This substance has 
been the subject of various synthesis both in racemic and enantiopure form.
27 
 
Our above described oxidation of trisubstituted THFs such as 51 allows the access to elaborated 
3,4,5-tryoxygenated acids. In particular, compound 52 derived from 51 was envisaged to be a good 
starting product to synthesize umbelatone (Scheme 24). Thus, tribenzoate 52 was converted into 
trihydroxy acid 75 in high yield by treatment with K2CO3 in MeOH. Successive treatment of crude 
75 with CH2N2 gave transient methyl ester 76 that spontaneously cyclised to the -lactone 77 in 
90% yield (81% from 51). The primary hydroxyl group in the latter was then protected as the TBS 
ether 78 by treatment with TBSCl/Imidazole in DMF (96% yield).
28
 Dehydration of 78 was 
accomplished with SOCl2-pyridine to give silylated umbelactone 79 in 95% yield. Eventually, 
desilylation of 79 with Et3N•3HF in THF cleanly gave umbelactone 80 (92% yield). 
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Scheme 24. Synthesis of umbelactone. 
Our synthetic route to umbelactone is short and highly efficient and does not require carbon-
carbon bond forming steps. In addition, it can be rendered enantioselective to give both the 
umbelactone enantiomers because mono-THF tribenzoate 51 (Table 1), the immediate precursor of 
52, can be obtained in both enantiomeric forms from commercially available geraniol in high yields 
and enantiomeric purity.
29
 Studies towards this goal as well exploitation of the above chemistry for 
the preparation of further functionalised butenolides are ongoing. 
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2.3. Conclusions  
In conclusion, in the present study we have examined the oxidative behaviour of some poly- and 
mono-THF compounds with PCC under classical conditions or with PCC(cat.)-H5IO6. Penta-THF 1 
and penta-THF dibenzoate 27 revealed as good model compounds to study the action of PCC on 
adjacently linked poly-THF compounds. Novel oxidative pathways leading to the modification-
degradation of the THF ring, as well as of the poly-THF backbone, have been disclosed. Plausible 
hypotheses, consistent with the known reactivity of PCC, have been put forward to explain the 
formation of all isolated substances. In particular, attack of the oxidant at the angular C-H bond of 
the target THF ring and formation of a mixed chromium ester, is thought to be the first event. Two 
main routes then follow. Oxidative carbon-carbon bond cleavage, to give dicarbonyl-containing 
products, occurs when 2,2,5-trisubstituted THFs are oxidised. Isolation of some minor side products 
of the process strongly supports the formation of cyclic enolether intermediates in this 
transformation. THF ring opening, with no C-C bond cleavage, is observed with 2,5-disubstituted 
mono-THFs. 1,4-Diketones, useful building blocks in organic synthesis
30
 are obtained in this case. 
The latter transformation proceeds with a remarkable, nearly quantitative yield. At the moment the 
factors governing the switch of the process toward one of the above routes are unclear and further 
work is needed to reach this goal. A third route, leading to the oxidative cleavage of a C-2 side-
chain, works when the THF ring is flanked by a ketone function. Isolation of minor C-8 oxygenated 
spiroketal compounds from the oxidation of 1 suggests that cyclic enolethers with -tethered 
tertiary alcohol portions can be used in a chromium-mediated spiroketalization process. Further 
clarification of this issue could come from theoretical studies.  
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2.4. Experimental Section  
2.4.1 General experimental methods  
All reagents were purchased at the highest commercial quality and used without further 
purification. Reactions were monitored by thin-layer chromatography carried out on precoated silica 
gel plates (Merck 60, F254, 0.25 mm thick). Merck silica gel (Kieselgel 40, particle size 0.063-0.200 
mm) was used for column chromatography. Na2SO4 was used as a drying agent for aqueous work-
up. HPLC separations were carried out on a Varian 2510 apparatus equipped with a Waters R403 
dual cell differential refractometer using Phenomenex 250 x 10 mm and 250 x 4.6 mm (both 5) 
and LiChrosorb RP-18 250 x 4.0 mm columns. NMR experiments were performed on Varian Unity 
Inova 700, Varian Unity-Inova 500, Varian Mercury Plus 400, Gemini 200 spectrometers in CDCl3. 
Proton chemical shifts were referenced to the residual CHCl3 signal (7.26 ppm). 
13
C-NMR chemical 
shifts were referenced to the solvent (77.0 ppm). J values are given in Hz. Abbreviations for signal 
coupling are as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. IR spectra were 
recorded on a Jasco FT-IR 430 spectrophotometer. The High Resolution MS were recorded on a 
Bruker APEX II FT-ICR mass spectrometer using electron spray ionization (ESI) technique. For all 
the reported products the numbering previously given
6e 
 for the penta-THF 1 is used. 
2.4.2 Oxidation of 1 with PCC/AcOH. Isolation of minor products 9, 10 and 12-14 
Penta-THF 1 was synthetized as previously described.
5g
 To a solution of 1 (332 mg, 0.63 mmol) 
in CH2Cl2 (5 mL) was added PCC (5 equiv. 3.16 mmol, 682 mg) and AcOH (70 equiv., 2.5 mL) 
and the resulting heterogeneous mixture was stirred at room temperature for 6h. A saturated 
aqueous NaHCO3 solution was added and the mixture extracted with CH2Cl2. The combined 
extracts were dried and evaporated in vacuo to give a yellow oil. Filtration on a silica gel pad 
(eluent CHCl3-MeOH, 9:1) afforded a colourless oil (310 mg) that was separated by HPLC (250x10 
mm column; flow: 2.5 mL/min; eluent: hexane-EtOAc, 65:35) to give spirolactone 4 (2.5 mg, 1%, 
tR = 13.5 min), spirolactone 5 (1.9 mg, 1%, tR = 18.5 min), spiroketone 9 (3.1 mg, 1%, tR = 15.0 
min), spiroalcohol 10 (1.6 mg, 0.5%, tr = 17.5 min), bislactone 12 (2.1 mg, 1 %, tR = 41.0 min). The 
fraction eluted in the range 26-38 min contained a mixture of bislactones 13 and 14. A further 
HPLC run of this fraction (eluent: hexane-EtOAc, 3:7) gave ca. 80% pure 13 (tR = 17.0 min) and 14 
(tR = 15.0 min). Final purification of these substances was carried out by reversed-phase HPLC (250 
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x 4.6 mm column; flow: 1.0 mL/min; 13: eluent CH3CN/H2O, 6:4, tR = 4.5 min; 14: eluent 
CH3CN/H2O, 7:3, tR = 3.0 min) to give 13 (1.0 mg, 0.5%) and 14 (0.8 mg, 0.5%). 
9: Amorphous solid; IR (neat) max 1763, 1699, 1045 cm
-1
. 
1
H-NMR (500 MHz, CDCl3)  3.91 (1H, 
d, J= 7.0), 3.87-3.79 (3H, m), 2.88 (1H, ddd, J=13.0, 9.7, 5.4), 2.86 (1H, d, J= 17.6, Ha-9), 2.76 
(1H, J= 17.6, 10.6, 9.4), 2.45 (J= 17.6, 10.3, 3.3), 2.36 (1H, d, J=7.6, Hb-9) 2.35 (1H, m, partially 
overlapped to the Hb-9 signal), 2.14-2.00 (3H, overlapped multiplets), 2.00-1.82 (7H, overlapped 
multiplets), 1.60 (1H, ddd, J= 12.1, 7.8, 4.8), 1.40 (1H, ddd, J= 12.8, 12.8, 4.2), 1.52, 1.35, 1.32, 
1.21, 1.06, 1.04 (3H each, s’s, 6xMe); 13C-NMR (125 MHz, CDCl3)  208.9, 178.0, 100.9, 86.3, 
85.8, 85.3, 84.9, 83.7, 82.6, 81.3, 78.7, 76.0, 44.9, 34.4, 32.4, 30.3, 30.0, 27.6, 26.7, 26.5, 26.2, 
26.1, 25.6, 25.0, 23.9, 23.4, 21.2; HRMS (ESI) m/z calcd for C27H40NaO8 [M+Na]
+
 515.2621, found 
515.2630. 
10. Amorphous solid;. IR (neat) max 3398 (br), 1763 cm
-1
; 
1
H-NMR (300 MHz, CDCl3)  4.09 (1H, 
dt, J= 11.1, 8.7, 8.7), 3.90 (1H, d, J= 6.9), 3.83 (1H, dd, J=7.3, 7.3), 3.75 (1H, m) 3.57 (1H, m), 
2.77 (1H, dt, J=16.9, 9.3, 9.3), 1.54, 1.33, 1.30, 1.26, 1.09, 1.02 (3H each, s’s, 6xMe); HRMS (ESI) 
m/z calcd for C27H42NaO8 [M+Na]
+
 517.2777, found 517.2789. 
12: Oil;. IR (neat) max 1769 cm
-1
; 
1
H-NMR (400 MHz, CDCl3)  3.88-3.81 (2H, m), 3.79 (1H, dd, 
J= 9.6, 5.5), 2.83-2.70 (2H, m), 2.52-2.32 (4H, overlapped multiplets), 2.09-1.76 (9H, overlapped 
multiplets), 1.68-1.60 (1H, m), 1.33 (6H, s, 2 x Me), 1.05 (3H, s, Me); 
13
C-NMR (100 MHz, 
CDCl3)  177.9, 177.6, 86.3, 86.1, 85.74, 85.68, 85.3, 84.7, 34.5, 32.6, 32.3, 29.9, 29.8, 27.2, 26.9, 
26.5, 23.9, 23.5, 23.0; HRMS (ESI) m/z calcd for C19H29O6 [M+H]
+
 353.1964, found 353.1948. 
13: Oil;. IR (neat) max 1769 cm
-1
; 
1
H-NMR 400 MHz, CDCl3)  3.94 (1H, dd, J = 7.4, 7.4), 3.84 
(1H, dd, J = 7.5, 7.5), 3.72 (1H, dd, J = 9.7, 4.4), 2.82-2.67 (2H, m), 2.54 (1H, bt, J = 12.7), 2.48-
2.37 (3H, overlapped multiplets), 2.10 (1H, m), 1.35, 1.31, 1.09 (3H each, s’s, 3 x Me); 13C-NMR 
(100 MHz, CDCl3)  178.1, 177.7, 86.7, 85.7, 84.89, 84.81, 84.0, 83.7, 34.8, 32.6, 32.2, 30.04, 
30.00, 27.1, 26.7, 26.6, 24.6, 24.0, 23.3; HRMS (ESI) m/z calcd for C19H29O6 [M+H]
+
 353.1964, 
found 353.1951. 
14: Oil;. IR (neat) max 1762 cm
-1
; 
1
H-NMR (200 MHz, CDCl3)  4.36 (1H, dd, J = 6.8, 6.8), 3.90 
(1H, dd, J = 7.8, 7.8), 2.74-1.87 (11H, overlapped multiplets), 1.80-1.72 (1H, m), 1.32 (3H, s, Me), 
1.15 (3H, s, Me); 
13
C-NMR (100 MHz, CDCl3)  177.7, 177.3, 86.9, 85.8, 85.3, 84.5, 34.0, 32.4, 
29.9, 28.6, 26.1, 23.8, 23.0, 22.8; HRMS (ESI) m/z calcd for C14H21O5 [M+H]
+
 269,1389, found 
269,1380. 
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2.4.3 Borohydride reduction of 9 
To a solution of 9 (3.0 mg, 0.0061 mmol) in anhydrous ethanol (1 mL) was added NaBH4 (a tip 
of spatula) at room temperature under stirring. After 1h the mixture was diluted with ethanol (1 mL) 
and AcOH (two drops) was added. The mixture was filtered and the solid was thoroughly washed 
with ethanol. The organic phase was dried (Na2SO4) and taken to dryness under reduced pressure to 
give  a colourless oil (3 mg). HPLC separation (250 x 4.6 mm column; flow: 1.0 mL/min; 
hexane/EtOAc, 1:1) gave pure samples of 10 (0.3 mg, 10%, tR = 6.8 min) and 11 (2.5 mg, 75%, tR = 
35.5 min). 
11: Oil;. IR (neat) max -3400 (br) cm
-1
; 
1
H-NMR (500 MHz, CDCl3) δ  4.11 (1H, q, J= 9.1), 3.90 
(1H, bd J= 7.5), 3.78 (1H), 3.72-3.80 (2H, m), 3.65 (2H, t J=5.4), 3.60 (1H, dd J= 9.1, 4.8), 2.57 
(1H, ddd, J= 12.9, 9.9, 4.7), 2.48 (1H, m), 2.14 (1H, bddd, J= 10.0, 10.0, 10.0), 2.00 (1H, ddd, J= 
13.0, 9.5, 5.4), 1.42 (1H, ddd, J= 12.6, 12.6, 4.8), 1.54, 1.52, 1.31, 1.25, 1.085, 1.080, 1.077 (3H 
each, s’s, 6xMe); 13C NMR (CDCl3, data from 500 MHz HMBC) δ 104.1, 86.1, 85.7, 84.7, 84.3, 
81.9, 81.7, 80.0, 75.4, 72.7, 72.1, 63.6, 44.2, 37.2 (two carbons), 34.5, 31.2, 27.0 (two carbons), 
26.7, 26.6, 26.3, 26.0, 25.0, 23.9, 21.4, 21.2; HRMS (ESI) m/z calcd for C27H46NaO8 [M+Na]
+
 
521.3090, found 521.3075. 
2.4.4 Synthesis of poly-THF substrates 27, 45 and 49  
Penta-THF 1, the tetrol precursor of 45 and dilactone 49 were synthesized as previously 
described.
5g
 Compound 1 was benzoylated as follows. To 1 (236 mg, 0.45 mmol) dissolved in 
CH2Cl2 (10 mL) was added benzoyl chloride (15 equiv., 6.75 mmol, 785 L) and DMAP (30 
equiv., 3.5 mmol, 11.6 g) and the mixture was stirred at r.t for 30 h. Water (2 mL) was added and 
the mixture stirred for 15 min. in a water bath and then taken to dryness. The residue was taken up 
in CH2Cl2 and washed with a sat. NaHCO3 solution and water. The organic phase was dried, filtered 
and evaporated in vacuo to give an oily product that was chromatographed on silica gel eluting with  
(40-70) petroleum ether/Et2O (8:2) to give 264 mg (80 %) of dibenzoyl penta-THF 27. Further 
purification of 27 was carried out by HPLC (250x10 mm column; flow: 2.5 mL/min, 
hexane/EtOAc, 75:25). 
Penta-THF dibenzoate 27: Oil. IR (neat): max = 1712, 1285, 710 cm
-1
. 
1
H NMR (200 MHz, 
CDCl3):  = 8.05-7.92 (4H, m), 7.58-7.35 (6H, m), 4.25-4.15 (2H, m), 4.02-3.75 (4H, overlapped 
multiplets, ), 1.64 (3H, s), 1.60 (6H, s), 1.58, 1.23, 1.16, 1.15, 1.11 (3H each, s’s, 5 x Me) ppm. 13C 
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NMR (50 MHz, CDCl3):  = 165.54, 165.45, 132.3, 132.2, 131.9, 131.7, 129.2, 128.0, 86.1, 85.7, 
85.1, 84.9, 84.4, 84.3, 83.83, 83.78, 83.5, 83.3, 82.5, 34.4, 34.3, 34.1, 32.5, 27.6, 26.9, 26.8, 26.7, 
26.5, 24.7, 24.0, 23.4, 23.2, 23.0, 22.6, 21.3, 21.1 ppm. HRMS (ESI) m/z calcd for C44H60NaO9 
[M+Na]
+
 755.4135, found 755.4144. 
The tris-THF tetrol corresponding to 45 was benzoylated as described for 1. To 77 mg of the 
tetrol (0.173 mmol) dissolved in CH2Cl2 (2.0 mL) was added benzoyl chloride (15 equiv., 2.6 
mmol, 305 L) and DMAP (60 equiv., 1.3 g, 10.4 mmol) and the mixture was refluxed for 10 h. 
The mixture was worked-up as for 1 to give an oily product. Column chromatography on silica gel 
eluting with petroleum ether (40-70)/Et2O (8:2) gave 108 mg (73 %) of tetrabenzoyl tris-THF 45. 
Tris-THF tetraBz, 45: Oil. IR (neat): max = 1714, 1275, 710 cm
-1
. 
1
H NMR (400 MHz, CDCl3):  
= 8.16-7.95 (8H, m), 7.64-7.45 (4H, m), 7.45-7.32 (8H, m), 4.54 (1H, dd, J = 6.6, 6.6 Hz), 4.32 (5H, 
m), 3.89-3.74 (2H, m), 1.63, 1.57, 1.12, 1.08 (3H each, s’s, 4xMe) ppm. 13C NMR (100 MHz, 
CDCl3):  = 166.50, 166.46, 165.6, 132.80, 132.78, 132.50, 132.46, 131.7, 131.6, 130.26, 130.24, 
129.5, 129.4, 128.26, 128.24, 128.16, 128.15, 85.9, 85.3, 85.2, 84.7, 84.4, 83.9, 83.7, 81.4, 65.2, 
65.1, 34.6, 34.4, 31.9, 31.5, 27.5, 27.2, 26.92, 26.86, 24.3, 23.7, 23.5, 23.1, 20.4, 20.0ppm. HRMS 
(ESI) m/z calcd for C52H60NaO11 [M+Na]
+
 883.4033, found 883.4028. 
2.4.5 Oxidation of 27 with PCC/AcOH 
To a solution of 27 (365 mg, 0.50 mmol) in CH2Cl2 (16 mL) was added PCC (5 equiv., 537 mg, 
2.5 mmol) and AcOH (70 equiv., 35 mmol, 2 mL) and the resulting mixture was refluxed for 16h. A 
saturated aqueous NaHCO3 solution was added and the organic phase was washed with water, dried 
and evaporated in vacuo to give a yellow oil. Filtration on a silica gel pad (eluent CHCl3-MeOH, 
9:1) afforded an oily product (350 mg). Further elution with CHCl3-MeOH (8:2) gave a mixture of 
polar products (57 mg) that was no further studied. The first-eluted fraction was separated by HPLC 
(250x10 mm column; flow: 2.5 mL/min; eluent: hexane-EtOAc, 75:25) to give still impure 
compounds 28-35. Analytical HPLC (250 x 4.6 mm column; flow: 1.0 mL/min; 3 mg/injection, 
hexane/EtOAc, 75:25) gave pure major acid 28 (58.4 mg, 25%, tR = 11.5 min) and minor acid 29 
(16.3 mg, 7%, tR = 10.0 min) along with slightly impure ketol 30 (tR = 5.0 min), lactone 37 (tR = 
18.0 min), lactone 33 (tR = 13.0 min), lactone 31 (tR = 13.5 min) and 35 (tR = 16.5 min). Pure 
aldehydes 34a (1.2 mg, 1%, tR = 13.8 min) and 34b (1.2 mg, 1%, tR = 10.0 min) were obtained by 
HPLC on the same column by using hexane/EtOAc, 85:15. A further reversed-phase HPLC run 
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(250 x 4.0 mm column; flow: 1.0 mL/min; 2 mg/injection) was required to obtain pure 30 
(MeCN/H2O, 9:1, 4.6 mg, 2%, tR = 14.0 min), 31 (MeCN/H2O, 85:15, 3.0 mg, 2%, tR = 5.2 min), 32 
(MeCN/H2O, 8:2, 5.0 mg, 4%, tR = 5.0 min), 33 (MeCN/H2O, 85:15, 2.5 mg, 2%, tR = 4.5 min) and 
35 (MeCN/H2O, 8:2, 1.8 mg, 2%, tR = 2.0 min). 
Acid 28 (major isomer): Oil; max 1714, 1288, 712 cm
-1
; 
1
H-NMR: (700 MHz, CDCl3)  7.95 (4H, 
bd, J= 7.6, phenyl orto protons), 7.52 (2H, bt, J= 7.4, phenyl para protons), 7.41 (4H, bt, J= 7.7, 
phenyl meta protons), 4.42 (1H, dd, J= 6.8, 6.8), 4.27 (1H, dd, J= 7.1, 7.1), 4.10 (1H, dd, J= 8.4, 
6.5), 4.06 (1H, dd, J= 10.0, 5.3), 3.95 (1H, dd, J= 8.4, 6.0), 3.58 (1H, bs), 3.30 (1H, d, J=14.9), 2.99 
(1H, d, J= 14.9), 2.36 (1H, ddd, J= 13.8, 8.4, 5.5), 1.62, 1.60, 1.59, 1.56, 1.55, 1.50, 1.20, 1.14 (3H 
each, s’s, 8xMe); 13C-NMR (175 MHz, CDCl3): 174.4, 171.9, 165.7, 165.6, 132.6, 132.5, 131.85, 
131. 78, 129.42, 129.37, 128.25, 128.20, 86.4, 85.5, 85.3, 84.6, 84.5, 83.9, 83.6 (two carbons), 83.2, 
82.8, 81.9, 42.,2, 36.5, 34.5, 32.9, 27.9, 27.2, 26.7, 26.6, 26.0, 24.3, 23.14, 23.09, 22.8, 22.3, 21.5, 
21.41, 21.38; HRMS (ESI) m/z calcd for C44H58NaO12 [M+Na]
+
 801.3826, found 801.3819. 
Acid 29 (minor isomer): Oil; max 1712, 1287, 712 cm
-1
; 
1
H-NMR: (400 MHz, CDCl3)  7.9 (4H, 
bd, J= 7.4, phenyl orto protons), 7.51 (2H, bt, J= 7.3, phenyl para protons), 7.40 (4H, bt, J= 7.4, 
phenyl meta protons), 4.35 (1H, dd, J= 7.2, 7.2), 4.24 (1H, dd, J= 9.3, 5.9), 4.07-3.99 (2H, m), 3.55 
(1H, dd, J= 7.2, 7.2), 3.31 (1H, d, J=15.0), 2.98 (1H, d, J= 15.0), 2.61-2.53 (1H, m), 2.19-2.10 (1H, 
m), 1.64, 1.63, 1.60, 1.59, 1.48, 1.47, 1,15, 1.12 (3H each, s’s, 8xMe); 13C-NMR (100 MHz, 
CDCl3):  174.8, 172.9, 165.8, 165.7, 132.6, 132.4, 132.0, 131.7, 129.5, 129.4, 128.19, 128.16, 
86.3, 86.0, 85.8, 85.5, 85.1, 84.3, 83.9, 83.8, 83.7, 83.4, 81.5, 43.0, 36.4, 34.7, 34.4, 26.95, 26.88 
(two carbons), 26.82 (two carbons), 25.2, 24.1, 23.0, 22.7 (two carbons), 21.7 (three carbons); 
HRMS (ESI) m/z calcd for C44H58NaO12 [M+Na]
+
 801.3826, found 801.3835. 
Ketol 30: Oil; max 3301, 1712, 1287, 712 cm
-1
; 
1
H-NMR: (700 MHz, CDCl3)  7.99 (2H, d, J= 6.9, 
phenyl orto protons), 7.98 (2H, d, J= 6.5, phenyl orto protons), 7.52 (2H, t, J=7.3, phenyl para 
protons), 7.43 (2H, t, J=7.7, phenyl meta protons), 7.40 (2H, t, J=7.6, phenyl meta protons), 4.16 
(1H, dd, J= 9.2, 6.0), 4.10 (1H, dd, J= 8.2, 7.0), 3.89 (1H, m), 3.72 (2H, m), 2.66 (1H, ddd, J= 12.7, 
10.5, 5.4), 2.55 (1H, d, J= 16.9), 2.44 (1H, d, J= 16.9), 2.18 (1H, ddd, J= 12.3, 9.3, 8.2), 1.60 (6H, 
s, 2 x Me),1.58, 1.55, 1.36, 1.29, 1.14, 1.07 (3H each, s’s, 6xMe); 13C-NMR (175 MHz, CDCl3):  
212.7, 165.8, 165.7, 132.6, 132.4, 132.0, 131.6, 129.6 (two carbons), 129.4 (two carbons), 128.2 
(two carbons), 128.1 (two carbons), 101.7, 86.4, 85.9, 85.70, 85.68, 85.65, 84.3, 83.51, 83.46, 83.2, 
82.9, 77.8, 48.4, 35.1, 34.4, 31.8, 27.0, 26.86, 26.83, 26.81, 26.0, 24.6, 24.4, 22.82, 22.79, 22.74, 
22.2, 21.6, 20.1; HRMS (ESI) m/z calcd for C44H58NaO11 [M+Na]
+
 785.3877, found 785.3884. 
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Lactone 31: Oil; IR (neat): max 1773, 1711, 1288, 1071, 713 cm
-1
; 
1
H-NMR: (500 MHz, CDCl3)  
7.96 (2H, bd, J= 7.0, phenyl orto protons), 7.53 (H, bt, J= 7.4, phenyl para proton), 7.41 (2H, bt, J= 
7.5, phenyl meta protons), 4.25 (1H, dd, J=7.0, 7.0), 3.94 (1H, dd, J=9.0, 6.2), 3.88 (1H, dd, J=7.2, 
7.2), 3.78 (1H, dd, J= 9.4, 5.1), 2.80 (1H, ddd, J= 17.4, 10.1, 10.2), 2.47 (1H, ddd, J= 17.4, 10.6, 
3.5), 2.39 (1H, ddd, J= 13.9, 10.7, 3.5), 1.63, 1.58, 1.31, 1.22, 1.11 (3H each, s’s, 5XMe); 13C-NMR 
(100 MHz, CDCl3):  177.6, 165.7, 132.5, 131.9, 129.4 (two carbons), 128.2 (two carbons) 86.5, 
85.7, 85.2, 84.6, 84.0, 83.6, 83.4, 82.7, 35.0, 32.7, 29.8, 27.8, 27.3, 26.8, 26.6, 23.5, 23.3, 23.2, 
23.0, ,22.9, 21.3; HRMS (ESI) m/z calcd for C29H40NaO7 [M+Na]
+
 523.2672, found 523.2668. 
Lactone 32 (major isomer): Oil; IR (neat): max 1775, 1712, 1288, 713 cm
-1
; 
1
H-NMR: (500 MHz, 
CDCl3)  7.96 (2H, dd, J= 8.0, 1.0, phenyl orto protons), 7.52 (H, dddd, J= 7.4, 7.4, 1.2, 1.2, phenyl 
para proton), 7.42 (2H, bt, J= 7.8, phenyl meta protons), 4.36 (1H, dd, J=7.9, 6.1), 4.19 (1H, dd, 
J=7.0, 7.0), 3.95 (1H, dd, J=9.2, 6.1), 2.56 (1H, ddd, J= 17.7, 10.1, 6.3), 2.40 (1H, ddd, J= 17.5, 
10.3, 7.1), 2.32-2.24 (1H, m), 2.20-2.09 (2H, overlapped multiplets), 2.08-2.0 (1H, m), 1.95-1.96 
(2H, overlapped multiplets), 1.84-1.75 (1H, m), 1.61, 1.59, 1.20, 1.19 (3H each, s’s, 4xMe); 13C-
NMR (100 MHz, CDCl3):  177.7, 165.7, 132.5, 131.8, 129.4 (two carbons), 128.2 (two carbons), 
84.4, 84.3, 83.8 (two carbons), 83.1, 83.0, 34.3, 32.3, 28.7, 27.6, 26.6, 23.1 (two carbons), 22.9, 
22.6, 21.5; HRMS (ESI) m/z calcd for C24H32NaO6 [M+Na]
+
 439.2097, found 439.2106. 
Lactone 32 (minor isomer): Oil; IR (neat): max 1776, 1712, 1288, 714 cm
-1
; 
1
H-NMR: (400 MHz, 
CDCl3)  7.98 (2H, bd, J= 8.2, phenyl orto protons), 7.52 (H, bt, J= 7.0, phenyl para proton), 7.41 
(2H, bt, J= 7.5, phenyl meta protons), 4.38 (1H, dd, J=7.4, 4.8), 4.19 (1H, dd, J=9.3, 5.6), 3.85 (1H, 
dd, J=9.5, 5.8), 2.65 (1H, ddd, J= 17.2, 9.8, 6.8), 2.45 (1H, ddd, J= 17.1, 10.6, 6.3), 1.60 (6H s, 
2xMe), 1.19, 1.13 (3H each, s’s, 2xMe); 13C-NMR (100 MHz, CDCl3):  177.7 165.7, 132.4, 129.4 
(two carbons), 128.1 (two carbons), 87.0, 85.9, 84.8, 83.6, 83.5, 83.3, 34.6, 34.1, 28.6, 26.9, 26.5, 
24.5, 23.5, 22.9, 22.8, 21.6; HRMS (ESI) m/z calcd for C24H32NaO6 [M+Na]
+
 439.2097, found 
439.2100. 
-unsaturated aldehydes 
34a: Oil; IR (neat): max 1712, 1288, 712 cm
-1
; 
1
H-NMR: (500 MHz, CDCl3)  9.41 (1H, d, J= 7.8), 
7.98 (2H, d, J= 8.0, phenyl orto protons), 7.52 (H, bt, J= 7.8, phenyl para proton), 7.40 (2H, bt, J= 
8.0, phenyl meta protons), 6.88 (1H, d, J=15.6), 6.17 (1H, dd, J= 15.6, 7.8), 4.21 (1H, dd, J=6.8, 
6.8), 4.06 (1H, dd, J=6.8, 6.8), 1.62, 1.61, 1.37, 1.22 (3H each, s’s, 4XMe); HRMS (ESI) m/z calcd 
for C23H30NaO5 [M+Na]
+
 409.1991, found 409.1996. 
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34b: Oil; IR (neat): max 1712, 1288, 712 cm
-1
; 
1
H-NMR: (500 MHz, CDCl3)  9.58 (1H, d, J= 7.9), 
7.98 (2H, d, J= 8.2, phenyl orto protons), 7.52 (H, bt, J= 7.4, phenyl para proton), 7.41 (2H, bt, J= 
8.0, phenyl meta protons), 6.84 (1H, d, J=15.6), 6.27 (1H, dd, J= 15.6, 7.9), 4.23 (1H, dd, J=9.6, 
5.6), 3.94 (1H, dd, J=6.0, 6.0), 1.61 (6H, s, 2xMe), 1.42, 1.18 (3H each, s’s, 2XMe); HRMS (ESI) 
m/z calcd for C23H30NaO5 [M+Na]
+
 409.1991, found 409.1990. 
Acid 35: Oil; max 1744, 1715, 1283, 712 cm
-1
; 
1
H-NMR: (500 MHz, CDCl3)  7.97 (2H, bd, J= 
7.3, phenyl orto protons), 7.55 (H, bt, J= 7.3, phenyl para proton), 7.44 (2H, bt, J= 7.7, phenyl meta 
protons), 5.62 (1H, dd, J= 9.3, 3.1), 2.86 (1H, dd, J= 16.1, 3.2), 2.74 (1H, dd, J= 16.1, 9.4), 2.11 
(3H, s, acetate), 1.66, 1.65 (3H each, s’s, 2x Me); 3C-NMR (100 MHz, CDCl3):  175.2, 170.1, 
165.1, 133.0, 131.1, 129.5 (two carbons), 128.4 (two carbons), 82.4, 73.9, 34.9, 22.4, 21.7, 20.9; 
HRMS (ESI) m/z calcd for C15H18NaO6 [M+Na]
+
 317.1001, found 317.1009. 
2.4.6 Oxidation of 27 with PCC(cat.)/H5IO6 
To a suspension of H5IO6 (4 equiv., 78.8 mg, 0.35 mmol) in acetonitrile (1.5 mL) at 0°C was 
added 1.0 mol% PCC (87 L of a 0.01 M stock solution in acetonitrile) under vigorous stirring. 
After 5 min compound 27 (61 mg, 0.083 mmol) dissolved in acetonitrile (650 L) was added. After 
3h CH2Cl2 (1.5 mL) was added followed by ethanol (40 L) and taken to dryness. Filtration through 
a short pad of sodium thiosulphate adsorbed on silica
8
 (CHCl3-MeOH, 9:1) gave an oily product (50 
mg). Further elution with CHCl3-MeOH (8:2) gave a mixture of polar products (14 mg) that was no 
further studied. The first-eluted fraction was separated as above described for the analogous process 
with PCC/AcOH to give compounds 28 (20.6 mg, 40%), 29 (2.2 mg, 4%), 32 (1.4 mg, 5%), 33 (0.3 
mg, 1%). 
2.4.7 Oxidation of 45 with PCC/AcOH 
To a solution of 45 (21.8 mg, 0.025 mmol) in CH2Cl2 (2 mL) was added PCC (4 eq., 21.8 mg, 
0.10 mmol) and AcOH (60 eq., 1.52 mmol, 87 L) and the resulting mixture was refluxed for 13h. 
A saturated aqueous NaHCO3 solution was added and the organic phase was washed with water, 
dried and evaporated in vacuo to give a yellow oil. Filtration on a silica gel pad (eluent CHCl3-
MeOH, 9:1) afforded an oily product (14 mg). Further elution with CHCl3-MeOH (8:2) gave a 
mixture of polar products (9.0 mg) that was no further studied. The first-eluted fraction was 
separated by HPLC (250 x 4.6 mm column; flow: 1.0 mL/min; 1 mg/injection, hexane/EtOAc, 
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75:25) to give 46 (2.4 mg, 15%, tr = 30.5 min), 47 (1.6 mg, 10%, tr = 33.5 min) and 48 (1.1 mg, 
7%, tr = 10.0 min). 
Acid 46 (major isomer): Oil; IR (neat): max 1717, 1279, 1119, 710 cm
-1
; 
1
H-NMR: (400 MHz, 
CDCl3)  8.02 (4H, d, J =8.2, phenyl orto protons), 7.96 (4H, d, J =8.0, phenyl orto protons), 7.55-
7.45 (4H, m, phenyl para protons), 7.44-7.38 (8H, m, phenyl meta protons), 5.40 (1H, dd, J =9.7, 
3.1), 4.49 (1H, dd, J =8.5, 6.2), 4.44 (1H, dd, J =7.4, 7.4), 4.40-4.28 (4H, overlapped multplets), 
2.73 (1H, dd, J = 15.8, 3.0), 2.64 (1H, dd, J = 15.8, 9.8), 2.37 (1H, ddd, J = 12.6, 7.9, 6.0), 2.29-
2.19 (2H, m), 2.17-2.00 (2H, m), 1.57, 1.55, 1.45, 1.19 (3H each, s’s, 4x Me); 13C-NMR (100 MHz, 
CDCl3):  174.2, 173.4, 166.8, 166.6, 165.8, 165.6, 132.93, 132. 87, 132.7 (two carbons), 131.5, 
131.4, 130.26, 130.21, 129.6, 129.55, 129.50 (two carbons), 128.32 (three carbons), 128.27, 85.2, 
85.0, 83.9, 83.5, 83.3, 81.3, 75.0, 65.3, 65.0, 36.1, 35.7, 33.7, 31.6, 31.5, 26.9, 25.9, 24.1, 23.5, 
23.2, 22.7, 20.4, 20.2; HRMS (ESI) m/z calcd for C52H58NaO14 [M+Na]
+
 929.3724, found 
929.3736. 
Acid 47 (minor isomer): Oil; IR (neat): max 1714, 1277, 1113, 711 cm
-1
; 
1
H-NMR: (400 MHz, 
CDCl3)  8.04 (2H, bd, J =7.0, phenyl orto protons), 8.02 (2H, bd, J =5.5, phenyl orto protons), 
7.98 (4H, bd, J =8.0, phenyl orto protons), 7.53 (4H, m, phenyl para protons), 7.41 (8H, m, phenyl 
meta protons), 5.41 (1H, dd, J =6.1, 6.1), 4.64 (1H, dd, J =7.4, 7.4), 4.49-4.44 (5H, m), 2.63 (1H, 
dd, J = 15.7, 7.3), 2.56 (1H, dd, J = 15.8, 5.9), 2.44 (1H, bddd, J = 12.5, 5.5, 5.5), 1.64, 1.53, 1.44, 
1.28 (3H each, s’s, 4x Me); 13C-NMR (100 MHz, CDCl3):  172.9, 171.3, 167.2, 167.0, 165.8, 
165.7, 133.03, 132.98, 132.7, 132.6, 131.6, 131.4, 130.1 (two carbons) 129.64 (two carbons), 
129.57, 129.4, 128.34 (three carbons), 128.29, 85.3, 84.6, 84.3, 84.1, 83.9, 83.5, 74.9, 65.5, 65.3, 
36.5, 35.0, 33.4, 32.0, 31.1, 26.9, 26.3, 24.8, 24.4, 23.6, 23.2, 20.8, 20.6; HRMS (ESI) m/z calcd for 
C52H58NaO14 [M+Na]
+
 929.3724, found 929.3742. 
Dketone 48: Oil; IR (neat): max 1710, 1274, 1111, 710 cm
-1
; 
1
H-NMR: (200 MHz, CDCl3)  8.10-
7.91 (8H, m, phenyl orto protons), 7.62-7.32 (12H, m, phenyl meta and para protons), 7.54-7.25 
(6H, overlapped multiplets, 2 x THF and 2 x CH2O- protons), 1.63 (3H, s, 2 x Me), 1.37, 1.34 (3H 
each, s’s, 2 x Me); 13C-NMR (100 MHz, CDCl3):  214.0, 212.7, 166.5 (two carbons), 165.7 (two 
carbons), 132.8, 132.7, 131.6, 131.4, 130.35, 130.31, 129.55, 129.53, 129.48, 129,43, 128.35, 
128.31, 88.9, 88.7, 84.93, 84.92, 84.2, 83.4, 65.0 (two carbons), 35.2, 34.8, 32.3, 31.8, 30.8, 29.9, 
26.3 (two carbons), 24.2, 23.7, 23.55, 23.51, 20.6, 20.4; HRMS (ESI) m/z calcd for C52H58NaO12 
[M+Na]
+
 897.3826, found 897.3815. 
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2.4.8 Oxidation of 45 with PCC(cat.)/H5IO6 
To a suspension of H5IO6 (4 eq., 34.2 mg, 0.15 mmol) in acetonitrile (600 L) at 0°C was added 
1.0 mol% PCC (38 L of a 0.01 M stock solution in acetonitrile) under vigorous stirring. After 5 
min compound 45 (32.3 mg, 0.037 mmol) dissolved in acetonitrile (150 L) was added. After 2h a 
further 1% PCC was added and the mixture kept at 0°C for an additional 1h. Then CH2Cl2 (700 L) 
was added followed by ethanol (40 L) and taken to dryness. Filtration through a short pad of 
sodium thiosulphate adsorbed on silica gave an oily product (19 mg). Further elution with CHCl3-
MeOH (8:2) gave a mixture of polar products (3.2 mg) that was no further studied. The first-eluted 
fraction was separated by HPLC as above described for the analogous process with PCC/AcOH to 
give compounds 46 (10.0 mg, 30%), 47 (2.0 mg, 6%) and 48 (2.9 mg, 9%). 
2.4.9 Oxidation of 49 with PCC(cat.)/H5IO6 
To a suspension of H5IO6 (4 equiv., 35.4 mg, 0.15 mmol) in acetonitrile (600 L) at 0°C was 
added 2.0 mol% PCC (80 L of a 0.01 M stock solution in acetonitrile) under vigorous stirring. 
After 5 min compound 49 (10.4 mg, 0.039 mmol) dissolved in acetonitrile (150 L) was added. 
After 3.5h CH2Cl2 (750 L) was added followed by ethanol (40 L) and taken to dryness. Filtration 
through a short pad of sodium thiosulphate adsorbed on silica gave almost pure 50 as an oil. HPLC 
(250 x 4.6 mm column; flow: 1.0 mL/min; CHCL3/MeOH 98:2, tr = 4.0 min) gave pure 50 (4.3 mg, 
45%). 
50: Oil; IR (neat): max 1774, 1717 cm
-1
; 
1
H-NMR: (500 mhz, CDCl3)  3.01-2.92 (2H, m), 2.92-
2.82 (2H, m), 2.65-2.53 (6H, m), 2.113-2.04 (2H, m), 1.55 (6H, s, 2x Me); 
13
C-NMR (125 MHz, 
CDCl3):  209.2, 175.9, 89.2, 31.3, 31.0, 28.2, 23.6; HRMS (ESI) m/z calcd for C14H18NaO6 
[M+Na]
+
 305.1001, found 305.1008. 
2.4.10 Synthesis of mono-THF 51, 54, 56, 59, 62, 64 
The title compounds were obtained by benzoylation of the corresponding THF diols in turn 
synthesized as previously described.
5h,5k, 21,23
 Purification of these compounds was achieved by 
column chromatography with the following eluent: 51 (40/70 petroleum ether-ethyl ether, 9:1), 54 
(40/70) petroleum ether-ethyl ether, 1:1), 56 (40/70 petroleum ether-ethyl ether, 6:4), 59 (40/70 
petroleum ether-ethyl ether, 1:1), 62 (40/70 petroleum ether-ethyl ether, 8:2), 64 (hexane-EtOAc, 
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8:2). 
51: Oil. IR (neat): max = 1719, 1281, 1111, 709 cm
-1
. 
1
H NMR: (200 MHz, CDCl3):  = 8.13 – 7.88 
(6H, m), 7.68 -. 7.28 (9H, m), 5.65 (1H, dd, J = 2.9, 8.8 Hz), 4.80 (1H, dd, J = 2.9, 12.2 Hz), 4.59 
(1H, dd, J = 12.2, 8.8 Hz), 4.33 (1H, dd, J = 6.3 Hz), 2.24 – 1.88 (4H, m), 1.67 (3H, s), 1.64 (3H, s), 
1.43 (3H, s) ppm. 
13
C NMR (50 MHz, CDCl3):  166.4, 166.0, 165.6, 133.0, 132.9, 132.5, 131.6, 
129.8, 129.6, 129.5, 129.3, 128.4, 128.3, 128.2, 83.5, 83.0, 82.8, 76.2, 63.9, 34.6, 26.9, 23.6, 23.2, 
21.3 ppm. HRMS (ESI) m/z calcd for C31H32NaO7 [M+Na]
+
 539.2046, found 539.2038. 
54: Oil. IR (neat): max = 1740, 1721, 1275, 712 cm
-1
. 
1
H NMR (200 MHz, CDCl3):  = 8.00 (4H, 
m), 7.66 – 7.30 (6H, m), 5.46 (1H, dd, J = 2.6, 8.8 Hz), 4.78 – 4.20 (5H, overlapped multiplets), 
2.02 (3H, s), 1.96 (3H, s), 1.67 (3H, s), 1.36 (3H, s) ppm. 
13
C NMR (50 MHz, CDCl3):  = 170.9, 
170.5, 166.1, 165.6, 133.1, 132.8, 131.0, 129.7, 129.6, 128.5, 128.3, 83.2, 83.0, 80.4, 76.1, 65.2, 
63.3, 34.5, 26.8, 23.5, 20.8, 18.9 ppm. HRMS (ESI) m/z calcd for C28H32NaO9 [M+Na]
+
 535.1944, 
found 535.1963. 
56: Oil. IR (neat): max = 1713, 1285, 1113, 710 cm
-1
. 
1
H NMR (200 MHz, CDCl3):  = 8.07 (2H, d, 
J = 8.5 Hz), 7.96 (2H, d, J = 7.1 Hz), 7.64-7.29 (6H, m), 5.20 (1H, s), 4.33 (1H, dd, J = 6.9, 7.7 Hz), 
3.72 (3H, s), 2.56-2.83 (1H, m), 2.19-1.75 (3H, m), 1.61 (3H, s), 1.59 (3H, s), 1.46 (3H, s) ppm.
 13
C 
NMR (50 MHz, CDCl3):  = 168.6, 166.0, 165.7, 133.3, 132.5, 131.6, 129.8, 129.4, 128.4, 128.2, 
83.5, 83.3, 82.8, 78.0, 52.2, 34.3, 26.5, 23.4, 23.0, 21.3 ppm. HRMS (ESI) m/z calcd for 
C25H28NaO7 [M+Na]
+
 463.1733, found 463.1717. 
59: Oil. IR (neat): max = 1712, 1278, 1109, 708 cm
-1
. 
1
H NMR (200 MHz, CDCl3):  = 8.07 (2H, d, 
J = 7.7 Hz), 7.96 (4H, d, J = 8.2 Hz), 7.64–7.30 (9H, m), 5.65 (1H, dd, J = 2.7, 8.6 Hz), 4.75 (1H, 
dd, J = 2.8, 11.9 Hz), 4.55 (1H, dd, J = 8.6, 11.9 Hz), 4.32 (1H, dd, J = 6.6, 8.1 Hz), 2.27–1.68 (4H, 
m), 1.60 (6H, s), 1.45 (3H, s) ppm. 
13
C NMR (50 MHz, CDCl3):  166.5, 166.0, 165.7, 133.0, 
132.4, 131.9, 130.1, 129.7, 129.6, 129.4, 128.4, 128.3, 128.2, 85.5, 83.0, 76.1, 64.0, 34.8, 26.7, 
24.1, 22.6, 21.5 ppm. HRMS (ESI) m/z calcd for C31H32NaO7 [M+Na]
+
 539.2046, found 539.2055. 
62: Oil. IR (neat): max = 1735, 1716, 1289, 712 cm
-1
. 
1
H NMR (200 MHz, CDCl3):  = 7.96–7.87 
(2H, d, J = 6.9 Hz), 7.59–7.35 (3H, m), 5.04 (2H, AB system, J = 17.8 Hz), 4.20 (1H, dd, J = 7.18 
Hz), 2.54–2.39 (1H, m), 2.08 (3H, s), 1.71 (3H, s), 1.61 (3H, s), 1.41 (3H, s) ppm. 13C NMR (50 
MHz, CDCl3):  = 206.5, 170.2, 165.7, 132.7, 131.4, 129.3, 128.4, 88.5, 85.9, 82.7, 65.7, 35.4, 26.0, 
23.6, 22.8, 22.6, 20.4 ppm. HRMS (ESI) m/z calcd for C19H24NaO6 [M+Na]
+
 371.1471, found 
371.1489. 
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64: Oil. IR (neat): max = 1715, 1268, 709 cm
-1
. 
1
H NMR (500 MHz, CDCl3):  = 8.05 (4H, bd, J = 
8.4 Hz), 7.55 (2H, bt, J = 7.4 Hz), 7.42 (4H, bt, J = 7.8 Hz), 4.42 (2H, overlapped multiplets), 4.39-
4.32 (4H, overlapped multiplets), 2.12 (2H, m), 1.89 (2H, m) ppm. 
13
C NMR (50 MHz, CDCl3):  = 
166.4, 132.9, 130.0, 129.6, 128.3, 77.5, 66.6, 27.8 ppm. HRMS (ESI) m/z calcd for C20H20NaO5 
[M+Na]
+
 363.1208, found 363.1220. 
2.4.11 Synthesis of 60 
To compound 51 (106 mg, 0.20 mmol) dissolved in MeOH (5 mL) was added K2CO3 (excess) 
and the mixture stirred at r. t. for 1.5 h. Water (1 mL) was added followed by acetic acid up to 
neutrality. The mixture was taken to dryness in vacuo and the solid partitioned between a sat. 
NaHCO3 solution and EtOAc. The organic phase was washed with water, dried and evaporated to 
give 65.9 mg of an oily product.  
To the crude obtained as above, dissolved in CH2Cl2 (5 mL), was added NaIO4 supported on wet 
silica (2.4 equiv., 0.47 mmol, 746 mg; 0.64 mmol/g) and the mixture was stirred fro 30 min. at r.t. 
The reaction mixture was filtered, the solid was thoroughly washed with CH2Cl2 and the filtrate was 
taken to dryness to give an oily product. 
The above oil (55.1 mg) dissolved in EtOH (4 mL) sodium borohydride (two spatula tips) was 
added. After 30 min. acetic acid was dropwise added until no gas evolution was observed. The 
mixture was filtered and the filtrate taken to dryness to give an oily product. 
The above oil (33.0 mg, 0.12 mmol) was dissolved in pyridine (500 L) and benzoyl chloride 
(1.1 equiv., 0.13  mmol, 15 L) was added. After 1 h water (100 L) was added and the mixture 
was taken to dryness. Purification by preparative TLC (hexane/EtOAc, 1:1) yielded pure 20 (33.0 
mg, 43% over four steps). 
60: Oil. IR (neat): max = 1712, 1277, 1112, 709 cm
-1
. 
1
H NMR (200 MHz, CDCl3):  = 8.06 (2H, d, 
J = 7.0 Hz), 7.98 (2H, d, J = 6.9 Hz), 7.61-7.33 (6H, overlapped multiplets), 4.38 (1H, d, J = 11.1 
Hz), 4.31 (1H, m), 4.20 (1H, d, J = 11.1), 2.20-1.73 (4H, m), 1.64 (3H, s), 1.61 (3H, s), 1.38 (3H, s) 
ppm. 
13
CNMR (50 MHz, CDCl3):  = 166.4, 165.7, 133.0, 132.5, 131.7, 130.1, 129.5, 129.4, 128.3, 
128.2, 83.8, 83.4, 81.8, 69.7, 34.5, 26.8, 24.1, 23.0, 21.4 ppm. HRMS (ESI) m/z calcd for 
C23H26NaO5 [M+Na]
+
 405.1678, found 405.1670. 
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2.4.12 General reaction procedure for the oxidation of mono-THF compounds 51, 54, 56, 59, 
60, 62, 64 
To a suspension of H5IO6 (4 eq.) in acetonitrile at r.t. was added 5.0 mol % PCC (from a 0.01 M 
stock solution in acetonitrile) under vigorous stirring. After 5 min. the mono-THF compound (1 eq.) 
dissolved in acetonitrile was added. The overall volume of acetonitrile was such that the final 
concentration of the solution was 0.05 M. After complete consumption of the starting material (TLC 
control, usually 45-60 min), ethanol (excess) was added and stirring continued until the colour of 
the solution turned from yellow to green. Then silica (excess) was added and the solvent evaporated 
in vacuo to give a fine powder that was loaded on the top of a silica gel column. Elution with 
CHCl3-MeOH (9:1) allowed recovery of the acid that resulted pure enough for successive spectral 
studies and/or synthetic steps. 
Compound 51 (112.0 mg, 0.22 mmol) was subjected to the standard oxidative procedure to give 
the crude acid as a yellow oil which was purified by column chromatography (CH2Cl2-MeOH, 95: 
5) to yield 52 (99 mg, 80%) and lactone 53 (8.0 mg, 10%) as oils. 
52: Oil. IR (neat): max = 1717, 1282, 1107, 709 cm
-1
. 
1
H NMR: (200 MHz, CDCl3):  = 8.00 (2H, 
d, J = 7.7 Hz), 7.87 (4H, m), 7.57-7.28 (9H, m), 5.89 (1H, dd, J = 7.8, 3.1 Hz), 4.74 (1H, dd, J = 
3.1, 12.2 Hz), 4.45 (1H, dd, J = 7.8, 12.2 Hz), 3.24 (2H, AB system, J = 15.6 Hz), 1.86 (3H, s), 1.71 
(6H, s) ppm. 
 13
C NMR (50 MHz, CDCl3):  = 174.1, 171.1, 166.0, 165.5, 165.2, 133.15, 133.12, 
133.0, 129.8, 129.5, 129.3, 128.3, 82.0, 79.0, 74.6, 62.8, 39.2, 24.55, 24.46, 21.3 ppm. HRMS (ESI) 
m/z calcd for C31H30NaO10 [M+Na]
+
 585.1737, found 585.1723. 
53: Oil. IR (neat): max = 1778, 1721, 1259, 709 cm
-1
. 
1
H NMR (200 MHz, CDCl3):  = 8.04 (2H, d, 
J = 7.9 Hz), 7.92 (2H, d, J = 8.0 Hz), 7.67-7.31 (6H, m), 5.66 (1H, dd, J = 8.3, 3.2 Hz), 4.85 (1H, 
dd, J = 12.1, 3.2 Hz), 4.52 (1H, dd, J = 12.1, 8.3 Hz), 2.61 (2H, t, J=7.6 Hz), 2.37 (1H, ddd, J = 
13.1, 7.6, 7.6 Hz), 2.08 (1H, ddd, J=13.1, 9.5, 9.5 Hz), 1.66 (3H, s) ppm. 
13
C NMR (50 MHz, 
CDCl3):  = 176.2, 166.2, 165.5, 133.7, 133.2, 129.9, 129.6, 129.4, 128.9, 128.7, 128.4, 85.2, 75.6, 
62.8, 31.5, 28.9, 24.2 ppm. HRMS (ESI) m/z calcd for C21H20NaO6 [M+Na]
+
 391.1158, found 
391.1167. 
Compound 54 (13.5 mg, 0.026 mmol) was subjected to the standard oxidative procedure to give 
the crude acid as an oil which was purified by column chromatography (CH2Cl2-MeOH, 95: 5) to 
yield 15 (9.4 mg, 65%) as an oil. 
55: Oil. IR (neat): max = 1721, 1273, 1226, 711 cm
-1
. 
1
H NMR (200 MHz, CDCl3):  = 8.0 (4H, 
Chapter 2 
 
53 
 
m), 7.65-7.29 (6H, m), 5.75 (1H, dd, J = 7.8, 2.9 Hz), 4.67-4.49 (3H, m), 4.21 (1H, dd, J = 12.1, 7.8 
Hz), 3.2 (2H, AB system, J = 15.7 Hz), 2.09 (3H, s), 1.94 (3H, s), 1.85 (3H, s), 1.73 (3H, s) ppm. 
13
C NMR (50 MHz, CDCl3):  = 172.4, 172.3, 170.5, 170.3, 165.24, 165.17, 82.8, 79.4, 74.3, 66.0, 
62.2, 38.9, 21.1, 20.71, 20.68, 19.7 ppm. HRMS (ESI) m/z calcd for C28H30NaO12 [M+Na]
+
 
581.1635, found 581.1651. 
Compound 56 (23.8 mg, 0.050 mmol) was subjected to the standard oxidative procedure to give 
the crude acid as an oil which was purified by column chromatography (CH2Cl2 to CH2Cl2-MeOH, 
95: 5) to yield 57 (7.3 mg, 30%) and lactone 58 (6.4 mg, 45%) as oils. 
57: Oil. IR (neat): max = 1719, 1287, 1110, 712 cm
-1
. 
1
H NMR (400 MHz, CDCl3):  = 8.02-7.89 
(4H, m), 7.61-7.44 (2H, m), 7.44-7.29 (4H, m), 5.69 (1H, s), 3.64 (3H, s), 3.42 (1H, d, J = 16.2 Hz), 
3.27 (1H, d, J = 16.2 Hz), 1.91 (3H, s), 1.65 (3H, s), 1.63 (3H, s) ppm. 
13
C NMR (100 MHz, 
CDCl3):  = 171.4, 171.0, 167.4, 165.4, 165.2, 133.4, 133.1, 129.8, 129.6, 128.4 128.2, 81.1, 78.8, 
75.8, 52.4, 39.0, 24.6, 24.1, 20.7 ppm. HRMS (ESI) m/z calcd for C25H26NaO10 [M+Na]
+
 509.1424, 
found 509.1418. 
58: Oil. IR (neat): max = 1781, 1726, 1271, 1112, 714 cm
-1
. 
1
H NMR (200 MHz, CDCl3):  = 8.06, 
(2H, d, J = 7.0 Hz), 7.63 (1H, t, J = 6.5 Hz), 7.48 (2H, t, J = 7.7 Hz), 5.26 (1H, s), 3.80 (3H, s), 2.76 
– 2.52 (3H, m), 2.20-2.01 (1H, m), 1.65 (3H, s) ppm. 13C NMR (50 MHz, CDCl3):  = 175.6, 167.3, 
165.5, 133,8, 129.9, 128.6, 84.3, 77.2, 52.9, 30.9, 28.7, 23.8 ppm. HRMS (ESI) m/z calcd for 
C15H16NaO6 [M+Na]
+
 315.0845, found 315.0853. 
Compound 59 (9.7 mg, 0.019 mmol) was subjected to the standard oxidative procedure to give 
the crude acid as an oil which was purified by column chromatography (CH2Cl2-MeOH, 95: 5) to 
yield 52 (7.3 mg, 70%). 
Compound 60 (31.0 mg, 0.081 mmol) was subjected to the standard oxidative procedure to give 
the crude acid as an oil which was purified by column chromatography (CH2Cl2-MeOH, 95: 5) to 
yield 61 (21.5 mg, 65%) as an oil. 
61: Oil. IR (neat): max = 1716, 1284, 1109, 710 cm
-1
. 
1
H NMR (200 MHz, CDCl3)  = 7.94 (4H, 
m), 7.60-7.44 (2H, m), 7.42-7.28 (4H, m), 4.60 (2H, AB system, J = 11.7 Hz), 3.12 (2H, bs), 1.71 
(3H, s), 1.63 (3H,s) ppm. 
13
C NMR (50 MHz, CDCl3):  = 174.9, 171.3, 165.8, 165.4, 133.05, 
133.02, 129.8, 129.65, 129.60, 129.5, 128.35, 128.3, 80.4, 78.9, 67.5, 39.9, 24.5, 21.0 ppm. HRMS 
(ESI) m/z calcd for C23H24NaO8 [M+Na]
+
 451.1369, found 451.1360. 
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Compound 62 (10.1 mg, 0.029 mmol) was subjected to the standard oxidative procedure to give 
the crude acid as an oil which was purified by HPLC (hexane-EtOAc, 7:3) to yield 1,4-diketone 63 
(5.3 mg, 70%), as an oil. 
63: Oil. IR (neat): max = 1715, 1287, 714 cm
-1
. 
1
H NMR (200 MHz, CDCl3)  = 8.04 (2H, d, J = 
8.3 Hz), 7.59 (1H, t, J = 7.2 Hz), 7.45 (2H, t, J = 7.7 Hz), 2.78 (4H, m), 2.19 (3H, s), 1.65 (6H, s) 
ppm. 
13
C NMR (50 MHz, CDCl3):  = 207.8, 207.3, 165.9, 133.4, 129.8, 128.4, 84.2, 37.0, 30.1, 
30.0, 23,8 ppm. HRMS (ESI) m/z calcd for C15H18NaO4 [M+Na]
+
 285.1103, found 285.1109. 
Compound 64 (107.0 mg, 0.313 mmol) was subjected to the standard oxidative procedure at 0°C, 
using a 2 mol % of PCC, to give 1,4-diketone 65 (109 mg, 98%). 
65: Amorphous solid. IR (neat): max = 1713, 1275, 715 cm
-1
. 
1
H NMR (200 MHz, CDCl3):  = 
8.09 (4H, d, J = 7.2 Hz), 7.58 (2H, t, J = 7.5 Hz), 7.45 (4H, t, J = 7.7 Hz), 4.95 (4H, s), 2.87 (4H, s) 
ppm. 
13
C NMR (50 MHz, CDCl3):  = 202.7, 165.8, 133.5, 129.9, 129.0, 128.4, 68.3, 32.0 ppm. 
HRMS (ESI) m/z calcd for C20H18NaO6 [M+Na]
+
 377.1001, found 377.1015. 
2.4.13 Synthesis of umbelactone 
Trihydroxiacid 75: To acid 52 (118.1 mg, 0.21 mmol) dissolved in MeOH (5 mL) was added 
K2CO3 (excess) and the mixture stirred at r. t. for 2.5 h. Water (1 mL) was added followed by acetic 
acid up to neutrality. The mixture was taken to dryness in vacuo and the solid partitioned between a 
sat. NaHCO3 solution and EtOAc. The organic phase was washed with water, dried and evaporated 
to give 31.2 mg (90%) of 75 that was used in the next step without further purification. 
75: 
1
H-NMR (500 MHz, CD3OD):  = 3.78 (1H, dd, J =10.9, 2.5), 3.58 (1H, dd, J =10.9, 7.9 Hz), 
3.53 (1H, dd, J =7.9, 2.5 Hz), 2.49 (1H, d, J =14.9 Hz), 2.53 (1H, d, J =14.9 Hz), 1.36 (3H, s) ppm. 
13
C NMR (125 MHz, CD3OD):  = 180.6, 79.0, 73.5, 63.9, 45.6, 24.7 ppm. HRMS (ESI) m/z calcd 
for C6H12NaO5 [M+Na]
+
 187.0582, found 187.0590. 
Dihydroxylactone 77: To Trihydroxiacid 75 (30.0 mg, 0.18 mmol) dissolved in MeOH (4 mL) was 
added axcess CH2N2 in Et2O until a yellow colour persisted. The mixture was stirred for further 10 
min. and then the excess of CH2N2 was destroyed by dropwise addition of acetic acid until the 
solution became colourless. The mixture was taken to dryness to give an oil which was purified by 
column chromatography (CH2Cl2-MeOH, 9:1) to yield lactone 77 (23.5 mg, 90%) as a clear oil. 
77: Oil. IR (neat): max = 3408, 1771 cm
-1
. 
1
H NMR (200 MHz, CDCl3):  = 4.30 (1H, dd, J = 6.0, 
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4.4 Hz), 3.86 (2H, m), 2.77 (1H, d, J = 17.2 Hz), 2.50 (1H, d, J = 17.2 Hz), 1.44 (3H, s) ppm.
13
C 
NMR (50 MHz, CDCl3):  = 177.9, 90.1, 75.7, 61.0, 45.6, 24.5 ppm. HRMS (ESI) m/z calcd for 
C6H10NaO4 [M+Na]
+
 169.0477, found 169.0472. 
Silylated lactone 78: To lactone 77 (21.3 mg, 0.14 mmol), dissolved in DMF (300 L), were added 
imidazole (3.0 equiv., 28.6 mg, 0.42 mmol) and tetr-butyldimethylsilyl chloride (1.5 equiv., 31.5 
mg, 0.21 mmol) and the mixture was stirred for 2.5 h at r.t.. Then MeOH (500 L) was added and 
stirring continued for 30 min. The reaction mixture was concentrated onto silica and purified by 
column chromatography (hexane-EtOAc, 1:1) to yield compound 78 (34.9 mg, 96%) as a clear oil. 
78: Oil. IR (neat): max = 3447, 1782 cm
-1
. 
1
H NMR (200 MHz, CDCl3):  = 4.19 (1H, dd, J = 3.8, 
2.8 Hz), 4.12 (1H, dd, J = 11.8, 2.8 Hz), 4.02 (1H, dd, J = 11.8, 3.8 Hz), 3.66 (1H, bs), 2.73 (1H, d, 
J = 17.6 Hz), 2.57 (1H, d, J = 17.6 Hz), 1.49 (3H, s), 0.90 (9H, s), 0.12 (6H, s) ppm. 
13
C NMR (50 
MHz, CDCl3):  = 174.7, 85.5, 75.4, 61.8, 44.9, 26.7, 25.7, 18.1, -5.6, -5.7 ppm. HRMS (ESI) m/z 
calcd for C12H24NaO4Si [M+Na]
+
 283.1342, found 283.1339. 
Unsaturated lactone 79: To lactone 78 (30.0 mg, 0.11 mmol), dissolved in pyridine (500 L), was 
added thionyl chloride (5 equiv., 0.55 mmol, 40 L, ), and the mixture was stirred at 0°C for 30 
min. Water (500 L) was added and the reaction mixture was evaporated in vacuo to give an oily 
product. Column chromatography (hexane-EtOAc, 8:2) yielded compound 79 (25.3 mg, 95%) as a 
clear oil. 
79: Oil. IR (neat): max = 1759, 1132, 837, 778 cm
-1
. 
1
H NMR (500 MHz, CDCl3):  = 5.83 (1H, 
bs), 4.82 (1H, bs), 3.94 (1H, dd, J =11.3, 3.7 Hz), 3.90 (1H, dd, J =11.3, 3.5 Hz), 2.10 (3H, s), 0,85 
(9H, s), 0.06 (3H, s), 0.05 (3H, s) ppm. 
13
C NMR (125 MHz, CDCl3):  = 173.2, 166.7, 118.1, 84.7, 
61.7, 25.7, 18.1, 14.1, -5.5, -5.6 ppm. HRMS (ESI) m/z calcd for C12H22NaO3Si [M+Na]
+
 265.1236, 
found 265.1244. 
Umbelactone 80: To lactone 79 (20.2 mg, 0.083 mmol), dissolved in dry THF (1 mL), Et3N·3HF 
(20 eq., 270 L) was added and the mixture stirred for 2.5 h at r.t. Et3N (500 L) was added and the 
mixture taken to dryness. The residue was co-evaporated with Et3N (2x500 L) and MeOH (3x 500 
L) and evaporated to give an oil which was purified by column chromatography (EtOAc) to yield 
umbelactone 80 (9.8 mg, 92%) as a clear oil. 
80: Oil. IR (neat): max = 3404, 1727, 1050 cm
-1
. 
1
H NMR (200 MHz, CDCl3):  = 5.89 (1H, bs), 
4.91 (1H, bs), 4.07 (1H, dd, J = 2.9, 12.7 Hz), 3.77 (1H, dd, J = 12.7, 3.9 Hz), 2.11 (3H, s) ppm. 
13
C 
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NMR (50 MHz, CDCl3):  = 172.8, 165.8, 118.3, 85.0, 61.5, 14.0 ppm. HRMS (ESI) m/z calcd for 
C6H8NaO3 [M+Na]
+
 151.0371, found 151.0375. 
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Chapter 3 
A general synthesis of bis--acyloxy 1,4- and 1,5-diketones 
through catalytic oxidative opening of acylated THF and THP  
3.1.  Introduction 
-Acyloxy ketones are important intermediates in organic synthesis, and their structural motif is 
found in a variety of natural products (e.g. taxol) and pharmaceutical agents. They can be seen as 
protected-hydroxy ketones, themselves structural subunits of several active natural substances 
and useful synthetic building blocks.
1 
The keen interest of synthetic organic chemists in -acyloxy ketones is demonstrated by the 
number of procedures that have been developed to obtain these substances.
2
 Generally, their 
synthesis features the introduction of the acyloxy group  to the ketone functional group. Recently, 
various asymmetric -oxybenzoylation methods have been reported.3 A thallium promoted 
preparation of -formyloxy ketones is also known.2f However, despite the potential uses of the 
products in organic synthesis, to the best of our knowledge, no general method for the synthesis of 
bis--acyloxy diketones has been developed to date, and the chemistry of these compounds and that 
of the corresponding free bis-ketols is still largely unexplored.
4 
Recent work in our laboratory has focused on the catalytic use of chlorochromatoperiodate (CCP 
for short, Scheme 1), generated by the condensation of PCC and periodic acid,
5
 as a powerful 
reagent capable of oxidising THF-containing compounds of various structural complexity
6
 (for a 
deeper insight see sections 1.3, 2.2.6 and 2.2.7). In a single case, we observed that the oxidative 
opening of a 2,5-bis-benzoyloxymethyl THF compound (1, Scheme 1) led to a bis--benzoyloxy 
1,4-diketone 2 in an excellent yield. 
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Scheme 1. Oxidative THF opening under previous conditions.
6
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This result was particularly interesting, since it suggested that the THF ring and possibly other 
ether rings, flanked by acylated hydroxymethyl groups, could be seen as masked bis--acyloxy 
diketones. With the above result in mind, we envisaged that 1,5- and 1,6-dienes could be 
transformed into bis--acyloxy 1,4- and 1,5-diketones through a short sequence consisting of 
transition metal-mediated oxidative cyclization of the diene
7
 to give THF or THP diols, followed by 
hydroxyl acylation and CCP-catalysed opening of the ether ring (Scheme 2).  
Since formation of the two ketone functionalities occurs at the ether carbons, the projected 
sequence should allow the bis-ketoacyloxylation of the starting diene to occur regioselectively, 
which is hardly achievable in a direct way. In a previous investigation by Smith III and 
Scarborough,
8
 the system RuO2 (cat.)/NaIO4 was used to accomplish the transformation of 
unfunctionalised THF or THP ring, mostly to give lactones. In a single case, a 2,5-disubstituted 
THF was converted into a 1,4-diketone, but the process required long reaction times (typically 24) 
and there were no chiral centres adjacent to the reaction centre. In this chapter we report the 
accomplishment of the above idea and the use of some of the synthesized 1,5-diketones to obtain 
six-membered nitrogen heterocycles.  
OCOROCOR
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Oxidative cleavage 
of the ether ring
 
Scheme 2. Projected general synthesis of bis--acyloxy diketones from dienes. 
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3.2. Results and Discussion 
To test the substrate scope of the projected transformation, a range of tetrahydrofuran and 
tetrahydropyran diols were synthesised mostly through well-established ruthenium
9
 or osmium
10
-
catalysed oxidative cyclization of suitable 1,5- and 1,6-dienes. The diols were then acylated (in one 
case tosylated) and subjected to our oxidative procedure (Table 1). 
Table 1. CCP-catalyzed oxidative opening of protected 2,5-disubstituted THF and 2,6-disubstituted 
THP diols.
[a]
 
Entry Substrate Product Yield (%)
[c]
 
1
[a] 
  
 
 1 (PG=Bz) 2 97 
2 3 (PG=Ac) 4 80 
3
[b] 
5 (PG=Ts) 6 85 
4 
  
74 
5 
  
61 
6 
  
75 
7 
  
85 
8 
  
95 
9 
  
83 
10 
 
 
78 
11 
 
 
26
[d] 
[a] Reagents and conditions. THF oxidations: 0.05 M substrate in CH3CN, 2 mol 
% PCC, 3.2 eq. H5IO6, 30-40 min, rt. THP oxidations: 0.05 M substrate in 
CH3CN, 4 mol % PCC, 4 eq. H5IO6, 6-8 h, rt. [b] This process required 24 h. [c] 
Isolated yields. [d] Isolated HPLC yield. 
Optimization of the oxidative protocol was carried out with THF 1 and THP 13 as model 
compounds. In particular, we found that the oxidation of 1 (entry 1, Table 1) proceeded in excellent 
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yields and short reaction times with 2 mol % of PCC, even reducing the amount of the co-oxidant to 
3 equiv. However, the opening of the THP ring of 13 proceeded very slowly or the reaction was 
incomplete under these conditions. A screening of the reaction conditions for this substrate showed 
that the best results were obtained with 4 mol % of catalyst and 4 equiv. of periodic acid. 
Oxidation of all the other substrates was then carried out under optimized conditions. As 
summarised in Table 1 both THF and THP-derivatives reacted well to give the expected diketones 
in generally good to excellent yields.
11
 The process was shown to be tolerant of various substitution 
patterns and of structural complexity in the substrate. Even bicyclic THF 11 (entry 6) gave a good 
yield of the corresponding diketone 12. Isomeric trans  and cis
9d
 THPs 15 and 17, respectively, 
gave the same product 16 in comparable yields. In an attempt to further expand the utility of this 
reaction, morpholine derivative 20 (entry 11, Scheme 3) was oxidised. However, a more complex 
reactivity pattern resulted in this case. The expected diketone 21 was obtained, albeit in a 
diminished 26% yield (HPLC)
12
 along with a non-negligible amount of by-products 22 (18%) and 
23 (12%). We believe that the Achilles’ heel of this substrate is the double bond character of the 
benzamide group, which favours the formation of the unsaturated morpholine intermediate 24, 
which is then oxidatively cleaved by CCP itself (Scheme 3).
13
 Presumably that higher yields of 21 
could be obtained by tuning the nitrogen-protecting group in 20. As can be seen, benzoate (entry 1), 
acetate, tosylate (entries 2 and 3) and amide functions (entry 11) were compatible with the ether-
cleavage reaction conditions. 
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Scheme 3. Oxidation of a morpholine-protected substrate. Reaction conditions as in Table 1 
An important aspect of the above process that must be addressed concernes the fate of the 
potentially epimerizable chiral centers adjacent to the newly-formed ketone functionalities in 
compounds such as 8, 10 and 12. Considering the oxidation of 11, NMR spectroscopic analysis of 
the by-products of the process ruled out the presence of stereoisomers of diketone 12. In addition, 
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an X-ray diffraction analysis of this compound (Figure 1)
14
 was carried out, and the results showed 
that the relative stereochemistry of the THF precursor 11 had been preserved in 12. This suggests 
that the synthesis of chiral, acyclic bis--acyloxy 1,4-diketones such as 8 and 10 is feasible, given 
the easy access to chiral THF-dimethanol substances such as 7 or 9 according to the OsO4-catalyzed 
protocol developed by Donohoe and Butterworth.
15
 
 
Figure 1. ORTEP drawing of diketone 12. Ellipsoids are drawn at 30% probability level. 
To test our procedure on a more elaborated substrate, acetylated and benzoylated cis-
reticulatacins 25 and 26, respectively were oxidised (Scheme 4).
16,17
 cis-Reticulatacin belongs to the 
Annonaceous acetogenins class, a group of plant-derived metabolites having a wide array of 
biological properties such as antitumor, immunosuppressive, antimicrobial and insecticidal 
activities.
18
 Several syntheses of some members of this group as well as preparation of analogues 
have been reported.
19
 We envisaged that our process could be used to cleave the THF ring in this 
compound to obtain non-THF analogues such as recently synthesized dihydro-coibin
20
 or other 
derivatives thereof. 
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Scheme 4. Oxidation of bis-acylated cis-reticulatacin. 
Indeed, reaction of 25 and 26 under slightly modified conditions gave the expected reticulatacin-
derived diketones 27 and 28, respectively, (Scheme 4) though in lower yields (30-40%).
 
Although 
the structures of the by-products (HPLC separation) of this process were not thoroughly 
investigated, 
1
H NMR spectroscopic data showed that they all incorporated the terminal unsaturated 
lactone functionality (characteristic proton signals at ca. 5 and 7 ppm) which indicates that even this 
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moiety is tolerant to the oxidising conditions. This transformation also highlights that the method 
may be useful to prepare analogues of a variety of biologically active natural substances, where 
saturated ether rings of various sizes are often flanked by hydroxyl groups. 
It is well known
1b,2
 that the -oxygenated carbonyl groups are susceptible of several 
transformations. The presence in the same molecule of two of these structural subunits further 
increases the synthetic utility of these compounds. Among the various conceivable synthetic uses of 
the synthesized substances, we planned to probe the transformation of the 1,5-dicarbonyl 
compounds into the corresponding pyridinedimethanol derivatives
21,22
 (Scheme 5). These 
substances have notable coordination properties, and belong to the oxido pincer ligands class.
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Scheme 5. Pyridine and pyrazine diol synthesis from bis -benzoyloxy-1,5-diketones. a) NH4OAc 
(7 eq.), AcOH (6.5 eq.), dry MeOH, 24 h rt and 48 h 55 °C; b) NH2OH·HCl (3.5 eq.), dry 
EtOH, 6 h-15 h, reflux; c) 10 mol % K2CO3, MeOH, rt, 30 min; d) MCPBA (1.2 eq.), 
CHCl3, rt, 90 min. 
Reaction of 16 with ammonium acetate and AcOH gave, in a reproducible manner, the expected 
pyridine 29a together with the corresponding debenzoylated compound 30 in a ca 2:1 ratio. Usually, 
it is believed that under these conditions, 1,4-dihydropyridine intermediates disproportionate to give 
the pyridine compounds and products with higher hydrogen content such as piperidines or tetra-
hydropyridines. However, our pr ocess was very clean, and no by-products of this type could be 
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detected. Thus, in agreement with Rodriguez et al.,
24
 we presume that atmospheric oxygen could be 
responsible for the oxidation step leading to aromatisation. 
Compound 14 failed to cyclize under these conditions. In an alternative approach, good yields of 
pyridine 31a were obtained by reaction of 14 with hydroxylamine hydrochloride under classical 
Knoevenagel conditions. Analogously, reaction of diketone 19 under the conditions employed to 
cyclize 14 led to pyridine oxide 32a. Even diketo-benzamide 21 could be cyclized to give 2,6-
bis(hydroxymethyl)pyrazine 33a in good yields and in a short time when compared with pyridine 
cyclizations. Formation of the pyrazine ring through cyclization of a diketoamide such as 21 has 
never been accomplished before and it is likely that variants of this process will be feasible. 
Debenzoylation of the mixture of 29a/30,
25
 and of compounds 31a-33a was then carried out with 
K2CO3 (cat.) in MeOH to give the corresponding diols. Compounds 29b and 31b are known. The 
structural relationship between 31b and 32b was proven by MCPBA (m-chloroperbenoic acid) 
oxidation of the former to the latter. 
The cyclizations of 19 and 21 are particularly interesting and deserve a comment. As for 
transformation of 19 to 32a (Scheme 6) the benzoate group on C-4 acts as a leaving group and, after 
formation of the intermediate N-hydroxydihydropyridine, aromatization occurs by elimination of 
benzoic acid. This is the first example of the synthesis of the pyridine nucleus using a 3-
benzoyloxy-1,5-diketone. An interesting new feature of this reaction is the direct formation of a 
pyridine oxide. 
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Scheme 6. Plausible pathways leading to pyridine oxide 32a and pyrazine 33a. 
A pathway leading to pyrazine 33a is shown in Scheme 6. In this case, the initial closure of the 
N-hydroxy-dihydropyrazine ring is followed by the elimination of the benzoyl portion, likely 
through a transamidation step driven by aromatization. Overall, the oxidative opening of the 
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morpholine ring in 20 to give diketone 21 (Scheme 7), followed by cyclization of the latter 
compound to pyrazine 33a, namely the transformation of a morpholine derivative into a pyrazine 
one, may have synthetic and pharmacological value.
26
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Scheme 7. Overall transformation of morpholine 20 into pyrazine 33a. 
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3.3. Conclusions 
In conclusion, we have developed the first general procedure to synthesize bis--acyloxy 1,4- 
and 1,5-diketones from 1,5- and 1,6-dienes, respectively, in a regioselective manner. An interesting 
feature of our procedure is the timing of the introduction of the acyloxy and ketone functionalities 
onto the diene, that allows for a variety of acyloxy moieties to be incorporated. In addition, it is 
reasonable that also THF or THP substrates that lack one or both of the neighbouring acyloxy 
groups could be cleaved using our procedure, which would give a wider spectrum of 1,4- and 1,5-
diketones. We have demonstrated that the process can be applied to acylated cis-reticulatacin, a 
representative mono-THF Annonaceous acetogenin, thus opening the way to the preparation of new 
non-THF analogues of these active substances to be used in biological assays. The 1,5-diketone 
products have been successfully cyclized to pyridine dimethanol derivatives, opening a new route to 
pyridine-based oxido pincer ligands, and, in one case, to a pyrazinedimethanol derivative. The 
direct conversion of a 3-benzoyloxy-1,5-diketone into a pyridine N-oxide is also unprecedented. 
The synthetic utility of the bis--acyloxy diketone products is currently under investigation. 
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3.4. Experimental Section 
3.4.1 General methods 
All reagents and anhydrous solvents were purchased (Aldrich and Fluka) at the highest 
commercial quality and used without further purification. Reactions were monitored by thin-layer 
chromatography carried out on precoated silica gel plates (Merck 60, F254, 0.25 mm thick). Merck 
silica gel (Kieselgel 40, particle size 0.063-0.200 mm) was used for column chromatography. 
Na2SO4 was used as a drying agent for aqueous work-up. HPLC separations were carried out on a 
Varian 2510 apparatus equipped with a Waters R403 dual cell differential refractometer using 
Phenomenex 250 x 10 mm and 250 x 4.6 mm (both 5) columns. NMR experiments were 
performed on Varian Unity Inova 700, Varian Unity Inova 500, Varian Mercury Plus 400 and 
Gemini 200 spectrometers in CDCl3 or CD3OD. Proton chemical shifts were referenced to the 
residual CHCl3 (7.26 ppm) or CD2HOD (3.31 ppm) signals. 
13
C-NMR chemical shifts were 
referenced to the solvents (CDCl3 77.0; CD2HOD 49.0 ppm). Coupling constants, J, values are 
given in Hz. Abbreviations for signal coupling are as follows: s=singlet, d=doublet, dd=double 
doublet, ddd=double double doublet, t=triplet, dt=double triplet, q=quartet, quin=quintet, 
m=multiplet, app=apparent, br=broad. Optical rotations were recorded on a Jasco P-1010 
polarimeter (using the sodium D line, 589 nm) and []D are given in units of degcm
3
g
-1
dm
-1
. IR 
spectra were collected on a Jasco FT-IR-430 spectrometer. Melting points were obtained with a 
Gallenkamp melting point apparatus. High Resolution MS were recorded on a Bruker APEX II FT-
ICR mass spectrometer using electron spray ionization (ESI) technique in positive mode. 
Crystals of 12 were grown by slow evaporation from a CHCl3-toluene (1:1) solution. A prismatic 
colourless crystal of 12 was selected for X-ray analysis. Single crystal X-ray diffraction data were 
collected using graphite monochromated MoK radiation ( = 0.71073 Å) on a Bruker-Nonius 
kappaCCD diffractometer at room temperature. Owing to the poorly diffracting features of the 
crystal, data were collected up to max = 25 °. Unit cell parameters were determined by least squares 
refinement of the θ angles of 35 strong reflections in the range 3.785° < θ < 11.308°. Data reduction 
and semiempirical absorption correction were done using SADABS program.
27
 The structure was 
solved by direct methods (SIR97 program
28
) and refined by the full matrix least-squares method on 
F
2
 using SHELXL-97 program.
 29
 All non-hydrogen atoms were refined anisotropically. H atoms 
were determined stereochemically and refined by the riding model with Uiso = 1.2∙Ueq of the carrier 
atom. 
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3.4.2 Synthesis of substrates  
The substrates 1,
9c
 3,
9c
 5,
9c
 7,
30
 9,
31
 11,
32
 13,
 9d
 15,
9d
 17,
9d
 and 20
9e
 were obtained by acetylation, 
benzoylation and tosylation of the corresponding THF, THP or morpholine polyols under standard 
conditions. The latter were synthesized according to literature procedures. 1
6
 is a known compound. 
Compound 18 was synthesized from hepta-1,6-dien-4-yl benzoate according to a literature 
procedure
9e
 and belzoylated under standard conditions. 
(±)-((2S,5R)-tetrahydrofuran-2,5-diyl)bis(methylene) diacetate (3): Oil; IR: max= 1742s, 
1372w, 1235br s, 1041m cm
-1
; 
1
H NMR (200 MHz, CDCl3) = 4.30 – 4.06 (m, 4H), 3.97 (dd, J = 
12.3, 7.2 Hz, 2H), 2.07 (s, 6H), 2.16 – 1.89 (m, 2H), 1.83 – 1.55 (m, 2H); 13C NMR (50 MHz, 
CDCl3) = 170.5, 77.0, 66.1, 27.3, 20.5; HRMS (ESI) m/z C10H16NaO5 requires [M+Na]
+
 239.0895, 
found 239.0884. 
(±)-((2S,5R)-tetrahydrofuran-2,5-diyl)bis(methylene) bis(4-methylbenzenesulfonate) (5): Oil; 
IR: max= 2957m, 2922m, 2855w, 1597w, 1356m, 1260w, 1189m, 1174s, 1094m, 969m, 812m, 
665m cm
-1
; 1H NMR (200 MHz, CDCl3): = 7.77 (d, J = 8.1 Hz, 4H), 7.34 (d, J = 8.1 Hz, 4H), 
4.17 – 4.02 (m, 2H), 3.93 (m, 4H), 2.45 (s, 6H), 2.03 – 1.85 (m, 2H), 1.84 – 1.64 (m, 2H); 13C NMR 
(50 MHz, CDCl3): =144.9, 132.8, 129.9, 127.9, 77.2, 71.1, 27.5, 21.6; HRMS (ESI) m/z 
C20H24NaO7S2 requires [M+Na]
+
 463.0861, found 463.0859. 
(±)-(4S)-4-(benzoyloxy)-4-[(2S,5R)-5-[(1R)-1,4-bis(benzoyloxy)butyl]oxolan-2-yl]butyl 
benzoate (7): Oil; IR: max= 2956br w, 2877br w, 1716 br s, 1601w, 1584w, 1451w, 1314w, 1272br 
s, 1176w, 1112m, 1069w, 1025w, 710m cm
-1
; 
1
H NMR (200MHz, CDCl3): = 8.09 (d, J = 7.6, 4H), 
8.01 (d, J = 7.0, 4H), 7.60 – 7.27 (m, 12H), 5.49 – 5.24 (m, 2H), 4.47 – 4.24 (br s, 4H), 4.24 – 4.04 
(m, 2H), 2.11 – 1.67 (m, 12H); 13C NMR (50 MHz, CDCl3): = 166.3, 166.1, 132.8, 132.7, 130.1, 
130.0, 129.5, 129.4, 128.2, 128.1, 79.8, 75.0, 64.4, 27.7, 27.4, 24.7; HRMS (ESI) m/z C40H40NaO9 
requires [M+Na]
+
 687.2570, found 687.2566. 
(±)-(R)-1-((2R,5S)-5-((S)-1-(benzoyloxy)undecyl)tetrahydrofuran-2-yl)butane-1,4-diyl 
dibenzoate (9): Oil; IR: max= 2924m, 2852w, 1718s, 1271s, 1112m, 1069w, 1026w, 710m cm
-1
; 
1
H NMR: (200MHz, CDCl3): = 8.18 – 7.91 (m, 6H), 7.60 – 7.31 (m, 9H), 5.42 – 5.14 (m, 2H), 
4.30 (t, J = 5.6 Hz, 2H), 4.21 – 4.06 (m, 2H), 2.07 – 1.51 (m, 12H), 1.46 – 1.05 (m, 10H), 0.84 (t, J 
= 6.8 Hz, 3H), 
13
C NMR (50 MHz, CDCl3): = 166.5, 166.3, 132.9, 132.81, 132.80, 130.4, 130.2, 
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130.1, 129.8, 129.7, 129.5, 128.35, 128.30, 80.1, 79.8, 75.9, 75.2, 64.6, 31.9, 30.9, 29.55, 29.53, 
29.50, 27.8, 27.5, 25.4, 24.9, 22.6, 14.1; HRMS (ESI) m/z C40H50NaO7 requires  [M+Na]
+
 
665,3454, found 665.3458. 
(±)-[(1R,4R,5S,7R)-4-(benzoyloxy)-6-oxabicyclo[3.2.1]octan-7-yl]methyl benzoate (11): Oil; IR: 
max= 2953br w, 2874br w, 1716s, 1450w, 1335w, 1313w, 1271s, 1176w, 1114w, 1098w, 1069w, 
1026w, 941w, 711m cm
-1
; 
1
H NMR (200 MHz, CDCl3): δ= 8.13 – 8.02 (d, J = 7.3 Hz, 2H), 7.63 – 
7.35 (m, 6H), 4.94 (dd, J = 9.2, 6.7 Hz, 1H), 4.75 – 4.51 (m, 3H), 4.40 (br dd, J = 9.6, 6.1 Hz, 1H), 
2.40 (br s, 1H), 2.34 – 1.84 (m, 4H), 1.78 (d, J = 11.8 Hz, 1H), 1.73 – 1.53 (m, 1H); 13C NMR (50 
MHz, CDCl3): = 166.5, 166.2, 133.0, 132.9, 130.3, 130.1, 129.9, 129.8, 128.3, 128.2, 80.3, 78.0, 
75.0, 63.8, 37.1, 35.8, 25.3, 24.0; HRMS (ESI) m/z C22H22NaO5requires [M+Na]
+
 389.1365, found 
389.1362.  
(±)-((2S,6S)-tetrahydro-2H-pyran-2,6-diyl)bis(methylene) dibenzoate (13): Oil; IR: max= 
2940br w, 1717s, 1601w, 1584w, 1451w, 1315w, 1275s, 1118br m, 1070w, 1026w, 710s cm
-1
; 
1
H 
NMR (200 MHz, CDCl3): = 7.98 (d, J = 7.1 Hz, 4H), 7.52 (t, J = 7.4 Hz, 2H), 7.33 (t, J = 7.6 Hz, 
4H), 4.58 (dd, J = 12.5, 9.0 Hz, 2H), 4.35 – 4.18 (m, 4H), 1.96 – 1.39 (m, 6H); 13C NMR (50 MHz, 
CDCl3): = 166.5, 132.8, 130.0, 129.6, 128.3, 69.6, 65.2, 26.3, 18.5; HRMS (ESI) m/z C21H22NaO5 
requires [M+Na]
+
 377.1365, found 377.1368. 
(±)-2-[(2S,6S)-6-[(benzoyloxy)methyl]oxan-2-yl]propan-2-yl benzoate (15): Oil; IR: max= 
2867w, 2940br w, 1720s, 1602w, 1583w, 1451m, 1386w, 1366w,1314m, 1275br s, 1113br m, 
1070w, 1026w, 710s cm
-1
; 
1
H NMR (200 MHz, CDCl3): = 8.00 (d, J = 8.1 Hz, 2H), 7.95 (d, J = 
8.1 Hz, 2H), 7.57 – 7.46 (m, 2H), 7.35 (td, J = 7.9, 3.3 Hz, 4H), 4.81 (dd, J = 10.4, 7.8 Hz, 1H), 
4.45 – 4.30 (m, 2H), 4.45 – 4.24 (m, 2H), 4.07 (d, J = 10.8 Hz, 1H), 1.97 – 1.36 (m, partly 
overlapped to methyl signals, 6H), 1.59 (s, 3H), 1.57 (s, 3H); 
13
C NMR (50 MHz, CDCl3): =166.4, 
165.5, 132.9, 132.4, 131.8, 130.1, 129.6, 129.4, 128.3, 128.1, 84.0, 74.5, 71.0, 62.9, 25.5, 25.0, 
22.9, 21.5, 19.0; HRMS (ESI) m/z C23H26NaO5 requires [M+Na]
+ 
405.1678, found 405.1676. 
(±)-2-[(2S,6R)-6-[(benzoyloxy)methyl]oxan-2-yl]propan-2-yl benzoate (17): Oil; IR: max= 
2983w, 2942br w, 2858w, 1716br s, 1602w, 1583w, 1451m, 1384w, 1367w, 1314m, 1290s, 1274s, 
1118m, 1069w, 1027w, 711s cm
-1
; 
1
H NMR (200 MHz, CDCl3): = 7.98 (m, 4H), 7.58 – 7.45 (m, 
2H), 7.37 (t, J = 7.6 Hz, 4H), 4.30 (app d, J = 5.3 Hz, 2H), 3.91 – 3.71 (m, 2H), 2.08 – 1.91 (m, 
1H), 1.62 (s, 3H), 1.57 (s, 3H), 1.80 – 1.21 (m, partly overlapped to methyl signals, 6H); 13C NMR 
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(50 MHz, CDCl3): = 166.4, 165.5, 132.8, 132.4, 131.8, 130.2, 129.5, 129.4, 128.2, 128.1, 83.8, 
81.4, 75.9, 67.6, 27.7, 24.9, 23.0, 21.6; HRMS (ESI) m/z C23H26NaO5 requires [M+Na]
+ 
405.1678, 
found 405.1677. 
(±)-((2S,6S)-4-(benzoyloxy)-tetrahydro-2H-pyran-2,6-diyl)bis(methylene) dibenzoate (19): Oil; 
IR: max=2857br w, 1720s, 1601w, 1583w, 1451m, 1315m, 1272br s, 1176w, 1110br m, 1026m, 
710m cm
-1
; 
1
H NMR (200 MHz, CDCl3): = 8.13 – 7.94 (m, 6H), 7.64 – 7.41 (m, 3H), 7.34 (t, J = 
7.6 Hz, 6H), 5.57 – 5.40 (m, 1H), 4.84 (dd, J = 11.5, 8.0 Hz, 1H), 4.74 – 4.49 (m, 2H), 4.50 – 4.21 
(m, 3H), 2.27 (dt, J = 13.7, 4.3 Hz, 1H), 2.05 (t, J = 5.5 Hz, 2H), 1.85 (dt, J = 13.8, 7.0 Hz, 1H); 
13
C 
NMR (50 MHz, CDCl3): = 166.3, 165.7, 133.2, 132.9, 129.9, 129.85, 129.80, 129.6, 129.5, 128.5, 
128.3, 68.9, 67.6, 67.1, 65.3, 65.1, 31.6, 31.4; HRMS (ESI) m/z C28H26NaO7 requires [M+Na]
+
 
497.1576, found 497.1573. 
(±)-((2S,6S)-4-benzoylmorpholine-2,6-diyl)bis(methylene) dibenzoate (20): Oil; IR: max= 
2955br w, 1721s, 1639br s, 1602w, 1451m, 1273br s, 1114m, 1070w, 1027w, 711s cm
-1
; 
1
H NMR 
(200 MHz, CDCl3) = 8.14 – 7.73 (br m, 6H), 7.53 (t, J = 7.3 Hz, 3H), 7.48 – 7.27 (m, 6H), 4.76 – 
4.43 (br m, 2H), 4.43 – 4.17 (br m, 4H), 4.17 – 3.75 (br m, 2H), 3.75 – 3.38 (br m, 2H); 13C NMR 
(50 MHz, CDCl3) = 171.1, 166.0, 134.7, 133.1, 130.0, 129.6, 129.5, 128.6, 128.3, 127.0, 68.8, 
62.8, 47.8, (br) 43.4 (br); HRMS (ESI) m/z C27H25NNaO6 requires [M+Na]
+
 482.1580, found 
482.1583. 
(1R)-1-[(2R,5S)-5-[(1S)-1-(acetyloxy)-15-[(5S)-5-methyl-2-oxo-2,5-dihydrofuran-3-
yl]pentadecyl]oxolan-2-yl]tridecyl acetate (25): Oil; IR: max= 2922br s, 2852m, 1735br s, 
1459w, 1370w, 1318w, 1237s, 1073w, 1025m, 949w cm
-1
; 
1
H NMR (200 MHz, CDCl3): = 6.98 
(br q, J = 1.3 Hz, 1H), 4.99 (br q, J = 6.7 Hz, 1H), 4.94 – 4.81 (m, 3H), 4.01 – 3.89 (m, 2H), 2.26 (t, 
J = 7.6 Hz, 2H), 2.07 (s, 6H), 2.01 – 1.16 (m, 48H), 1.40 (d, J = 6.8 Hz, 3H), 0.87 (t, J = 6.1 Hz, 
5H); 
13
C NMR (50 MHz, CDCl3): = 173.8, 170.7, 148.8, 134.3, 79.8, 77.4, 75.4, 31.9, 30.8, 29.6, 
29.6, 29.3, 29.3, 29.2, 27.8, 27.4, 25.3, 25.2, 22.7, 21.1, 19.2, 14.1; HRMS (ESI): m/z C41H72NaO7 
requires [M+Na]
+
 699.5176, found 699.5180. 
 
(1R)-1-[(2R,5S)-5-[(1S)-1-(benzoyloxy)-15-[(5S)-5-methyl-2-oxo-2,5-dihydrofuran-3-
yl]pentadecyl]oxolan-2-yl]tridecyl benzoate (26): Oil; IR: max= 2917m, 2850w, 1716s, 1599w, 
1585w, 1451m, 1361w, 1311w, 1272s, 1248m, 1121m, 1023w, 771w, 714m cm
-1
; 
1
H NMR (200 
Chapter 3 
 
73 
 
MHz, CDCl3) = 8.07 (d, J = 7.3 Hz, 4H), 7.53 (t, J = 7.4 Hz, 2H), 7.38 (t, J = 7.4 Hz, 4H), 6.98 (s, 
1H), 5.23 (app q, J = 5.5 Hz, 2H), 4.99 (br q, J = 7.3 Hz, 1H), 4.17 – 4.03 (m, 2H), 2.26 (t, J = 7.9 
Hz, 2H), 2.05 – 1.09 (m, 48H), 1.40 (d, J = 6.8 Hz, 3H), 0.87 (t, J = 6.0 Hz, 3H); 13C NMR (50 
MHz, CDCl3) = 174.5, 166.3, 166.2, 148.8, 134.3, 132.7, 130.5, 129.7, 128.3, 79.9, 77.4, 76.0, 
31.9, 30.8, 29.63, 29.56, 29.50, 29.3, 29.2, 27.9, 27.4, 25.5, 25.2, 22.7, 19.2, 14.1; HRMS (ESI): 
m/z C51H76NaO7 requires [M+Na]
+
 823.5489, found 823.5491. 
3.4.3 Oxidative cleavage of substrates 
Procedure A for the oxidative cleavage of tetrahydrofuran substrates 
To a suspension of H5IO6 (3.2 eq.) in CH3CN at rt was added PCC (2 mol % from a 0.01 M 
stock solution in CH3CN) under vigorous stirring. After 5 min the THF compound (1 eq.) dissolved 
in CH3CN was added. The overall volume of CH3CN was such that the final concentration of the 
solution was 0.05 M. After complete consumption of the starting material (TLC control, typically 
30-40 min), EtOH (excess) was added and stirring continued until the colour of the solution turned 
from yellow to green (ca. 5 min). Then silica (excess) was added and the solvent evaporated under 
reduced pressure. The resulting powder was loaded on the top of a silica gel column. Flash 
chromatography eluting with CHCl3/MeOH (100:0 to 9:1) gave the desired product. 
Procedure B for the oxidative cleavage of tetrahydropyran substrates 
 To a suspension of H5IO6 (4.0 eq.) in CH3CN at rt was added PCC (4 mol % from a 0.01 M stock 
solution in CH3CN) under vigorous stirring. After 5 min the THP compound (1 eq.) dissolved in 
CH3CN was added. The overall volume of CH3CN was such that the final concentration of the 
solution was 0.05 M. After complete consumption of the starting material (TLC control, typically 6-
8 h), EtOH (excess) was added and stirring continued until the colour of the solution turned from 
yellow to green (ca. 5 min). Then silica (excess) was added and the solvent evaporated under 
reduced pressure. The resulting powder was loaded on the top of a silica gel column. Flash 
chromatography eluting with chloroform/methanol (100:0 to 9:1) gave the desired product. 
2,5-dioxohexane-1,6-diyl dibenzoate (2): Benzoate-protected tetrahydrofuran 1 (22.0 mg, 0.065 
mmol) was subjected to General Procedure A to furnish the title compound 2 (22.3 mg, 0.063 
mmol, 97 %) as a colorless solid. m.p. 138-140 °C; IR (thin film): νmax = 2949w, 1724s, 1600w, 
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1451w, 1408m, 1271s, 1128w, 1101w, 1063w, 1028w, 988w, 702m; 
1
H NMR and 
13
C NMR see 
ref. 6. 
2,5-dioxohexane-1,6-diyl diacetate (4): Acetate-protected tetrahydrofuran 3 (24.5 mg, 0.113 
mmol) was subjected to General Procedure A to furnish the title compound 4 (20.8 mg, 0.090 
mmol, 80%) as a colorless solid. m.p. 86-88 °C; IR (thin film): νmax= 3004w, 2934w, 1763s, 1722s, 
1415s, 1367m, 1304w, 1281m, 1232br s, 1102w, 1038br m, 1034w, 960w, 841w, 755br w, 713w, 
682w, 619w cm
-1
; 
1
H NMR (200 MHz, CDCl3): =4.69 (s, 4H), 2.74 (s, 4H), 2.15 (s, 6H); 
13
C 
NMR (50 MHz, CDCl3): = 202, 170.2, 67.9, 31.9, 20.4; HRMS (ESI) C10H14NaO6 requires 
[M+Na]
+
 253.0688, found 253.0691. 
2,5-dioxohexane-1,6-diyl bis(4-methylbenzenesulfonate) (6): Tosylate-protected tetrahydrofuran 
5 (15.7 mg, 0.036 mmol) was subjected to General Procedure A to  furnish the title compound 6 
(13.8 mg, 0.030 mmol, 85 %) as an oil. IR (thin film): νmax= 2922br w, 2852w, 1732m, 1597w, 
1359m, 1189m, 1176s, 1091w, 1003br m, 814m, 667m cm
-1
; 
1
H NMR (200 MHz, CDCl3): δ= 7.81 
(d, J = 8.3 Hz, 4H), 7.37 (d, J = 8.1 Hz, 4H), 4.52 (s, 4H), 2.80 (s, 4H), 2.46 (s, 6H); 
13
C NMR (50 
MHz, CDCl3): δ= 201.7, 145.6, 132.1, 130.1, 128.1, 71.7, 32.2, 21.7; HRMS (ESI) C20H22NaO8S2 
requires [M+Na]
+
 477.0654, found 477.0658. 
(±)-(4R,9S)-5,8-dioxododecane-1,4,9,12-tetrayl tetrabenzoate (8): Benzoate-protected 
tetrahydrofuran 7 (122.0 mg, 0.184 mmol) was subjected to General Procedure A to furnish the title 
compound 8 (92.3 mg, 0.136 mmol, 74 %) as a white solid. m.p. 123-125 °C; IR (thin film): νmax= 
2960br w, 2917w, 1716br s, 1600w, 1584w, 1451w, 1315w, 1272br s, 1112br m, 1070w, 1026w, 
710m cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ= 8.06 (t, J = 8.3 Hz, 8H), 7.82 – 7.26 (m, 12H), 5.36 (t, J 
= 5.9 Hz, 2H), 4.39 (t, J = 5.8 Hz, 4H), 3.15 – 2.62 (m, 4H), 2.33 – 2.07 (m, 2H), 2.07 – 1.87 (m, 
2H); 
13
C NMR (50 MHz, CDCl3): δ= 205.7, 166.5, 166.0, 133.5, 132.8, 130.1, 129.8, 129.5, 129.1, 
128.5, 128.3, 78.3, 64.1, 31.8, 27.4, 24.5; HRMS (ESI) C40H38NaO10 requires [M+Na]
+
 701.2363, 
found 701.2367. 
(±)-(4R,9S)-5,8-dioxononadecane-1,4,9-triyl tribenzoate (10): Benzoate-protected 
tetrahydrofuran 9 (11.6 mg, 0.018 mmol) was subjected to General Procedure A to furnish the title 
compound 10 (7.2 mg, 0.011 mmol, 61 %) as an oil. IR (thin film): νmax= 2923br m, 2853w, 1717br 
s, 1602w, 1451w, 1315w, 1271br s, 1176w, 1112m, 1070w, 1026w, 711m cm
-1
; 
1
H NMR (500 
MHz, CDCl3) δ= 8.08 (d, J = 7.6 Hz, 4H), 8.03 (d, J = 7.7 Hz, 2H), 7.59 (dd, J = 7.9, 5.9 Hz, 2H), 
7.54 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.7 Hz, 4H), 7.42 (t, J = 7.7 Hz, 2H), 5.35 (dd, J = 8.0, 4.5 Hz, 
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1H), 5.25 (dd, J = 6.9, 5.9 Hz, 1H), 4.43 – 4.34 (m, 2H), 2.95 (dt, J = 14.9, 6.0 Hz, 2H), 2.85 – 2.75 
(m, 2H), 2.23 – 2.08 (m, 2H), 1.96 (dq, J = 13.4, 6.2 Hz, 4H), 1.48 (s, 2H), 1.28 (t, J = 23.1 Hz, 
14H), 0.87 (t, J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ= 206.2, 205.8, 166.5, 166.2, 166.1, 
133.5, 133.4, 132.9, 130.1, 129.83, 129.81, 129.6, 129.4, 129.1, 128.54, 128.49, 128.34, 79.0, 78.4, 
64.2, 31.87, 31.83, 30.8, 29.7, 29.53, 29.51, 29.35, 29.29, 29.21, 27.5, 25.3, 24.6, 22.7, 14.1; HRMS 
(ESI) C40H48NaO8 requires [M+Na]
+
 679.3247, found 679.3245. 
(±)-2-[(1S,4R)-4-(benzoyloxy)-3-oxocyclohexyl]-2-oxoethyl benzoate (12): Benzoate-protected 
tetrahydrofuran 11 (17.7 mg, 0.048 mmol) was subjected to General Procedure A to furnish the title 
compound 12 (13.7 mg, 0.036 mmol, 75 %) as white needles. m.p. 156-157 °C; IR (thin film): 
max= 2934br w, 1721br s, 1601w, 1584w, 1451m, 1414w, 1316m, 1274br s, 1177w, 1114m, 
1065m, 1026w, 996w, 710m cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ= 8.17 – 8.00 (m, 4H), 7.75 – 7.34 
(m, 6H), 5.38 (dd, J = 8.9, 6.2 Hz, 1H), 5.12 (d, J = 16.8 Hz, 1H), 4.85 (d, J = 16.8 Hz, 1H), 3.64 – 
3.09 (m, 1H), 2.85 (ddd, J = 14.5, 4.4, 1.5 Hz, 1H), 2.58 (ddd, J = 14.5, 5.7, 0.6 Hz, 1H), 2.49 – 
2.09 (m, 4H); 
13
C NMR (50 MHz, CDCl3): δ= 204.0, 201.6, 165.9, 165.5, 133.6, 133.3, 130.0, 
129.9, 129.4, 128.9, 128.5, 128.4, 75.7, 67.0, 45.4, 40.0, 28.9, 24.5; HRMS (ESI): m/z C22H20NaO6 
requires [M+Na]
+
 403.1158, found 403.1161. Single crystal X-ray diffraction data for 12 (Fig 1): 
C22H20O6, M = 380.38, monoclinic, a = 5.300(5), b = 10.946(4), c = 32.574(9) Å,  =  97.37(3)°, V 
= 1874(2) Å
3
, T = 298 K, space group P21/c, Z = 4, (Mo-K) = 0.098 mm-1, 10511 reflections 
measured, 3248 unique (R(int) = 0.0690) which were used in all calculations. Final agreement 
indices were R = 0.0573 (I>2(I)). and wR(F2) = 0.1421 (all data). 
2,6-dioxoheptane-1,7-diyl dibenzoate (14): Benzoate-protected tetrahydropyran 13 (24.1 mg, 
0.068 mmol) was subjected to General Procedure B to furnish the title compound 14 (21.3 mg, 
0.058 mmol, 85 %) as a white solid. m.p. 123-125 °C; IR (thin film): νmax= 2949br w, 2918w, 
2850w, 1724br s, 1600w, 1451w, 1408m, 1271br s, 1128w, 1101m, 1063m, 1028m, 988w, 702m 
cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ= 8.09 (d, J = 7.0 Hz, 4H), 7.60 (t, J = 7.3 Hz, 2H), 7.46 (t, J = 
7.4 Hz, 4H), 4.87 (s, 4H), 2.61 (t, J = 6.8 Hz, 4H), 2.01 (quin, J = 6.8 Hz, 2H); 
13
C NMR (50 MHz, 
CDCl3): δ= 203.6, 165.9, 133.4, 129.9, 129.6, 128.5, 68.4, 37.2, 16.7; HRMS (ESI): m/z 
C21H20NaO6 requires [M+Na]
+
 391.1158, found 391.1159. 
7-methyl-2,6-dioxooctane-1,7-diyl dibenzoate (16): Benzoate-protected tetrahydropyrans 15 (26.4 
mg, 0.068 mmol) and 17 (21.0 mg, 0.055 mmol) were subjected to General Procedure B to furnish 
the title compound 16 (25.7 mg, 0.065 mmol, 95 % from 15; 18.2 mg, 0.046 mmol, 83 % from 17) 
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as an oil. IR (thin film): νmax= 2990w, 2937br w, 1721br s, 1601w, 1584w, 1451m, 1416w, 1367w, 
1316m, 1286br s, 1113m, 1070m, 1026m, 712s cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ= 8.07 (d, J = 
7.2 Hz, 2H), 8.01 (d, J = 7.2 Hz, 2H), 7.60 – 7.54 (m, 2H), 7.45 (t, J = 7.4 Hz, 2H), 7.43 (t, J = 7.4 
Hz, 2H), 4.88 (s, 2H), 2.66 – 2.50 (q, 4H), 1.97 (quin, J = 6.8 Hz, 2H), 1.59 (s, 6H); 13C NMR (50 
MHz, CDCl3): δ= 208.4, 203.8, 165.8, 133.3, 129.9, 129.8, 129.2, 128.4, 84.1, 68.4, 37.2, 33.8, 
23.7, 16.9; HRMS (ESI): m/z C23H24NaO6 requires [M+Na]
+
 419.1471, found 419.1473. 
2,6-dioxoheptane-1,4,7-triyl tribenzoate (19): Benzoate-protected tetrahydropyran 18 (27.0 mg, 
0.057 mmol) was subjected to General Procedure B to furnish the title compound 19 (21.5 mg, 
0.044 mmol, 78 %) as a white solid. m.p. 148-150 °C; IR (thin film): νmax= 3068w, 2929w, 1720s, 
1601w, 1583w, 1451w, 1406br w, 1314w, 1275s, 1177w, 1112w, 1069w, 1026w, 711m cm
-1
; 
1
H 
NMR (200 MHz, CDCl3) δ= 8.18 – 7.91 (m, 6H), 7.67 – 7.52 (m, 3H), 7.50 – 7.34 (m, 6H), 5.86 
(quin, J = 6.0 Hz, 1H), 4.96 (d, J = 16.9 Hz, A part of an AB system, 2H), 4.87 (d, J = 16.9 Hz, B 
part of an AB system, 2H), 3.23 – 2.97 (m, 4H); 13C NMR (50 MHz, CDCl3): δ= 201.0, 165.8, 
165.6, 133.5, 133.3, 129.9, 129.7, 129.6, 129.0, 128.5, 68.7, 66.5, 41.9; HRMS (ESI): m/z 
C28H24NaO8 requires [M+Na]
+
 511.1369, found 511.1366. 
3,3’-benzamidobis(2-oxopropane-3,1-diyl) dibenzoate (21): Benzoate-protected morpholine 20 
(20.0 mg, 0.044 mmol) was subjected to General Procedure B. The reaction mixture was filtered, 
taken to dryness and separated by HPLC (hexane/EtOAc, 6:4) to give the title compound 21 (5.2 
mg, 0.011 mmol, 26 %), compounds 22 (3.9 mg, 0.008 mmol, 18 %) and 23 (2.3 mg, -0.005 mmol, 
12 %). 21: Oil; IR (thin film): νmax= 2921w, 2848w, 1725br s, 1644m, 1601w, 1451m, 1414w, 
1315w, 1275s, 1112m, 1069m, 1027w, 712m cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ= 8.10 (d, J = 7.6 
Hz, 2H), 7.99 (d, J = 7.7 Hz, 2H), 7.60 (t, J = 7.3 Hz, 2H), 7.54 – 7.31 (m, 9H), 5.04 (s, 2H), 4.74 
(s, 2H), 4.52 (s, 2H), 4.42 (s, 2H); 
13
C NMR (50 MHz, CDCl3): δ= 200.0, 199.8, 172.3, 166.0, 
165.7, 134.2, 133.7, 133.6, 130.5, 129.94, 129.87, 128.80, 128.5, 126.8, 67.5, 67.0, 56.8, 52.6; 
HRMS (ESI): m/z C27H23NNaO7 requires [M+Na]
+
 496.1372, found 496.1373. 
1-(benzoyloxy)-3-(N-formyl-1-phenylformamido)propan-2-yl 2-(benzoyloxy)acetate (22): Oil; 
IR (thin film): νmax= 2949br w, 2926br w, 2849w, 1762w, 1727s, 1673s, 1602w, 1451w, 1275br s, 
1206br m, 1117br m, 1071w cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ= 8.96 (s, 1H), 8.06 (d, J = 7.7 Hz, 
2H), 8.03 (d, J = 8.4 Hz, 2H), 7.62 – 7.53 (m, J = 8.1 Hz, 5H), 7.51 – 7.39 (m, 6H), 5.72 (d, J = 3.4 
Hz, 1H), 4.85 (d, J = 16.0 Hz, A part of an AB system, 1H), 4.79 (d, J = 16.0 Hz, B part of an AB 
system, 1H), 4.60 (dd, J = 12.2, 3.8 Hz, 1H), 4.54 – 4.43 (m, 3H), 4.15 (dd, J = 14.0, 2.9 Hz, 1H); 
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13
C NMR (50 MHz, CDCl3): δ= 172.1, 167.7, 166.0, 165.8, 164.2, 133.4, 133.3, 133.0, 132.3, 
129.9, 129.8, 129.4, 129.3, 129.0, 128.9, 128.5, 128.4, 70. 6, 63.6, 61.1, 40.5; HRMS (ESI) m/z 
C27H23NNaO8 requires [M+Na]
+
 512.1321, found 512.1320. 
1-(benzoyloxy)-3-(phenylformamido)propan-2-yl 2- (benzoyloxy)acetate (23): Oil; IR (thin 
film): νmax= 3380br w, 3300br w, 3061w, 2934w, 1726s, 1645w, 1537br w, 1451w, 1275s, 1203w, 
1117m, 709m cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ= 8.06 – 7.95 (m, 4H), 7.83 (d, J = 7.9 Hz, 2H), 
7.65 – 7.35 (m, 9H), 6.75 (br t, J = 5.4 Hz, 1H), 5.59 – 5.42 (m, J = 7.3 Hz, 1H), 4.92 (d, J = 15.8 
Hz, A part of an AB system, 1H), 4.82 (d, J = 15.8 Hz, B part of an AB system, 1H), 4.60 (dd, J = 
12.2, 4.1 Hz, 1H), 4.49 (dd, J = 12.2, 5.5 Hz, 1H), 3.99 (ddd, J = 14.5, 6.5, 3.9 Hz, 1H), 3.67 (ddd, J 
= 14.5, 7.2, 5.6 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ= 167.7, 167.4, 166.7, 166.2, 133.8, 133.7, 
133.3, 131.6, 129. 9, 129.7, 129.6, 129.3, 128.555, 128.548, 128.5, 127.1, 126.6, 72.2, 63.3, 61.7, 
40.1; HRMS (ESI): m/z C26H23NNaO7 requires [M+Na]
+
 484.4531, found 484.4520. 
(13R,18S)-18-(acetyloxy)-32-[(5S)-5-methyl-2-oxo-2,5-dihydrofuran-3-yl]-14,17-
dioxodotriacontan-13-yl acetate (27): Cis-reticulatacin diacetate 25 (5.4 mg, 0.008 mmol) was 
subjected to General Procedure B. After being stirred for 12h, the reaction mixture was filtered, 
taken to dryness and separated by HPLC (hexane/EtOAc, 8:2) to give the title compound 27 (1.4 
mg, 0.002 mmol, 30 %) as a colorless oil. IR (thin film): νmax= 2924s, 2853m, 1747br s, 1374w, 
1235br m, cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ= 6.99 (s, 1H), 5.04 – 4.92 (m, 3H), 2.88 – 2.75 (m, 
2H), 2.75 – 2.62 (m, 2H), 2.26 (t, J = 7.6 Hz, 2H), 2.14 (s, 6H), 1.90 – 1.65 (m, 6H), 1.66 – 1.17 (m, 
38H), 1.40 (d, J = 6.8 Hz, 3H), 0.88 (t, J = 6.7 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): δ= 206.1, 
173.9, 170.7, 148.8, 134.3, 78.6, 77.4, 31.9, 31.7, 30.5, 29.6, 29.5, 29.4, 29.2, 27.4, 25.21, 25.20, 
22.7, 20.7, 19.2, 14.1; HRMS (ESI): m/z C41H70NaO8 requires [M+Na]
+
 713.4968, found 713.4966. 
(13R,18S)-18-(benzoyloxy)-32-[(5S)-5-methyl-2-oxo-2,5-dihydrofuran-3-yl]-14,17-
dioxodotriacontan-13-yl benzoate (28): Cis-reticulatacin dibenzoate 26 (3.6 mg, 0.004 mmol) was 
subjected to General Procedure B. After being stirred for 8h, the reaction mixture was filtered, taken 
to dryness and separated by HPLC (hexane/EtOAc, 85:15) to give the title compound 28 (1.6 mg, 
0.002 mmol, 40 %) as a colorless oil. []D
30
 = -23.3 (c=0.03, CHCl3); IR (thin film): νmax= 2924s, 
2853m, 1756m, 1720s, 1453w, 1316w, 1271m, 1112br w, 1028w, 712m cm
-1
; 
1
H NMR (200 MHz, 
CDCl3) δ= 8.08 (d, J = 7.1 Hz, 4H), 7.60 (t, J = 7.3 Hz, 2H), 7.46 (t, J = 7.4 Hz, 4H), 6.98 (br q, J = 
1.7 Hz, 1H), 5.24 (t, J = 6.4 Hz, 2H), 4.99 (br q, J = 6.8 Hz, 1H), 3.05 – 2.67 (m, 4H), 2.26 (t, J = 
7.6 Hz, 2H), 1.94 (app q, J = 6.5 Hz, 4H), 1.64 – 1.15 (m, 40H), 1.40 (d, J = 6.8 Hz, 3H), 0.87 (t, J 
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= 6.4 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): δ= 206.2, 173.9, 166.9, 166.2, 148.9, 134.3, 133.4, 
129.8, 129.3, 128.5, 79.0, 77.4, 31.9, 31.8, 30.7, 29.7, 29.6, 29.5, 29.3, 29.2, 27.4, 25.3, 25.1, 22.7, 
19.2, 14.1; HRMS (ESI): m/z C51H74NaO8 requires [M+Na]
+
 837.5281, found 837.5284. 
3.4.4 Synthesis of six-membered nitrogen heterocycles 
2-[6-(hydroxymethyl)pyridin-2-yl]propan-2-ol (29b): To a solution of diketone 16 (12.0 mg, 
0.030 mmol) in dry MeOH (300 L) were added NH4OAc (4.0 mg, 0.052 mmol) and AcOH (3 L). 
After being stirred for 24 h at rt and 48 h at 55°C the reaction mixture was diluted with EtOAc (2 
mL) and washed with a sat. aqueous NaHCO3 solution and water. The organic phase was dried, 
filtered and concentrated under reduced pressure. Separation by preparative TLC (hexane/EtOA, 
3:7) gave 29a (6.3 mg, 55%) and 30 (2.1 mg, 25%) as colorless oils. 29a: oil; IR (thin film): νmax= 
2923br w, 2849w, 1716s, 1594w, 1450w, 1314w, 1265br s, 1151w, 1108s, 1070w, 1026w, 709s 
cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ=  8.11 (d, J = 7.2 Hz, 2H), 8.06 (d, J = 7.2 Hz, 2H), 7.71 (t, J = 
7.8 Hz, 1H), 7.60 – 7.54 (m, 2H), 7.48 – 7.42 (m, 4H), 7.39 (d, J = 8.0 Hz, 1H), 7.32 (d, J = 7.6 Hz, 
1H), 5.52 (s, 2H), 1.94 (s, 6H); 
13
C NMR (50 MHz, CDCl3): δ= 166.3, 165.3, 155.3 154.9, 137.2, 
133.1, 132.7, 129.7, 129.6, 128.4, 128.3, 119.3, 117.9, 83.3, 67.2, 27.6; HRMS (ESI): m/z 
C23H21NNaO4 requires [M+Na]
+
 398.1368, found 398.1367. 
To a solution of 30 (2.1 mg, 0.008 mmol) in MeOH, was added K2CO3 (1.0 mg, 10 mol %). After 
being stirred for 30 min at rt, AcOH was added up to neutrality and the mixture was evaporated 
under reduced pressure. The residue was redissolved in CHCl3 and filtered to give pyridine diol 29b 
(1.2 mg, 0.007 mmol, 85 %) as an oil. 29b: IR (thin film): νmax= 3420br m, 2920br m, 2853m, 
1736br m, 1462br w, 1376br w, 1260br w, 1169br w, 1099br w, 1022br w, 802w cm
-1
; 
1
H NMR 
(200 MHz, CDCl3): δ= 7.72 (t, J = 7.7 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.19 (d, J = 7.8 Hz, 1H), 
4.79 (s, 2H), 1.57 (s, 6H); HRMS (ESI): m/z C9H13NNaO2 requires [M+Na]
+
 190.0844, found 
190.0842. 
[6-(hydroxymethyl)pyridin-2-yl]methanol (31b): To a solution of diketone 14 (9.4 mg, 0.024 
mmol) in dry EtOH (1 mL) was added NH2OH·HCl (5.8 mg, 0.084 mmol). After being stirred for 
16 h at rt and 8 h at reflux, sat. aqueous NaHCO3 was added up to neutrality and the mixture was 
concentrated under reduced pressure and filtered through a short pad of silica gel (CHCl3/MeOH, 
8:2). Purification by preparative TLC (hexane/EtOA, 3:7) gave 31a (5.4 mg, 0.016 mmol, 65%) as a 
colorless oil. 31a: IR (thin film): νmax=  2917br m, 2850m, 1716m, 1600w, 1585w, 1451w, 1361w, 
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1311w, 1272s, 1248m, 1173w, 1121m, 1023w, 771w, 714m cm
-1
;  cm
-1
; 
1
H NMR (200 MHz, 
CDCl3) δ= 8.16 – 8.08 (m, 4H), 7.76 (t, J = 7.7 Hz, 1H), 7.65 – 7.54 (m, 2H), 7.52 – 7.43 (m 4H), 
7.41 (d, J = 7.2 Hz, 2H), 5.51 (s, 4H); 
13
C NMR (50 MHz, CDCl3): δ= 166.2, 155.9, 137.6, 132.2, 
129.8, 128.6, 128.5, 120.7, 67.0; HRMS (ESI): m/z C21H17NNaO4  requires [M+Na]
+
 370.1055, 
found 370.1053. Debenzoylation of 31a (4.5 mg, 0.013 mmol) with K2CO3 in MeOH as described 
for 30 gave pyridine-2,6-diyldimethanol 31b (1.5 mg, 0.011 mmol, 82%) as an oil. Spectroscopic 
data for 31b were consistent with those previously reported for this compound.
33
 
2,6-bis(hydroxymethyl)-1-pyridin-1-olate (32b): To a solution of diketone 19 (10.5 mg, 0.021 
mmol) in dry EtOH (500 L) was added NH2OH·HCl (5.1 mg, 0.0073 mmol). After being stirred 
for 32 h at rt and 15 h at reflux, sat. aqueous NaHCO3 was added up to neutrality and the mixture 
was concentrated under reduced pressure and filtered through a short pad of silica gel 
(CHCl3/MeOH, 8:2). Purification by preparative TLC (hexane/EtOA, 1:1) gave 32a (5.3 mg, 0.014 
mmol, 68 %) as a colorless oil. 32a: IR (thin film): νmax= 2924br m, 2852w, 1717s, 1601w, 1449w, 
1368w, 1264s, 1174m, 1115s, 1071m, 1027w, 845m, 769w, 709s cm
-1
;
 1
H NMR (500 MHz, CDCl3) 
δ= 8.15 (d, J = 7.5 Hz, 4H), 7.62 (t, J = 7.2 Hz, 2H), 7.50 (t, J = 7.7 Hz, 4H), 7.46 (d, J = 7.6 Hz, 
2H), 7.34 (t, J = 8.0 Hz, 1H), 5.71 (s, J = 32.9 Hz, 4H); 
13
C NMR (125 MHz, CDCl3): δ= 165.7, 
147.3, 133.5, 129.8, 129.3, 128.6, 125.5, 122.2, 60.8; HRMS (ESI): m/z C21H17NNaO5  requires 
[M+Na]
+
 386.1010, found 370.1012. Debenzoylation of 32a (3.8 mg, 0.010 mmol) with K2CO3 in 
MeOH as described for 30 gave the corresponding diol 32b (1.2 mg, 0.008 mmol, 78%) as an oil. 
32b: IR (thin film): νmax= 3418br m, 2918w, 2849w, 1644br m, 1416w, 1358w, 1212w, 1166w, 
1085w, 1031w cm
-1
;
1
H NMR (200 MHz, CDCl3): δ= 7.36 (br s, 3H), 4.84 (br s, 4H); 
13
C NMR 
(175 MHz, CD3OD): δ= 157.6, 130.1, 122.4, 59.7; HRMS (ESI): m/z C7H9NNaO3 requires 
[M+Na]
+
 178.0480, found 178.0481. 
Converson of 31b to 32b: To a solution of pyridine diol 31b (3.5 mg, 0.025 mmol) in CHCl3 (500 
L)) was added MCPBA (1.2 eq., 0.030 mmol, 500 L,) from a stock solution (0.060 mM) in 
CHCl3. The mixture was stirred for 90 min at rt and concentrated under reduced pressure. 
Separation by preparative TLC (CHCl3/MeOH, 8:2) gave 32b (1.4 mg, 0.009 mmol, 36%) as a 
colorless oil. 
[6-(hydroxymethyl)pyrazin-2-yl]methanol (33b): To a solution of diketone 21 (10.8 mg, 0.023 
mmol) in dry EtOH (500 L) was added NH2OH·HCl (4.8 mg, 0.069 mmol). After being stirred for 
6 h at rt, sat. aqueous NaHCO3 was added up to neutrality and the mixture was concentrated under 
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reduced pressure and filtered through a short pad of silica gel (CHCl3/MeOH, 8:2). Purification by 
HPLC (hexane/EtOA, 6:4) gave 33a (5.6 mg, 0.016 mmol, 68 %) as a colorless oil. 33a: νmax= 
2917m, 2849w, 1719s, 1601w, 1451w, 1315w, 1266s, 1176w, 1110m, 1071w, 1025w, 709s cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ= 8.74 (s, 2H), 8.11 (d, J = 7.0 Hz, 4H), 7.61 (t, J = 7.3 Hz, 2H), 7.47 
(t, J = 7.3 Hz, 4H), 5.54 (s, 4H); 
13
C NMR (50 MHz, CDCl3): δ= 166.1, 150.9, 142.6, 133.5, 129.8, 
129.4, 128.6, 65.1; HRMS (ESI): m/z C20H16N2NaO4 requires [M+Na]
+
 371.3418, found 371.3419. 
Debenzoylation of 33a (6.5 mg, 0.019 mmol) with K2CO3 in MeOH as described for 30 gave the 
corresponding diol 33b (1.7 mg, 0.012 mmol, 66%) as an oil. 33b: IR (thin film); νmax=  3364br m, 
2924s, 2854m, 1723br m, 1641br m, 1576w, 1539w, 1490w, 1456w, 1418br w, 1275br m, 1160br 
w, 1083br m, 1022w, 713m cm
-1
; 
1
H NMR (200 MHz, CDCl3): δ= 8.58 (2H, br s), 4.86 (4H, br s); 
13
C NMR (50 MHz, CDCl3): δ= 153.6, 141.5, 62.9; HRMS (ESI): m/z C6H8N2NaO2 requires 
[M+Na]
+ 
163.0483, found 163.0485. 
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Chapter 4 
Discovery of a novel one-step RuO4-catalysed tandem 
oxidative polycyclization/double spiroketalization process. 
Access to a new type of polyether bis-spiroketal compounds 
displaying antitumor activity 
4.1. Introduction 
The ruthenium tetroxide mediated oxidative polycyclization of polyenes characterised by a 
repetitive 1,5-diene structural motif is a unique stereoselective process discovered a few years ago 
in our laboratories
1
 (see § 1.2). It allows to obtain adjacently linked poly-tetrahydrofuran products 
in a single step employing catalytic amounts of ruthenium tetroxide in the presence of NaIO4 as co-
oxidant. In particular, the penta-cyclization of squalene (Scheme 1)
1a,1c
 is a remarkable 
transformation in terms of stereoselectivity, overall yield and stereochemical complexity of the final 
penta-THF product (1) that includes ten newly-generated chiral centres. The cheapness and the 
availability of the starting material
2
 allowed the straightforward preparation of multi-gram amounts 
of this substance.  
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Scheme 1. Structurally complex poly-THF and spiroketal compounds through RuO4-catalysed and 
PCC-mediated oxidative chemistry starting from squalene. 
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More recently, we have discovered that penta-THF 1 when treated with PCC undergoes a 
stereoselective oxidative spiroketalization process to give compounds 2 and 3 (Scheme 1, see also § 
1.3 and 2.1) characterised by an unprecedented terminal tricyclic (A/B/F rings) spiroketal moiety.
3
 
In addition, we have devised a high-yielding route leading to small-sized spiroketals of the same 
type (4 and 5, Scheme 1) starting from 2 and/or 3. Preliminary citotoxicity tests carried out on 2 and 
3 showed that both displayed a significant inhibition on HEY ovarian-derived cancer cell line and 
BT474 breast-derived cancer cell line.
3
 
In continuing our studies in this field we report here the discovery of a novel RuO4-catalysed 
tandem oxidative polycyclization/double oxidative spiroketalization process, a transformation partly 
related to the above PCC-mediated process, that allows the one-step assembly of the new 
structurally complex polyether bis-spiroketals 6-9 (Scheme 2) starting from squalene. 
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Scheme 2. Novel C30 bis-spiroketals by RuO4-catalysed tandem oxidative polycyclization/double 
oxidative spiroketalization of squalene. Letters marking THF rings in 6 highlight the 
structural relationship with compounds 1 and 2 of scheme 1. 
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4.2. Results and Discussion 
4.2.1 Isolation of new spiroketal compounds 
Aimed at preparing higher amounts of spiro-compounds 2-5 (scheme 1) to gain further insight 
into the chemistry and anticancer activity of this new type of substance, we planned to prepare a 
large amount of penta-THF 1 (Scheme 1) by scaling-up the RuO4-mediated oxidative cyclization of 
squalene. A problem encountered on this road was the too large volume of solvent (14 L of a 3:3:1, 
CH3CN/EtOAc/H2O, mixture) required to completely dissolve the co-oxidant (NaIO4) under 
standard poly-cyclization conditions.
1a,1c
 Therefore, in one of the experiments devised to this end, 
squalene was oxidized with the same (RuO2 (cat.)/NaIO4) oxidising system using about one tenth of 
the above volume in the new 3:3:2, CH3CN/EtOAc/H2O, solvent mixture, at 0°C, where the co-
oxidant was in part undissolved. We reasoned that the complete dissolution of periodate could 
nonetheless take place during the process due to the precipitation of sodium iodate concomitant to 
the oxidation of the substrate.
4
 The new conditions allowed to oxidise a 50 g amount (122 mmol) of 
squalene using a volume of solvent (1.6 L) acceptable on a laboratory scale. Interestingly, squalene 
oxidation under the new conditions followed in part a new path. In particular, though under the new 
conditions squalene was completely consumed, penta-THF 1, usually produced in good yields under 
standard conditions, was only obtained in a less than 4% yield besides to a ca. 1% amount of the 
terminal monolactone 10
1c
 (Scheme 3), likely derived from 1 by oxidative cleavage of the 
hydroxypropyl terminus bonded to the terminal trans-THF ring, as previously observed for PCC 
(Scheme 1, see conversion of 2 to 3 and § 2.2.2 for a mechanistic rationalisation). Formation of 
such a terminal lactone had also been observed in the oxidative polycyclization of digeranyl with 
the same oxide.
1f
 However, contrary to what observed under previously employed conditions,
1
 an 
abundant less polar fraction was now produced along with a very abundant more polar fraction 
comprising most of the recovered material.  
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Scheme 3. Further poly-THF products derived from the oxidation of squalene. 
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HPLC separation of the less polar fraction, revealed it to be composed of a mixture of spiroketal 
compounds, structurally related to compounds 2-5 (Scheme 1) on the basis of the characteristic 
chemical shifts of the methyl proton signals pertinent to the spiroketal moieties (1.46-1.47 and 1.01 
ppm: Me-1/Me-25 and/or Me-24/Me-30, Scheme 2; numbering in these compounds follows the one 
of penta-THF 1 shown in Scheme 1). In particular, the four isomeric polyether bis-spiroketals 6-9 
were isolated as the main products belonging to this fraction, in an overall 5% yield (their 
approximate ratio is 6/7/8/9, 1.1:1.7:1.0:3.3). 
The stereostructure of the non-symmetric compound 6 was determined by X-ray diffraction 
analysis (Figure 1) carried out on a single crystal of the substance obtained from hexane/EtOAc 
(9:1) by slow evaporation of the solvent. It is made up of a central cis-THF ring flanked by two 
structurally similar terminal tricyclic spiroketal moieties only differing by the configuration of the 
THF rings (B and D) engaged into the spiroketal junctions. In particular, O2/Me-27 are cis and 
O7/Me-28 are trans (Figure 1 and Scheme 2). The two bridging THF rings (A and E) involved into 
the spiroketal portions both possess cis configuration and, in addition, an all-threo relationship 
subsists between the central THF and the flanking THFs, a fact that has significant mechanistic 
implications (see later Schemes 4 and 5).
1a,1c 
Bis-spiroketals 7-9 (Figure 1 and Scheme 2) proved to be isomeric with 6 and possessed 
symmetric structures as indicated by the halving of the 
1
H and 
13
C NMR signals. 2D NMR data 
could give unambiguous information on the spiroketal moiety in all these compounds. In particular, 
as previously observed for related mono-spiroketals 2 and 3 (Scheme 1), the rigidity of the 
spiroketal portions invariably produced strong nOe correlations between Me-25 and Me-27 when B 
ring is cis, as in 6, 7 and 9 or, alternatively, between Me-26 and Me-27 when B ring is trans as in 8 
(Figure 2). However, NMR data could not settle the cis/trans identity of the central THF ring in 
these compounds due to their symmetry. The complete stereostructure of 7-9 was eventually 
determined by X-ray diffraction analysis for these compounds as well (Figure 1). Crystals suitable 
for these experiments were obtained for all three substances from hexane by slow evaporation of the 
solvent. Compounds 7 and 8 are both CS-symmetric. The former possesses the three THF rings of 
the molecule (A, C and E)) in a cis configuration and O2/Me-27 and O7/Me-28 are both cis as well. 
Compound 8 still possesses the same three A, C, and E cis-THF rings but O2/Me-27 and O7/Me-28 
are now trans. Compound 9 possesses a C2 symmetry differing from 7 only for the trans nature of 
the central THF ring. In addition, a threo relationship exists between B,C and C,D pair of rings in 
compounds 7-9 as well.  
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Figure 1. ORTEP drawings of bis-spiro-compounds 6-9. Ellipsoids are drawn at 30% probability 
level. 
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Figure 2 Characteristic nOe correlations within the spiroketal moiety, including a cis (left) or trans 
(right) ring-B THF, observed for 6-9. 
Interestingly, contrary to what expected on the basis of the similarity of the RuO4- and PCC-
mediated spiroketalization processes, formation of mono-spiroketals 2 and/or 3, derived from the 
sole spiroketalization of the penta-THF 1 at its cis-cis-terminus (see scheme 1), was not observed. 
However, it cannot be excluded that these compounds once formed could undergo further oxidative 
transformations. 
From a mechanistic point of view, seven consecutive cyclization steps should take place to built 
up the structure of spiroketals 6-9 from squalene (Scheme 4), simply taking into account the closure 
of the seven rings composing these compounds. Actually, given the catalytic nature of the overall 
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process, the reoxidation of ruthenium bonded to the various intermediates (see scheme 5 later) takes 
place more or less doubling the involved steps. The threo nature of all inter-THF relationships in all 
four bis-spiroketals suggests that a penta-THF backbone (see 11) was preliminarily assembled 
through a cascade process (five consecutive THF-forming steps) where the syn-addition of two 
oxygens across each reacting trans double bond takes place according to the mechanism previously 
hypothesised for the formation of penta-THF 1.
1a,1e
 The configuration of each THF shown in 11 
reflects the ones found in bis-spiroketals 6-9 to which it eventually give rise. Once formed each bis-
THF terminus of the proper penta-THF diol 11 is involved into an oxidative spiroketalization step 
where the C-7 and C-18 spirocentres are formed very likely through the action of a close-in-space 
oxoruthenium appendage tethered to C-2 or C-23 on the C(7)-H or C(18)-H bonds, respectively. 
Though the ability of RuO4 to attack the -hydrogens of tetrahydrofuran (oxidation of 
tetrahydrofuran to -butyrolactone) is known,5 this type of reactivity is unprecedented. 
As for the formation of the penta-THF diol intermediate 11 (Scheme 4), the first steps of the 
cascade process leading to this species are shown in Scheme 5. In particular, the sequence begins 
with the attack of RuO4 at the terminal double bond of squalene to give a ruthenium(VI) diester 
(12). Closure of the first THF ring proceeds with cis stereocontrol, as usually observed in the 
oxidative mono-cyclizations of 1,5-dienes mediated by all three related oxo-species RuO4,
6
 OsO4
7
 
and MnO4
-8
 as well as for the RuO4-catalysed polycyclizations of both linear and isoprenoid 
polyenes.
1a-f
 Thus, a cis-threo mono-THF intermediate species (14) is obtained through a 3+2 
cycloaddition of an O-Ru=O portion of the ruthenium bis-glycolate 12 across the second (6) C-C 
double bond, with the molecule adopting the chair-like conformation 13 in the transition state. 
Then, the metal, is oxidised at an “active” oxidation state (see intermediate 15) by NaIO4, thereby 
allowing for the second cyclization step to take place via another [3+2] cycloaddition reaction once 
again involving a O-Ru=O portion and the successive (10) double bond in the carbon chain, to give 
the bis-threo, bis cyclised, intermediate 16. Usually, this second cyclization step is cis-selective as 
well but in one case, the oxidation of digeranyl,
1f
 we observed a trans selectivity. Reiteration of the 
cyclization/ruthenium oxidation sequence then occurs with a Ru-containing portion (likely RuO3) 
migrating along the carbon chain to eventually deliver penta-THF 11 diol by hydrolysis or more 
likely this species is not formed and the Ru-containing appendage tethered to its terminus C(23)-OH 
initiate the first spiroketalization as shown in scheme 4. Therefore, in the new process leading to 
bis-spiroketals 6-9, only the first THF-forming step proceeds with the usual cis stereoselectivity 
with all-the other THF being formed in a non stereoselective manner with a cis or trans 
configuration. 
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Scheme 4. A plausible mechanistic hypothesis explaining the formation of bis-spiroketals 6-9 from 
squalene 
We have evidence indicating that the spiroketal-forming steps involved in the sequence shown in 
Scheme 4 proceed with retention of configuration at the involved (C-7 or C-18) carbon centres. In 
particular, besides bis-spiroketals 6-9, mono-spiroketal 17 (Scheme 6), possessing the same 
constitution of 2 (see Scheme 1), was isolated from the reaction mixture as well (0.5% yield), likely 
originating from a single spiroketalisation of the suitable penta-THF precursor according to the 
mechanism shown in Scheme 4. Its structure, was deduced by 2D NMR spectroscopic evidences. In 
particular, inter alia, a strong nOe correlation (shown in Scheme 6) was observed between the 
angular Me-28 and the C(18)-H that unambiguously settled the cis configuration of the D THF ring 
in this compound. Compound 17 is likely the immediate precursor of the bis-spiroketal 9 along the 
path highlighted in Scheme 4. We decided, therefore, to study the possible spiroketalization of 17 to 
9 both to confirm the hypothesis postulated in Scheme 4 and to disclose the stereochemical course 
of this transformation. 
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Scheme 5. Ru-catalysed cascade sequence leading to the intermediate penta-THF 11 shown in 
Scheme 4. 
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Scheme 6. RuO4-mediated oxidative mono-spiroketalization and the competing oxidative cleavage. 
As for this reaction, the same RuO2(cat)/NaIO4 system employed to convert squalene into 
compounds 6-9 was initially used, but four equiv. of the co-oxidant were employed now. In this 
way compound 9 was obtained in a 25% yield from 17 along with a 25% of the terminal lactone 18 
derived from a competing process where the hydroxypropyl terminus in 17 is oxidatively cleaved 
(scheme 6). This result indicated that the transformation of 17 to 9 proceeds with retention of the 
configuration at the C18-forming spirocentre, as previously observed for the analogous PCC-
mediated process (Scheme 1).
3
 Therefore, very interestingly, the chemical behaviour of RuO4 in this 
transformation parallels that displayed by PCC which is able to both induce spiroketalization and 
cause the oxidative scission of the hydroxypropyl terminus in 1 (scheme 1).
1c,1f,3,9
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Pleasingly, the yield of 9 raised to 51% when the reaction was conducted using the catalytic 
system RuCl3(10%)/NaIO4 (6 equiv.) in the biphasic mixture CH3CN/EtOAc/H2O (1:1:1). 
Meanwhile, a diminished yield (21%) of lactone 18 was obtained, though the process stopped at 
80% conversion. The above transformation is still unoptimised and its synthetic potential towards 
mono- or bis-spiroketals of the above type is to be further evaluated on a broader range of 
substrates. However, it is worth noting that the effectiveness of this process is higher than that 
displayed by the analogous PCC–mediated reaction previously tested on penta-THF 1 (Scheme 1). 
With a sample of lactone 18 in hand we were also able to isolate a little amount (ca. 0.1%) of this 
substance in the crude derived from the initial oxidation of squalene. This is further evidence that 
indeed, in the course of the oxidation of squalene, the above spiroketalization of 17 takes place 
along the path leading to 9. The concomitant formation of 9 and 18 seems to suggest that the above 
hypothesised oxoruthenium appendage tethered to the C-23 OH (see Scheme 4) could both attack 
the H-18 and the H-22 through competing, and possibly strictly related, paths, as shown in Scheme 
7. This step is reminiscent of the hydride abstraction postulated by Lee and Van den Engh
5
 to occur 
as the first, rate determining, step in the oxidation of tetrahydrofuran by ruthenium tetroxide in 
aqueous perchloric acid solutions, leading to an oxonium ion intermediate. Further studies are 
currently ongoing to collect evidence on the mechanism of the above Ru-mediated spiroketalization 
process. 
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Scheme 7. Possible first step of the competing Ru-mediated oxidative cleavage and oxidative 
spiroketalization of 17 
4.2.2 Antitumor activity of spiroketal compounds 6-9 and 17 
It has been reported that poly-THF
10
 and spiroketal
11
 compounds display cytotoxic activity. 
Based on these precedents and the significant cell killing effect exhibited by mono-spiroketals 2 and 
3 on HEY ovarian-derived cancer cell line and BT474 breast-derived cancer cell line,
3
 cytotoxicity 
tests on the same cellular lines were carried out by using different concentrations (0.1 M, 1.0 M 
and 10 M) of spiroketals 6-9 and 17. After two weeks of treatment the viability of the cells was 
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assessed measuring the mitochondrial activity
12
 using the phosphate buffer saline (PBS) medium as 
negative control (Figure 3). In the HEY cell line (Figure 3, panel A) compound 9 showed the 
highest activity killing around 20% of cells already at the concentration of 0.1 M, while it doubled 
its activity (40% of cell death) at the concentration of 10 M. A lower activity was observed for its 
isomers 7 and 8 (20-25% of cell death). Interestingly, non-symmetric compound 6 differing from 7 
and 8 only for the configuration of the D or B THF rings, respectively, proved to be inactive thus 
highlighting the importance of symmetry in maintaining the antitumor activity. Likewise, mono-
spiroketal 17, the precursor of bis-spiroketal 9 (Scheme 6), was scarcely active (5-10% cell death) 
at both 1.0 M and 10 M. However, it is worth comparing the activities of 17 and the 
diastereomeric mono-spioroketal 2 (Scheme 1 and Figure. 3), previously tested on the same HEY 
cells,
3
 differing from 17 only for the configuration of the terminal bis-THF moiety (trans-trans in 2 
and cis-cis in 17; Figure 3 right). Compound 2 caused a 70% cell death after 14 days at a 10 M 
concentration. This remarkable difference between the two diastreomers indicated that the 
configuration of the terminal bis-THF portion in these compounds plays an important role in 
determining the significantly higher activity of 2. 
Higher activities were observed when the BT474 cell line (Figure 3, panel B) was treated with 
symmetric bis-spiroketals 7-9 at the same concentrations, suggesting that some degree of specificity 
exists for these compounds. In particular, compound 7 possesses the strongest cell killing activity 
on BT474 cell line (a 60% of cell death was observed already at the lowest concentration of 0.1M 
that increased to 70% at 10 M). Compound 8 was scarcely active at 0.1 M and 1.0M but a 65% 
of cell death was observed at 10M. Isomer 9 caused a 60% cell death at 10 M though a 30-40% 
cell death was already observed at lower concentrations. As observed in the HEY cell line, non-
symmetric 6 was inactive at 0.1 M and 1.0M while a 30% cell death was observed at 10 M. In 
addition, compound 17 showed no activity on this cell type as well. Once again, its diastereomer 2 
showed a good activity causing a 76% cell death at 10 M. 
In summary, in the bis-spiroketal series the activity seems to be related to the configuration of 
the spiroketal moiety with symmetric compounds 7-9 possessing a higher activity. On the other 
hand, the activity of mono-spiroketals 2 and 17 appears to be due to not only to the spiroketal 
portion but also to the presence of a terminal poly-THF portion of suitable configuration.  
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Figure 3. Cytotoxic effect of spiro-compounds 6-9 and 17 in two different tumor-derived cell 
lines. Ovarian cancer-derived cell line (HEY; Panel A) and breast cancer-derived cell line 
(BT474; Panel B) were treated with compounds 6, 7, 8, 9 and 17 at the concentration of 
0.1μM (black bars), 1.0 μM (white bars), 10 μM (grey bars) and cell viability was 
assessed by MTS assay. Phosphate buffer saline (PBS) was used as control. Data for 2 are 
from ref. 3. The structure of 2 and 17 are shown on side. The structural portion in the 
boxes is common to the two substances. 
4.2.3 Isolation of a bis-iodurated tetra-THF as a trace product 
Careful further HPLC separation of the reaction mixture allowed also the isolation of tetra-THF 
19 (Figure 4), a very minor side-product of the process, possessing a CS-symmetric structure 
embodying two terminal cis-threo-trans bis-THF moieties connected by a central bis-iodurated 
tetracarbonious segment.  
OO
OHI I H H
OO
H HOH
1
3 6 10
11 14
15
19
threoerythrothreo erythro
 
Figure 4. Bis-iodurated tetra-THF isolated as a trace product from the reaction mixture. 
Chapter 4 
 
96 
 
The structure of compound 19 was determined by X-ray diffraction analysis carried out on a 
single crystal of the substance obtained by slow evaporation of a chloroform solution. The most 
interesting, and unusual feature of this compound is the double erythro configuration around the 
C10/C11 and C14/C15 bonds. In fact, previous studies from our group had demonstrated that the 
oxidation of both linear and isoprenoid polyenes constantly furnishes poly-THF compounds 
possessing threo inter-THF relationships (see Scheme 5).  
Based on these precedents, formation of 19 was intriguing and could be rationalised through a 
double cis/trans-selective oxidative bis-cyclization process (Scheme 8). Each bis-cyclization event 
involves three consecutive double bonds of the polyene chain starting from the terminal ones. In 
particular, attack of RuO4 to the 
2
 double bond induces two successive cyclization steps giving rise 
to bis-THF intermediate 20, in the same manner as shown for the synthesis of 1 (see intermediate 
16, Scheme 5). A second bis-cyclization would then occur at the other side of the molecule by 
attack of RuO4 at the terminal, 
22
, double bond to give the all-threo tetra-THF 21 still possessing 
two oxoruthenate appendages linked to C-11 and C-14. It can be presumed that a double 
substitution of the ruthenium-containing portions, with inversion of configuration at involved 
carbon centres, would then occur during the reductive quenching of the process, by iodide ions 
probably generated in situ by the action of tiosulphate on iodate in turn produced during the 
oxidation of RuO2 to RuO4. It cannot be excluded that iodide could originate from reduction of 
periodate itself not completely consumed in the reaction medium. It is probable that such a side-
process could be due to the higher concentration of the reaction medium in the new experimented 
conditions. 
In order to enlarge the range of polyether substances accessible through the Ru-mediated 
polycyclization process we began an exploration of the possible post-synthetic modifications of 
some of the poly-THF backbones obtained through the above process. We have previously 
demonstrated that progressive structural simplification of compound 1 to small-sized poly-THF 
compounds can be achieved via an iterative PCC-mediated oxidative cleavage/reduction sequence.
1c
 
The entire process is possible due to the two alcohol functionalities adjacent to the terminal THF 
rings that are prone to be intercepted by PCC.
20
 In addition, a new type of cytotoxic spyroketal 
poly-THF compound, strictly related to bis-spiroketals 2-5, could be accessed through a PCC-
mediated oxidative spiroketalization process starting from 1 (Scheme1, § 1.3 and 2.1).
 [3]
 In a more 
recent study we have also shown that the same oxidant, or the related system PCC-H5IO6, is able to 
attack the angular CH position of the THF ring in various mono and poly-THF substrates leading to 
either the oxidative opening of the THF ring or the oxidative cleavage of suitable inter-THF bonds 
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(see § 2.2.4 and 2.2.5).
21
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Scheme 8. A plausible path for the formation of tetra-THF 19. 
As a continuation of this project, we envisaged that compound 19, possessing a central bis-(-
iodo-THF) portion, could be a good model compound to probe a double rearrangement-ring 
expansion process involving the two internal THF rings as a means to access a new type of mixed 
THF-THP polyether compounds further functionalised for successive synthetic manipulations 
providing access to new polyether polycyclic materials. This type of reaction has previously been 
carried out on substances containing a single -iodo-THF subunit22 but has never been attempted on 
a substrate containing two -iodo-THF moieties and, in particular, to the best of our knowledge, the 
double rearrangement-ring expansion of a bis-THF substance has never been accomplished. Related 
chemistry has been successfully employed for example in the synthesis of salynomicin
23
 as well as 
in the synthesis of a bis-oxepane portion of hemibrevetoxin.
24
 Pleasingly, when compound 19 was 
reacted with excess Ag2CO3 (5 equiv.) in acetone/water (8:2, 40 °C, 4 h), compound 22 was 
obtained in a 65% yield demonstrating the feasibility of the projected transformation (Scheme 9). 
Proof for the structure 22 was gained by chemical and high-field 2D NMR evidence. Attempted 
acetylation and benzoylation under standard conditions only delivered unreacted 21 indicating, as 
expected, the presence of tertiary hydroxyl groups in this compound. 
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Scheme 9. Double rearrangement-ring expansion of compound 19. 
A 
1
H
1
H COSY experiment at 700 MHz indicated the presence in 22 of the two five-proton spin 
systems H-3/H2-4/H2-5 and H-7/H2-8-H2-9 belonging to the two adjacent rings as well as the H-
11/H2-12 spin system. Assignment of each of these spin systems to the proper ring came from 
considerations of spectral data and comparison with strictly related THF- and THP-containing 
substances. In particular, the signals resonating at  3.86 and 2.36 were assigned, respectively, to 
the angular THF proton (H-3) and to the H-5 proton based on the good agreement of their 
chemical shift values with those typically exhibited by these protons in strictly analogous poly-THF 
substances including the same cis-THF-containing substructure, previously synthesised in our 
laboratories.
1
 This deduction suggested that the two higher field one-proton resonances at  3.26 
(H-7) and 3.16 (H-11) could be ascribable to the angular hydrogens in the THP ring. 
The good proton dispersion of the signals in the 
1
H NMR spectrum of 22 allowed us to fully 
analyse some crucial signals. In particular, the presence of a THP ring in 22 was corroborated by J 
values (J = 12.5, 3.6 Hz) of the H-9 equatorial proton resonating as a clean double triplet at  1.89, 
as expected for an equatorial proton next to a quaternary centre (C-10) in a six-membered ring 
possessing a chair conformation. In addition, a W coupling observed between the signal at  1.54 
for Hax-9 and the singlet methyl resonance at  1.19, ascribable to the C-10 methyl group, also 
pointed to the presence of a THP ring and the axial nature of that methyl. W-type long-range 
couplings were also observed between the singlet resonances at  1.23 and 1.05 allowing 
assignment of these signals to the two methyls belonging to the terminal 2-hydroxyisopropyl group. 
Similarly, a long-range coupling between the methyl signal at  1.12 and the Ha-5 resonance at 
2.36 allowed to assign the former resonance to the angular methyl of the THF ring (C6-Me). 
These conclusions were reinforced by data from a very informative 700 MHz NOESY 
experiment (Figure 5) that also provided conclusive information on the relative configuration of the 
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C-7, C-10 and C-11 centres belonging to the THP ring in 22. In particular, the cis nature of the THP 
ring was inferred by the presence of a strong correlation peak between signals for the H-7 and H-11 
angular protons. Similarly, the axial nature of the C-10 methyl, was further corroborated by a nOe 
correlation between its resonance at  1.19 and that of the Hax-8 proton at  1.74. The rest of nOe 
cross peaks shown in Figure 5 were in full agreement with the given stereostructure. 
 
Figure 5. Summary of some significant 700 MHz NOESY correlations for compound 22 (due 
to the symmetry, half molecule is shown). 
X-ray crystallography of compound 19 
Molecules of 19 in the crystals are centrosymmetric (Ci point group) as they lie on 
crystallographic inversion centres (Figure 6). The molecules have a stretched winding shape, which 
is due to the double cis-trans sequence of the 2,5-disubstituted THF rings and to the trans-planar 
conformation of the carbon chain.  
 
Figure 6. ORTEP view of 19. 
The molecular conformation is stabilized by an intramolecular H bonding between OH donor 
and the oxygen acceptor of the inner THF ring (O1−H∙∙∙O3 0.983, 2.224, 3.175(9) Å, 163°). Ring 
puckering coordinates of the inner THF ring are q2 = 0.356(6) Å 2 = 211(1)°, and of the outer are 
q2 = 0.316(7) Å 2 = 324(1)°. On the basis of the calculated phase angles, it can be argued that both 
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are basically in envelope conformation, with C7 and C4 atoms out of the envelope plane. 
The packing of molecules is accomplished through weak H bonding interactions between iodine 
atoms as bifurcated acceptors and methyne CH donors.25 This is clearly shown in Figure 7. Chains 
of H-bonded molecules are formed which run along b + c and b – c lattice directions. The weak H-
bonding leads to the formation of ring patterns having graph set descriptor . Along a 
molecules are stacked in layers through van der Waals contacts. 
 
Figure 7. Crystal packing of 19 viewed down b. 
)7(12R
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4.3. Conclusions 
In conclusion, a novel RuO4-catalysed oxidation of squalene, characterised by a tandem penta-
cyclization/double oxidative spiroketalization, has been discovered. Preliminary experiments 
conducted on the mono-spiroketalization step of the sequence leading to bis-spiroketal 9 highlighted 
the potential of this transformation for the synthesis of the spiroketal moiety included in substances 
of the above type. The symmetric bis-spiroketals 7-9 showed the highest antitumor activity and a 
selectivity for the breast cancer-derived cell line. Though the yield of these bis-spiro compounds is 
low it should not be forgotten that these products are formed through a complex cascade process 
made up of at least seven steps each proceeding with an overall average yield of about 65%. In 
addition, the starting product, squalene, is a commercially available, cheap material
2
 and the process 
can be carried out on a large scale allowing the access, in a single step, to hundred milligrams of 
new materials characterised by a remarkable sterostructural complexity, hardly accessible through 
alternative synthetic routes. The process allows to obtain an almost complete set of stereoisomeric 
substances thus opening up the way to further structure-activity relationship studies concerning, for 
example, their citotoxicity as well as the possible metal-binding ability or ionophoric aptitude.
13
 
The present study has also evidenced a close similarity in the oxidative chemical behaviour 
(oxidative spiroketalization/oxidative cleavage) of PCC and RuO4 towards poly-THF substances 
possessing terminal tertiary alcoholic portions of suitable configuration, that is worth of further 
investigation. As far as we know this is the most complex process involving RuO4 ever 
discovered.
14 
Eventually, the isolation of bis-iodocompound 19 was interesting from both a 
mechanistic and a synthetic point of view. Its existence among the oxidation products of squalene 
with RuO4 was indicative of the existence of an intermediate species (see 21, Scheme 8), carrying 
oxoruthenium substituents, likely ORuO3 groups, adjacent to the two internal THF rings, able to 
undergo a facile nucleophilic displacement, that enforces the mechanistic hypothesis previously put 
forward to explain the formation of penta-THF 1 from the same substrate (Scheme 5). In addition, 
the postulated mechanism for the formation of 19 also suggests a new possible use of the RuO4-
catalysed polycyclization process where suitable polyenes can be induced to undergo bidirectional 
poly-THF-forming oxidative sequences. The facile access to a novel type of bis-THF-bis-THP 
compound (22) has been demonstrated via a double ring-enlargement process. Studies are in 
progress to further develop the chemistry presented here toward the synthesis of new THP-
containing polyether compounds.
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4.4. Experimental Section 
4.4.1 General methods 
All reagents were purchased (Aldrich and Fluka) at the highest commercial quality and used 
without further purification. Reactions were monitored by thin-layer chromatography carried out on 
precoated silica gel plates (Merck 60, F254, 0.25 mm thick). Merck silica gel (Kieselgel 40, particle 
size 0.063-0.200 mm) was used for column chromatography. HPLC separations were carried out on 
a Varian 2510 apparatus equipped with a Waters R403 dual cell differential refractometer using 
Phenomenex 250 x 10 mm and 250 x 4.6 mm (both 5) and NUCLEOSIL C18 250/10 columns. 
NMR experiments were performed on Varian Unity-Inova 500 and Gemini 200 spectrometers in 
CDCl3. Proton chemical shifts were referenced to the residual CHCl3 signal (7.26 ppm); 
13
C-NMR 
chemical shifts were referenced to the solvent (77.0 ppm). J values are given in Hz. Abbreviations 
for signal coupling are as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. IR spectra 
were collected on a Jasco FT-IR-430 spectrometer. ESI mass spectrometric analyses were recorded 
on an Applied Biosystems API 2000 mass spectrometer equipped with an Electrospray source used 
in the positive mode. The High Resolution MS were recorded on a Bruker APEX II FT-ICR mass 
spectrometer using electron spray ionization (ESI) technique. For all the reported products the 
numbering previously given
1c
 for the penta-THF 1 is used. 
4.4.2 Bis-spiroketals 6-9, monospiroketal 17 and lactone 18 
Squalene (50 g, 122 mmol), placed into a 5L round-bottomed flask equipped with a mechanical 
stirrer, was dissolved in the biphasic mixture EtOAc/CH3CN/H2O (3:3:2, 1.6 L). The solution was 
cooled to 0 °C and NaIO4 (8 equiv., 976 mmol, 209 g) and RuO2•2H2O (20 mol%, 24.4 mmol, 3.25 
g) were sequentially added under vigorous stirring. A voluminous amount of a grey solid formed 
within a few minutes. After 30 min excess Na2S2O3•5H2O was added and the mixture was stirred 
for further 10 min and then filtered through a Buchner funnel. The solid left on the Buchner was 
thoroughly washed with EtOAc and the resulting biphasic solution was concentrated in vacuo. The 
aqueous suspension was extracted with EtOAc (3 x 300 mL). The combined organic phase was 
dried (Na2SO4) and evaporated in vacuo to give an oily product that was chromatographed on silica 
gel (50 x 8 cm column) eluting with petroleum ether (40-70)/Et2O mixtures (from 7:3 to 100% 
ether) and then with CHCl3/MeOH mixtures (up to CHCl3/MeOH 8:2) to give three fractions: 
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fraction A (7.40 g) eluted before penta-THF 1; fraction B (4.75 g) containing penta–THF 1 and 
lactone 10; fraction C (35.18 g) eluted after penta-THF 1. 
A sample (500 mg) of the less polar fraction A was separated by HPLC (250 x 10 mm column, 
eluent: hexane-EtOAc, 65:35, flow 2.5 mL/min, 30 mg/injection) to give bis-spiroketal 9 (133 mg, 
2.3 %, tR = 7.0 min), a mixture of bis-spiroketals 6 and 7 in an approximate ratio of 2:3 (113 mg, 
1.98 %, tR = 8.5 min; 6: 0.8%; 7: 1.2%), bis-spiroketal 8 (38 mg, 0.7 %, tR = 9.6 min) and mono-
spiroketal 17 (40 mg) impure of lactone 18. Their separation was eventually achieved by reverse-
phase HPLC (eluent: MeOH-H2O, 8:2, flow 2.5 mL/min; 17: tR = 10 min; 18: tR = 8.5 min) to give 
28 mg (0.5 %) of 17 and 5 mg (0.1%) of 18. A pure samples of 6 was obtained from the above 
mixture of 6 and 7 by reverse-phase HPLC (eluent: MeOH-H2O, 8:2, flow 2.5 mL/min, 17 
mg/injection. 6: tR = 11.6 min). A sample of 7 still contaminated by 6 was obtained from the same 
separation (tR = 12.0 min). A further HPLC run was necessary to obtain pure 7 (250 x 4 mm 
column, hexane-EtOAc, 85:15, tR = 13.8 min). 
Fraction B was chromatographed on silica gel (50 x 5 cm column) eluting with petroleum ether 
(40-70)/Et2O (1:1) to give 2.93 g of a mixture of 1 and the corresponding lactone 10 in an 
approximate ratio of 4:1 (1: 3.8%; 10: 1.0%). Further elution with CHCl3/MeOH (9:1) gave 2.18 g 
of a more polar material that was no further investigated. 
 
6: Amorphous solid. IR (neat) max 2969, 2870, 1457, 1378, 1364, 1216, 1174, 1104, 1042 (str), 
993, 962, 918, 889, 870, 846  cm
-1
. 
1
H-NMR (500 MHz, CDCl3)  3.92 ( 1H, t, J= 7.1), 3.850 (1H, 
d, J= 7.0), 3.846 (1H, d, J= 7.0), 3.64 (1H, dd, J= 9.7, 5.5), 1.47 (3H, s), 1.45 (3H, s), 1.36 (3H, s), 
1.33 (3H, s), 1.31 (3H, s), 1.18 (3H, s), 1.01 (3H, s), 1.00 (3H, s); 
13
C-NMR (75 MHz, CDCl3) C 
109.44, 109.39, 86.9, 85.3, 84.9, 84.6, 82.58, 82.50, 82.4, 82.1, 74.6, 74.5, 36.2, 35.1, 33.73, 33.67, 
31.8, 31.6, 27.2, 26.7, 26.5 (3xC), 26.3, 26.2, 25.2, 25.1, 22.5, 21.3, 21.0; ESIMS: m/z 543 
[M+Na]
+
, 559 [M+K]
+
; HRESIMS: m/z 543.3278 ([M+Na]
+
, C30H48O7Na, requires 543.3298). 
 
7: Amorphous solid. IR (neat) max 2969, 2870, 1457, 1376, 1218, 1174, 1101, 1041 (str), 993, 961, 
919, 888, 869, 848, 754 cm
-1
. 
1
H-NMR (500 MHz, CDCl3)  3.85 (1H, d, J= 7.2), 3.65 (1H, bt, J= 
5.3), 1.47 (3H, s), 1.36 (3H, s), 1.30 (3H, s), 1.01 (3H, s); 
13
C-NMR (125 MHz, CDCl3) C 109.3, 
85.5, 84.2, 82.5, 82.4, 74.5, 36.3, 33.6, 31.8, 26.65, 26.56, 26.51, 26.1, 25.2, 21.2; ESIMS: m/z 543 
[M+Na]
+
, 559 [M+K]
+
; HRESIMS: m/z 543.3283 ([M+Na]
+
, C30H48O7Na, requires 543.3298). 
 
8: Amorphous solid. IR (neat) 2969, 2870, 1457, 1374, 1213, 1174, 1105, 1042 (str), 989, 963, 906, 
Chapter 4 
 
104 
 
889, 869, 845 max cm
-1
. 
1
H-NMR (500 MHz, CDCl3)  3.94 (1H, bt, J= 5.3), 3.84 (1H, d, J= 7.0), 
1.45 (3H, s), 1.34 (3H, s), 1.19 (3H, s), 1.00 (3H, s); 
13
C-NMR (50 MHz, CDCl3) C 109.4, 86.9, 
85.1, 82.5, 82.0, 74.5, 34.9, 33.6, 31.6, 27.4, 26.5, 26.3, 25.0, 22.3, 21.0; ESIMS: m/z 543 [M+Na]
+
, 
559 [M+K]
+
; HRESIMS: m/z 543.3307 ([M+Na]
+
, C30H48O7Na, requires 543.3298). 
 
9: Amorphous solid. IR (neat) max 2968, 2867, 1456, 1375, 1218, 1175, 1105, 1043 (str), 998, 962, 
933, 915, 904, 889, 867, 846 cm
-1
. 
1
H-NMR (500 MHz, CDCl3)  3.85 (1H, d, J= 7.1), 3.74 (1H, 
bdd, J= 8.0, 6.1), 1.47 (3H, s), 1.32 (3H, s), 1.23 (3H, s), 1.02 (3H, s); 
13
C-NMR (125 MHz, CDCl3) 
C -109.6, 85.3, 85.2, 82.5, 82.3, 74.4, 36.0, 33.7, 33.6, 27.2, 26.5 (2xC), 26.0, 25.2, 21.3; ESIMS: 
m/z 543 [M+Na]
+
, 559 [M+K]
+
; HRESIMS: m/z 543.3272 ([M+Na]
+
, C30H48O7Na, requires 
543.3298). 
 
17: Amorphous solid. IR (neat) max 3470 (OH), 2969, 2871, 1455, 1372, 1217, 1176, 1150, 1104, 
1065, 1042(str), 996, 961cm
-1
. 
1
H-NMR (500 MHz, CDCl3)  3.85 (4H, overlapped m’s), 3.80 
(1H, t, J= 6.8), 3.1 (1H, bs, OH) 1.47, 1.31, 1.24, 1.21, 1.15, 1.11, 1.07, 1.01 (3H each, s’s, 8x Me); 
13
C-NMR (125 MHz, CDCl3) C 109.5, 85.5, 85.0, 84.8, 84.2, 83.9, 83.6, 82.6, 82.29, 82.26, 74.4, 
71.6, 36.0, 34.1, 33.8, 33.7, 33.2, 27.8, 27.6, 27.17, 27.12, 26.51, 26.49, 26.0, 25.7, 25.2, 24.6, 23.5, 
23.3, 21.2; ESIMS: m/z 545 [M+Na]
+
; HRESIMS: m/z 545.3465 ([M+Na]
+
, C30H50O7Na, requires 
545.3454). 
 
18: Oil; IR (neat) max 2968, 2870, 1774, 1460, 1375, 1237, 1158, 1016, 962 cm
-1
. 
1
H-NMR (500 
MHz, CDCl3) 3.85 (2H, m), 3.77 (2H, m), 2.75 (1H, m), 2.48-2.38 (2H, m), 1.47, 1.35, 1.31, 
1.25, 1.11, 1.01 (3H each, s’s, 6x Me); 13C-NMR (125 MHz, CDCl3) C 177.5, 109.6, 85.9, 85.39, 
85.38, 84.8, 84.3, 83.6, 82.6, 82.3, 74.3, 36.0, 34.0, 33.6, 33.4, 31.8, 29.8, 27.5, 27.1, 26.6, 26.52, 
26.50, 25.7, 25.2, 24.5, 23.2, 21.2; ESIMS: m/z 501 [M+Na]
+
; HRESIMS: m/z 501.2840 ([M+Na]
+
, 
C27H42O7Na, requires 501.2828). 
4.4.3 Mono-spiroketalization of 17 to 9 
Catalytic procedure I 
To mono-spiroketal 17 (6.6 mg, 0.0126 mmol) dissolved in a mixture of CH3CN/H2O (3:2, 60 
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L/40 L) was added NaIO4 (4 equiv, 18 mg, 0.083 mmol) followed by 60 L (20 mol %) of a 
RuO4 stock solution (0.032 mM) in EtOAc at 0°C. After 30 min stirring, Na2S2O3 5H2O (excess) 
was added and the mixture was extracted with EtOAc (3x 1 mL), dried (Na2SO4) and taken to 
dryness to give 5.3 mg of an oily product. The crude was chromatographed on silica gel using 
hexane-EtOAc mixtures as eluent to give 1.2 mg of pure 9 and 2.5 mg of a mixture of unreacted 17 
and lactone 18 in a ratio of 1.3/1 as estimated by 500 MHz 
1
H-NMR. Yields based on reacted 17 at 
70% conversion are as follows: bis-spiroketal 9 (25%), lactone 18 (25%). 
Preparation of the RuO4 stock solution 
The RuO4 stock solution employed in the above experiment was prepared as follows. To a 
solution of NaIO4  (4 equiv, 17.7 mg) in H2O (1 mL) was added RuO2 2H2O (2.8 mg) and the 
mixture was vigorously stirred until all the black dioxide was converted in RuO4. The latter was 
then extracted in EtOAc (0.5 mL) and used in the above process. 
Catalytic procedure II 
Mono-spiroketal 17 (6.0 mg, 0.011 mmol) was dissolved in a mixture of CH3CN/EtOAc/H2O 
(1:1:1; 0.5 mL each) and NaIO4 (6 equiv, 15 mg, 0.068 mmol) were added followed by RuCl3 (10 
mol %, 12 L) from a stock solution in EtOAc, at room temperature. After 2.5 h stirring iso-
propanol (excess) was added and the mixture stirred for further 10 min. The mixture was taken to 
dryness and partitioned between EtOAc and water (1 mL each). The aqueous layer was further 
extracted with EtOAc (2 x 1mL) and the combined organic phase was dried (Na2SO4) and 
evaporated in vacuo. The crude (6.4 mg) was analysed at 700 MHz and integration of the well 
separated methyl resonances allowed to determine the following yields (based on reacted 17 at 80% 
conversion): bis-spiroketal 9 (51 %) and lactone 18 (21%). 
4.4.4 Description of the Assay 
Cell viability was assessed by MTS assay as described elsewhere.
12
 Briefly, ovarian (HEY cell 
line) and breast (BT474 cell line) cancer cells were seeded at the concentration of 0.5X10
5
 cells per 
well on 96-well plate and maintained under appropriate condition (RPMI 1640 or DMEM, 
completed with 10% FCS, 2 mmol L-glutamine and 100 units/mL of penicillin (all from Sigma, St. 
Luis MO). Every second day cells were washed with PBS and media containing different 
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concentration of compounds were replaced in every well, except for the controls where only the 
solvent used to dissolve the compounds was present. At the indicated time point cell viability was 
assessed using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega), i.e., the 3-
(4,5,dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt (MTS) assay and compared with their control. 
4.4.5 Single-crystal X-ray diffraction report for compounds 6-9 
Prismatic colourless crystals of 6, 7, 8 and 9 were selected for X-ray analysis. Single crystal X-
ray diffraction data were collected using graphite monochromated MoK radiation ( = 0.71073 Å) 
on a Bruker-Nonius kappaCCD diffractometer at room temperature. Owing to the poorly diffracting 
features of the crystals, data were collected up to max = 25 ° for all the structures. Cell parameters 
and intensity data were processed using Dirax/lsq
15
 and Collect programs.
16 
The structures were solved by direct methods
17
 and refined by the full-matrix least squares 
method on F
2
 using SHELXL program.
18
 Intensities were corrected for absorption effects by the 
multi-scan method using SADABS program.
19
 All non H atoms were refined with anisotropic 
displacement parameters; H atoms were determined stereochemically and are fined by the riding 
model with Uiso in the range 1.2-1.5 times Ueq of the carrier atom. 
Single crystal X-ray diffraction data for 6 
C30H48O7, M = 520.68, triclinic, a = 5.954(4), b = 14.236(8), c = 17.250(8) Å,  = 99.08(5),  =  
99.10(7),  = 92.48(6)°, V = 1422(1) Å3, T = 293 K, space group 1P  (no. 2), Z = 2, (Mo-K) = 
0.085 mm
-1
, 11495 reflections measured, 4948 unique which were used in all calculations. Final 
agreement indices were wR(F
2
) = 0.2810 (all data) and R = 0.0633 (I>3(I)). Crystallographic data 
(excluding structure factors) for compound 6 have been deposited with the Cambridge 
Crystallographic Data Centre as supplementary publication CCDC 767599. Copies of the data can 
be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK 
(fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk). 
Single crystal X-ray diffraction data for 7 
C30H48O7, M = 520.68, orthorhombic, a = 26.501(8), b = 21.742(7), c = 9.795(4) Å, V = 5644(3) 
Å
3
, T = 293 K, space group Aba2 (no. 41), Z = 8, (Mo-K) = 0.085 mm-1, 10335 reflections 
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measured, 4508 unique which were used in all calculations. Final agreement indices were wR(F
2
) = 
0.1745 (all data) and R = 0.0576 (I>3(I)). Crystallographic data (excluding structure factors) for 
compound 7 have been deposited with the Cambridge Crystallographic Data Centre as 
supplementary publication CCDC 767600. Copies of the data can be obtained, free of charge, on 
application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44-(0)1223-336033 or e-
mail: deposit@ccdc.cam.ac.uk). 
Single crystal X-ray diffraction data for 8 
C30H48O7, M = 520.68, monoclinic, a = 19.089(8), b = 13.070(6), c = 11.780(6) Å,  =  
101.32(4), V = 2882(2) Å
3
, T = 293 K, space group cP /21  (no. 14), Z = 4, (Mo-K) = 0.084 mm
-
1
, 15654 reflections measured, 5021 unique which were used in all calculations. Final agreement 
indices were wR(F
2
) = 0.1304 (all data) and R = 0.0424 (I>3(I)). Crystallographic data (excluding 
structure factors) for compound 8 have been deposited with the Cambridge Crystallographic Data 
Centre as supplementary publication CCDC 767601. Copies of the data can be obtained, free of 
charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44-(0)1223-
336033 or e-mail: deposit@ccdc.cam.ac.uk). 
Single crystal X-ray diffraction data for 9 
C30H48O7, M = 520.68, triclinic, a = 8.295(2), b = 12.299(4), c = 14.972(5) Å,  = 107.96(3),  =  
90.65(2),  = 97.83(3)°, V = 1437.2(8) Å3, T = 293 K, space group 1P  (no. 2), Z = 2, (Mo-K) = 
0.084 mm
-1
, 13483 reflections measured, 5039 unique which were used in all calculations. Final 
agreement indices were wR(F
2
) = 0.1565 (all data) and R = 0.0503 (I>3(I)). Crystallographic data 
(excluding structure factors) for compound 9 have been deposited with the Cambridge 
Crystallographic Data Centre as supplementary publication CCDC 767602. Copies of the data can 
be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK 
(fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk). 
4.4.6 Isolation of the bis-iodurated tetra-THF 19 
Compound 19 was isolated from the less polar fraction A by HPLC separation (250×10 mm 
column, eluent: hexane-EtOAc, 8:2, flow 2.5 mL/min). The fraction eluted in the range 20-30 min 
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was subjected to a further reversed-phase HPLC separation (250×10 mm column; flow: 1.0 
mL/min, eluent: MeOH/H2O, 8:2, tR = 14.5 min) to give pure 19 (2.5 mg, 0.03%).  
 
19: IR (neat): max 3706, 3780, 1054, 1013 cm
-1
; 
1
H-NMR: (400 MHz, CDCl3)  4.00 (1H, bd, J = 
9.7), 3.91 (1H, m), 3.85 (1H, dd, J = 7.7, 5.2), 2.32 (1H, m), 2.23 (1H, ddd, J = 12.1, 8.7, 8.7), 1.45, 
1.25, 1.13, 1.09 (3H each, s’s, 4xMe); 13C-NMR (50 MHz, CDCl3):  85.6, 85.0, 84.4, 83.0, 71.9, 
47.9, 39.9, 36.4, 34.7, 27.9, 27.2, 25.8, 24.9, 24.3, 22.9; HRMS (ESI) m/z calcd for C30H52I2NaO6 
[M+Na]
+
 785.1751, found 785.1748. 
Ring expansion of 19 to 22 
To compound 19 (1.5 mg, 0.02 mmol) dissolved in acetone-water (4:1, 500 L) was added silver 
carbonate (16.8 mg, 0.1 mmol) and the mixture stirred at 40 °C. After 4 h, the mixture was filtered 
and the solid thoroughly washed with acetone. The organic phase was taken to dryness to give an 
oily product. HPLC purification (250 × 4.6 mm column; flow: 1.0 mL/min; CHCl3MeOH, 98:2) 
gave pure 22 (0.7 mg, 65%, tR =16.5 min).  
 
22: Oil; IR (neat): max 3440 cm
-1
; 
1
H-NMR: (700 MHz, CDCl3)  3.86 (1H, dd, J = 8.4, 3.7), 3.26 
(1H, bdd, J = 7.0, 7.0), 3.16 (1H, bd, J = 6.3), 2.36 (1H, ddd, J = 10.0, 10.0, 10.0), 2.05 (1H, dddd, 
J = 12.7, 9.6, 3.7, 3.7), 2.03-1.94 (2H, m), 1.89 (1H, ddd, J = 12.5, 3.6, 3.6), 1.75 (2H, m), 1.54 
(2H, m), 1.31 (1H, m), 1.23, 1.19, 1.12, 1.05 (3H each, s’s, 4 × Me); HRMS (ESI) m/z calcd for 
C30H54NaO8 [M+Na]
+
 565.3716, found 565.3710. 
X-Ray Crystallography of compound 19 
Crystals of 19 suitable for X-ray analysis were obtained from CHCl3 by slow evaporation of the 
solvent. Data were collected at 298 K on a Bruker-Nonius Kappa-CCD diffractometer using 
graphite monochromated MoKα radiation (λ = 0.71073 Å). Data reduction and multi-scan 
absorption correction were done using SADABS program.
26
 The structure was solved by direct 
methods (SIR97 program)
27
 and refined by the full matrix least-squares method on F
2
 using 
SHELXL-97 program 
28
 with the aid of the program WinGX [40]. Non-hydrogen atoms were 
refined anisotropically. H atoms of the hydroxy group was located in difference Fourier maps and 
refined with Uiso = 1.2∙Ueq of the carrier atom. The positions of the other H atoms were determined 
stereochemically and refined by the riding model with Uiso = 1.2∙Ueq of the carrier atom (1.5∙Ueq for 
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H atoms of methyl groups). Ring puckering coordinates 
29
 were determined using the program 
PARST.
30
 The analysis of the crystal packing and the drawing of the molecule were performed 
using the programs Mercury 
31
 and ORTEP
32
. Crystal and refinement data are summarized in Table 
1. CCDC reference number 821334 contains the supplementary crystallographic data for 19. 
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Chapter 5 
Synthesis of new nucleoside analogues 
5.1. Introduction 
Besides being involved in nucleic acid replication and therefore in the transfer of genetic 
heritage from generation to generation, nucleosides take part in many metabolic processes by 
interacting with specific enzymes such as polymerases, kinases, reductases, motor proteins, 
membrane receptors and structural proteins, all targets of biological importance. No wonder then 
that nucleosides are among the most studied biological molecules and that they are currently used as 
antiviral,
1,2
 antineoplastic
3-6
 as well as antifungal
7-9
 agents.  
Recently, an increasing number of research groups have focused their attention on the preparation 
of new nucleoside and nucleotide analogues in order to widen the pool of these molecules with 
potential biological activity. To that end, structural modifications were made on the heterocyclic 
base and/or on the sugar. Most active derivatives contain modification on sugar portion so a large 
number of nucleobase analogues have been synthesized and employed against cancer and viral 
diseases. An important class of nucleoside analogues is that of purine bases and nucleosides bearing 
a C- or N-substituent at C-6. These molecules posses a wide range of biological effects including 
cytostatic, antiviral, antibacterial as well as receptor-modulation activity.
10
  
The C-6 halogenation of the nucleo-base has opened the way to the construction of new libraries 
of C-6 modified nucleosides, generally through direct aromatic nucleophilic substitution (SNAr),
11
 
or metal-mediated cross-coupling processes
12, 13
 (Figure 1). The most reliable methods to access C-
6 C-substituted nucleosides use metal or organometal-mediated reactions.
12 
 
The need for new methods for the C-6 derivatization led us to consider the possibility to exploit 
the reactivity of nitrones to reach this goal. Indeed, nitrones are precious substrates used in organic 
synthesis for the assembly of structurally complex nitrogen-containing compounds. Their most 
well-studied reactions are the 1,3-dipolar cycloadditions (1,3-DC) and the nucleophilic addition of 
organometallic reagents.
14 
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Figure 1. Approaches to C-6 functionalization of purine nucleosides 
In the frame of a project joined in collaboration with the group of prof. L. Mayol from the 
“Dipartimento di Chimica delle Sostanze Naturali”, oxidative processes have been applied to the 
synthesis of new nucleoside analogues possessing different base modifications. We reasoned that 
the formation of a purine N1-oxide by treatment of the purine with MeReO3 followed by addition of 
a Grignard reagent to the electrophilic C-6 carbon of the substrate could allow the C-6 
functionalization of the purine base (Figure 1).
15
 Using this unprecedented approach new C-6 
substituted purine nucleosides have been synthesized, without using metal catalysts. Inspired by 
these findings we envisaged that C-6 substituted nucleosides could be further derivatized at C-2 
through formation of a new reactive C6-N1-O
-
 nitrone moiety and successive reaction of Grignard 
reagent to the electrophilic C-2 carbon. During our early experiments, serendipitously, 
unprecedented bis-alkylated imidazo[4,5-d][1,2,6]oxadiazepine nucleosides were obtained
16
 instead 
of expected 2,6-disubstituted purine nucleosides. A small collection of these compounds have been 
synthesized and subjected to preliminary cytotoxicity tests on breast (MCF-7) and lung (A549) 
cancer cell lines. However, in subsequent experiments, our initial goal was successfully reached and 
a colletion of 2,6-dialkyl(aryl) purine nucleosides has been synthesized. In this chapter is therefore 
described the first general approach that allows either the synthesis of ring-expanded nucleosides 
(RENs), containing the unprecedented bis-alkylated imidazo[4,5-d][1,2, 6]oxadiazepine 
heterocyclic ring system, or the 2,6-dialkyl(aril)purine moiety.  
 
 
 
Chapter 5 
 
116 
 
5.1.1 Ring-expanded nucleosides (RENs) and 2,6-disubstituted purine nucleosides 
Nucleosides containing a 5:7-fused ring system as nucleobase, also known as ring-expanded 
nucleosides (RENs), are very interesting molecules from several points of view. They are 
mimics of purine nucleosides and most of them possess significant biological activities due to 
their interference with the enzymes involved in the purine metabolism.
17
 Coformycin and 
pentostatin (2'-deoxycoformycin) are two naturally occurring RENs containing an imidazo[4,5-
d][1,3]diazepine ring system. They show a potent antitumor activity due to the strong inhibition 
of adenosine deaminase (ADA), acting as transition-state analogues.
18,19
 Pentostatin is a drug 
approved in 1991 by FDA for the treatment of hairy cell leukemia. However, it is characterized 
by a severe toxicity that limits its use in therapy.
17
 A number of coformycin analogues have 
been synthesized, both to investigate the structure-activity relationship and to produce less toxic 
derivatives.
20-25
 Furthermore, imidazo[4,5-c]azepine nucleosides, ring-expanded derivatives of 
xanthosine, guanosine and inosine, have been investigated and their cytotoxic activity has been 
reported.
26
 RENs have shown antiviral properties as well. Coformycin and some of its 
derivatives are able to enhance the activity of therapeutic antiviral drugs such as 2′,3′-
dideoxyadenosine (ddA) and 2'-fluoro-2',3'-dideoxyadenosine (FddA). Other RENs, for 
example those containing the 6-alkylamino-substituted imidazo[4,5-e][1,3]diazepine or the 
imidazo[4,5-e][1,2,4]triazepine moiety, show direct antiviral activity against human hepatitis B 
virus and West Nile Virus.
24
 
Due to their noncanonical steric hindrance, RENs have been inserted in oligonucleotides to 
study conformational and stability changes in duplex, triplex and other DNA secondary 
structures, as well as H-bonding profile, base stacking, endo/exo sugar puckering and  
anomeric ribose configuration.
27
 From a synthetic point of view, the construction of a 
nucleoside containing a 5:7-fused ring base system can be performed using a sugar unit bearing 
a functionalized imidazole (or other 5-terms cycles), on which the seven-membered ring closure 
can be accomplished by inserting an appropriate molecular moiety.
25, 26, 28
  
Alternatively, a pre-synthesized 5:7-terms heterocyclic system can be joined to a sugar 
moiety by reaction with an activated glycosyl donor.
23, 29, 30
 The latter approach is longer but it 
does not suffer from problems due to the weakness of N-glycosidic bond and it also offers the 
chance to synthesize both nucleoside isomers. 
A considerable number of 2,6-disubstituted purines, their nucleosides, and nucleotides exert 
inhibitory activity in various biological systems. 
31 
In a recent paper by Hocek, the synthesis of 
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2-substituted 6-phenylpurine has been reported. Two alternative approaches for the synthesis of 
these compounds have been used. The first is based on the suzuki-Miayaura cross-coupling 
reaction of 2,6-dihalopurines with phenylboronic acid, the second features the deaminative 
transformation of 2-amino-6-phenylpurine nucleosides. 
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5.2. Results and Discussion 
5.2.1 Synthesis and biological evaluation of unprecedented ring-expanded nucleosides 
(RENs) containing the imidazo[4,5-d][1,2,6]oxadiazepine ring system 
We have developed the synthesis of new ring-expanded nucleosides (Scheme 1) containing 
the unprecedented imidazo[4,5-d][1,2,6]oxadiazepine heterocyclic system as the base moiety 
through a new approach featuring the opening/reclosure of the pyrimidine ring system of 
2',3',5'-tri-O-(tert-butyldimethylsilyl) nebularine N1-oxide 1. Our synthetic strategy allowed us 
to prepare a small set of 5,8-dialkyl(aryl)-substituted imidazo[4,5-d][1,2,6]oxadiazepine 
nucleosides (7a-c, Table 1), in high yields, exploiting the previously reported reactivity of 1 
towards Grignard reagents.
16 
O
N
N
N
N
ORRO
RO
OH R'
N
NO
ORRO
RO
N
+
N
O
O
N
N
N
N
ORRO
RO
R'
N
NO
ORRO
RO
N
+
N
O R'
O
N
N
N
N
OHOH
OH
N
NO
ORRO
RO
N
OH R'
N
R''
O
N
N
N
N
ORRO
RO
R'
O
R''
6
2
R'MgBr (2 eq.),
THF, 2 h, r.t.
82-85%
Ac2O-Piridine (6:4),
      1 h, 50 °C
        98-99%
R'= Alkyl or Aryl
 Piridine
16 h, 70 °C
75-78%
Nebularina
1.TBDMSCl (3.2 eq),
Imidazole (6.5 eq),
DMF
2. MeReO3-H2O2
(30% aq)
MeOH, r.t.15 h
R''MgBr (4 eq.),
 THF, 2 h, t.a.
         60%
t-BuOOH (10 eq.),
CCl4, reflux, 1 h
        90-92%
R=TBDMS
R''= Alkyl or 
      or Aryl
MeReO3-H2O2 (30% aq)
         MeOH, r.t., 15 h
1
X
2a-c 3a-c
4a-c5a-c
6a-c, R= TBDMS 
7a-c, R= H
NH4F (10 eq.), 
MeOH
5 h, reflux
 
Scheme 1. Synthesis of new ring-expanded nucleosides from Nebularine. 
Table 1. 5,8-dialkyl(aryl)-substituted imidazo[4,5-d][1,2,6]oxadiazepine nucleosides synthesized. 
Entry R' R'' 7a-c* 
a -Et -Me 34 
b -Me -Et 34 
c -Ph -Et 32 
*Reaction yields (%) from 1. 
The reactivity of -carbons towards Grignard reagents in aromatic nitrones has previously 
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been observed for pyridine N-oxide
32-34
 which results in cleavage of the N-Cbond with the 
concomitant formation of oxime and trans alkene functions. In our previous studies
16
 we 
observed that reaction of nitrone 1 with a Grignard reagent leads to addition at C6 furnishing 
the adducts 2, as a mixture of C6 diastereomers, which slowly decomposed on standing, partly 
giving dehydration to C6-alkyl(aryl)nebularines 3. This process was pushed towards 
aromatization by treatment of the crude adduct 2 with Ac2O in pyridine at 50°C, to give 3 in 
nearly quantitative yields.
35 
We reasoned that the introduction of a N1-nitrone function on 3 could induce an electrophilic 
behaviour on C2 as well, thus allowing to obtain, at least in priciple, 2,6-dialkylpurine. To 
probe this hypothesis the representative compound 3a was treated with catalytic amounts of 
methyltrioxorhenium (MeReO3) in the presence of H2O2, the same oxidizing mixture used to 
obtain nitrone 1 from silylated nebularine. Under these conditions, 3a produced only traces of 
N1-oxide 4a. Alternatively, the oxidation of the N1-hydroxy derivative 2a with air in pyridine 
at 70 °C afforded the C6-ethylnebularine N1-oxide 4a in 78% yield. The similar procedure 
using DMF as a solvent was reported for 2,6-alkyl(aryl)-substituted N-hydroxypyridine 
derivatives.
34 
The successive reaction of 4a with Grignard reagents confirmed the electrophilic reactivity 
of C2 but, in this case, the addition was followed by the breaking of the N1/C2 bond leading to 
compound 5a (60% yield) as a 1:1 mixture of (E/Z) isomers at the imine double bond (Scheme 
2). In particular, 2D NMR experiments and HRMS data confirmed the structure of 5a. The 
HMBC experiment supported the presence of the aldimine moiety showing clear correlations 
between the aldimine proton and both the aldimine carbon and the Grignard residue R''. 
Furthermore, the absence of correlation between aldimine proton and C6 of the purine ring 
strongly suggested the opening of the cycle at the N1/C2 bond. Next, we tested the reactivity of 
the open system of 5a as for the possible ring reclosure. In particular, treatment of 5a with 
t
BuOOH (10 equiv.) in refluxing CCl4 gave nucleoside 6a, containing the imidazo[4,5-
d][1,2,6]oxadiazepine framework (Scheme 3) in a 92% yield.  
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Scheme 2. Proposed mechanism for the formation of compounds 5a-c. 
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Scheme 3. Proposed mechanism for the formation of compounds 6a-c. 
The obtainment of the seven-membered ring could be explained invoking the formation of 
the oxaziridine 8a (Scheme 3) through oxidation of the aldimine functionality.
36
 
It is reported that nucleophiles usually open the oxaziridine ring by attack at the nitrogen or 
oxygen
37
 atom rather than on the carbon atom. However, it is known that oxaziridines 
containing aromatic substituents could easily rearrange to nitrones on heating,
38
 making the 
carbon the preferred attacked site. Accordingly, nitrone 9a, derived from 8a, would undergo a 
fast ring reclosure by nucleophilic attack of the oxime hydroxyl function
‡,39
 on the nitrone 
carbon,
40
 to give intermediate 10a (not isolable) which would lead to the oxadiazepine cycle of 
6a by water loss.  
Previous mechanistic studies on the reactivity of 2-haloquinazoline 3-oxide system with 
alkali
41
 showed that the opening of the pyrimidine ring by nucleophilic attack of the hydroxyl 
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ion at C2 afforded an anti-oxime. In our case, 2D-NMR studies on compound 5a performed in 
pyridine-d5 did not give conclusive information on the oxime configuration, although a (Z) 
configuration is needed for the ring closure (9a  10a). 
The same reaction sequence leading to 6a furnished compounds 6b-c in comparable yields to 
6a (Scheme 1). Compounds 5a-c are rather unstable and decompose on standing within few 
hours. Therefore, reactions on 5b and 5c were performed on the crude reaction mixture without 
observing lowering of the yields. 
Finally, nucleosides 6a-c were deprotected at ribose using NH4F in MeOH
42
 to give, after 
HPLC purification, compounds 7a-c (94-97% yield, Scheme 1).  
The structure of nucleosides 6a-c and 7a-c was confirmed by 2D-NMR experiments and 
HRMS data. Moreover, the disappearance of the characteristic purine band around 260 nm in 
the UV spectra of 6a-b
43
 provided further evidence of the 7-membered ring formation, 
excluding the presence of the isomeric 2,6-disubstituted purine N1-oxide system. 
Considering that RENs significantly inhibit the growth of several cancer cell lines,
17
 we 
tested the cytotoxicity of the novel RENs by treating lung A549 and breast MCF-7 cancer cell 
lines with different concentrations (0.1, 1.0, 10 and 100 µM) of 7a-c. At different time points 
for each concentration the cell viability was determined by measuring the mitochondrial 
activity.
44
 Cisplatin was used as the control since its activity in these cell lines has been 
extensively studied.
45, 46
 We found that at day 7 all tested compounds significatively reduced 
the cell viability of breast cancer derived MCF-7 cells at the highest tested concentration (also 
at 10 µM in the case of 7a). An explanation for such a delayed activity could be the slow 
formation of an active metabolite during the assay. At the same time point the inhibition of 
A549 cells growth, albeit observed, was only marginal (Figure 2 MCF-7 cell line; Figure 3 
A549 cell line, see also § 5.4.3 and 5.4.4). 
Chapter 5 
 
122 
 
 
Figure 2. Cytotoxic effect of RENs 7a-c and cisplatin in MCF-7 breast cancer-derived cell line. 
MCF-7 cell line was treated with four different concentrations (0.1 µM, 1 µM, 10 µM and 
100 µM) of compound 7a-c and cisplatin. Cell viability (% referred to untreated cells) was 
assessed at day 1 (Panel A), day 3 (Panel B) and day 7 (Panel C). Columns, mean of 
quadruplicates; bars, SE (*p < 0.05; **p < 0.01;***p < 0.001). 
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Figure 3. Cytotoxic effect of RENs 7a-c and cisplatin in A549 lung cancer-derived cell line. 
A549 cell line was treated with four different concentrations (0.1 µM, 1 µM, 10 µM and 
100 µM) of compound 7a-c and cisplatin. Cell viability (% referred to untreated cells) was 
assessed at day 1 (Panel A), day 3 (Panel B) and day 7 (Panel C). Columns, mean of 
quadruplicates; bars, SE (*p < 0.05; **p < 0.01;***p < 0.001). 
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5.2.2 Synthesis of 2,6-disubstituted purine nucleosides 
The synthesis of 2,6-disubstituted purine nucleosides, our initial goal, has been achieved in 
subsequent experiments. Indeed, it was found that by treating intermediate 5 (Scheme 4) with Ac2O 
in pyridine the expected compounds were obtained in good yields (60-83%). The scope of the 
process has been successfully proven using various Grignard reagents pairs carrying both alkyl and 
aryl substituents (Table 2). In this way, a collection of six 2,6-disubstituted nucleoside analogues 
has been synthesized. We are currently planning to synthesize other compounds of this type, which 
will be then deprotected and used in biological assays and SAR studies. 
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Scheme 4. Synthesis of 2,6-disubstitued purine. 
Table 2. 2,6-dialkyl(aryl)-substituted nucleosides synthesized. 
Entry R’ R’’ Yield* (%) 
a CH2
CH
3
 -CH
3
 80 
b -CH2
CH
3
 - Ph 75 
c -CH3
 -CH
2
CH
3
 80 
d -Ph - Ph 83 
e -(CH2
)
3
OTBDPS -Ph 60 
f -(CH2
)
3
OTBDPS -Et 61 
*Reaction yields (%) from 1. 
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From a mechanistic point of view we assume that the open system of 5, once acylated at the 
ketoxime functionality (12), undergoes an electrocyclic process with ring reclosure (13) and 
successive rearomatization by elimination of acetic acid (Scheme 5). 
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Scheme 5. Mechanistic hypotesis for the formation of 2,6-disubstituted purine nucleosides. 
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5.3. Conclusions 
In conclusion, we have developed new reactions on the purine nucleobase enlarging the 
synthetic toolbox to obtain novel nucleoside analogues. The reactivity of the herein proposed 
C6-alkyl(aryl)purine-N1-oxides towards Grignard reagents afforded the new 4,5-disubstituted 
imidazo-nucleosides 5 from which the unprecedented imidazo[4,5-d][1,2,6]oxadiazepine 
nucleosides were built in good yields by treatment with 
t
BuOOH. It is to be noted that this 
heterocyclic system has not been so far reported and the proposed synthetic strategy allows the  
introduction of C-substituents on C5 and C8 of the oxadiazepine cycle. We have also reported 
that new RENs are able to inhibit the cell growth of breast cancer derived MCF-7 cells. The 
observed cytotoxic effects of 7a-c were dose-dependent and comparable to those of cisplatin. 
In addition, we have also reported that, treating the same intermediate 5 with Ac2O-pyridine 
it is possble to synthetize 2,6-dialkyl(aryl)-substituted purine nucleosides. 
Further studies to enlarge the collection of the above nucleoside analogues, to investigate the 
reactivity of nebularine N1-oxide toward other C-nucleophiles, including organo-lithium 
reagents, as well as the reactivity of the open intermediates 5a-c, will be carried out. 
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5.4. Experimental section 
5.4.1 General methods 
All the reagents were obtained from commercial sources (Sigma-Aldrich) and were used without 
further purification. 
1
H and 
13
C-NMR spectra were acquired on a Varian Mercury Plus 400 MHz 
and on a Varian Unit Inova 700 MHz in CD3OD or CDCl3. Chemical shifts are reported in parts per 
million (δ) relative to the residual solvent signals: CD2HOD 3.31 and CHCl3 7.27 for 
1
H-NMR; 
CD2HOD 49.0 and CHCl3 77.0 for 
13
C-NMR. 
1
H-NMR chemical shifts were assigned by 2D NMR 
experiments. The abbreviations s, bs, d, dd and m stand for singlet, broad singlet, doublet, doublet 
of doublets and multiplet, respectively. HPLC analyses and purifications were carried out on a Jasco 
UP-2075 Plus pump equipped with a Jasco UV-2075 Plus UV detector using a 4.60 x 150 mm 
LUNA (Phenomenex) silica column (particle size 5 µm) eluted with a linear gradient of MeOH in 
AcOEt (from 0 to 5% in 15 min, flow 1.0 mL min
-1
, system A), with a linear gradient of AcOEt in 
n-hexane (from 0 to 100% in 30 min, flow 1.0 mL min
-1
, system B) or using a 4.8 x 150 mm C-18 
reverse-phase column (particle size 5 µm) eluted with a linear gradient of MeOH in H2O (from 0 to 
100% in 30 min, flow 1.3 mL min
-1
, system C). UV spectra were recorded on a Jasco V-530 UV 
spectrophotometer. High Resolution MS spectra were recorded on a Bruker APEX II FT-ICR mass 
spectrometer using electrospray ionization (ESI) technique in positive mode. Elemental analyses 
were performed on a Thermo Finnigan Flash EA 1112 CHN analyser. IR spectra were recorded on 
a Jasco FT-IR 430 spectrophotometer. Optical rotations were determined on a Jasco polarimeter 
using a 1 dm cell at 25 °C; concentrations are in g/100 mL. Preparative PLC chromatography was 
performed using F254 silica gel plates (0.5 mm thick, Merck). Analytical TLC analyses were 
performed using F254 silica gel plates (0.2 mm thick, Merck). TLC spots were detected under UV 
light (254 nm). For MTS assays the UV absorbance at 490 nm was read using a Beckman Anthos 
96 well Microplate Reader. 
5.4.2 Experimental procedures for preparation of RENs 7a-c 
For the general procedure for the preparation of compounds 3a-c see ref. 15. 
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General procedure for the preparation of compounds 4a-c 
The mixtures of diastereomers 2a-c (0.030 mmol), prepared as previously described
15
 were 
dissolved in pyridine (0.5 mL) and stirred at 70 °C for 18 h. Pyridine was evaporated under reduced 
pressure and the crudes were purified on silica gel plates (developing system: AcOEt/MeOH, 95:5). 
The bands were scratched from the plates and the products were eluted with AcOEt/MeOH, 7:3 (50 
mL), affording compounds 4a-c, the purity of which was checked by HPLC (system A, see General 
Methods).  
2’,3’,5’-Tri-O-(tert-butyldimethylsilyl)-6-ethyl nebularine N-1 oxide 4a  
Oil (15.0 mg, 0.023 mmol, 78%). []D -14.0 (c =0.9 ,CH3OH). 
1
H-NMR (400 MHz, CD3OD) ppm 
8.98 (s, 1H, H-2), 8.80 (s, 1H, H-8), 6.11 (d, J = 5.0 Hz, 1H, H-1’), 4.80-4.75 (m, 1H, H-2’), 4.46-
4.42 (m, H-3’), 4.20-4.15 (m, 1H, H-4’), 4.05 (dd, J = 11.5, 4.3 Hz, H-5’a), 3.87 (dd, J = 11.5, 2.9 
Hz, H-5’b), 3.37 (q, J = 7.5 Hz, 2H, CH2CH3), 1.14 (t, J = 7.5 Hz, 3H, CH2CH3), 0.97 (s, 9H, 
C(CH3)3), 0.96 (s, 9H, C(CH3)3), 0.81 (s, 9H, C(CH3)3), 0.17 (s, 3H, CH3), 0.16 (s, 3H, CH3), 0.15 
(s, 6H, 2 x CH3), 0.020 (s, 3H, CH3), -0.21 (s, 3H, CH3). 
13
C-NMR (100 MHz, CDCl3) ppm 154.5, 
145.6 (two C), 141.6, 132.9, 88.3, 86.0, 76.1, 72.0, 62.5, 26.1, 25.8, 25.6, 19.8, 18.5, 18.0, 17.8, 
10.3,  -4.4, -4.6, -4.7, -5.2, -5.4. m/z 661.3620 (HRESIMS) ([M+Na]
+
, C30H58N4NaO5Si3, requires 
661.3613). IR (neat)max 2923, 1470, 1251, 1122, 834, 781 cm
-1
; UV (MeOH) max 226, 325 nm, 
shoulders 240, 267 nm.
 
 
2’,3’,5’-Tri-O-(tert-butyldimethylsilyl)-6-methyl nebularine N-1 oxide 4b 
Amorphous white solid (14.4 mg, 0.023 mmol, 78%). []D -19.0  (c =0.2 ,CHCl3). 
1
H-NMR (400 
MHz, CD3OD) ppm 8.99 (s, 1H, H-2), 8.80 (s, 1H, H-8), 6.11 (d, J = 5.0 Hz, 1H, H-1’), 4.78-4.74 
(m, 1H, H-2’), 4.45-4.40 (m, H-3’), 4.19-4.15 (m, 1H, H-4’), 4.05 (dd, J = 11.5, 4.3 Hz, H-5’a), 3.86 
(dd, J = 11.5, 2.8 Hz, H-5’b), 2.85 (s, 3H, CH3), 0.96 (s, 9H, C(CH3)3), 0.95 (s, 9H, C(CH3)3), 0.81 
(s, 9H, C(CH3)3), 0.16 (s, 3H, CH3), 0.15 (s, 6H, 2 x CH3), 0.14 (s, 3H, CH3), 0.020 (s, 3H, CH3), -
0.21 (s, 3H, CH3). 
13
C-NMR (100 MHz, CD3OD) ppm 152.0, 148.5, 146.2, 144.0, 134.5, 90.0, 87.2, 
77.2, 73.2, 63.5, 26.5, 26.4, 26.2, 19.3, 18.9, 18.7, 12.3, -4.1, -4.3, -4.8, -5.2, -5.3 m/z (HRESIMS) 
647.3463 ([M+Na]
+
, C29H56N4NaO5Si3, requires 647.3456). IR (neat)max 2927, 1475, 1248, 1126, 
831, 787 cm
-1
; UV (MeOH) max  240, 328 nm, shoulders 226, 266 nm. 
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2’,3’,5’-Tri-O-(tert-butyldimethylsilyl)-6-phenyl nebularine N-1 oxide 4c 
Pale yellow oil (15.0 mg, 0.022 mmol, 75%). []D -38.2 (c =1.9, CH3OH). 
1
H-NMR (400 MHz, 
CD3OD) ppm 9.01 (s, 1H, H-2), 8.81 (s, 1H, H-8), 8.20-8.16 (m, 2H, HPh), 7.65-7.60 (m, 3H, 
HPh), 6.15 (d, J = 4.9 Hz,1H, H-1’), 4.81-4.76 (m, 1H, H-2’), 4.48-4.43 (m, 1H, H-3’), 4.21-4.16 
(m, 1H, H-4’), 4.07 (dd, J = 11.5, 4.2 Hz, 1H, H-5’a), 3.87 (dd, J = 11.5, 2.7 Hz, 1H, H-5’b), 0.98 (s, 
9H, C(CH3)3), 0.95 (s, 9H, C(CH3)3), 0.84 (s, 9H, C(CH3)3), 0.17 (s, 3H, CH3), 0.15 (s, 9H, 3 x 
CH3), 0.050 (s, 3H, CH3), -0.15 (s, 3H, CH3). 
13
C-NMR (100 MHz, CD3OD) ppm 152.4, 149.3, 
148.9, 147.5, 145.3, 133.6, 132.6, 132.2 (two C), 129.2 (two C), 127.8, 90.0, 87.1, 77.3, 73.1, 63.4, 
26.5, 26.3, 26.2, 19.3, 18.9, 18.7, -4.1, -4.3, -4.8, -5.2, -5.3. m/z (HRESIMS) 709.3624 ([M+Na]
+
, 
C34H58N4NaO5Si3, requires 709.3613). IR (neat)max 2950, 2928, 2851, 1253, 1157, 836, 776 cm
-1
; 
UV (MeOH) max 258, 346 nm, shoulder 300 nm. 
General procedure for the preparation of compounds 6a-c 
In a flamed round bottom flask charged with dry nitrogen, 4a-c  (0.020 mmol), dissolved in dry 
THF (0.5 mL), were added via cannula. To the flasks, fresh Grignard reagents (0.080 mmol) were 
quickly added in one portion and the mixtures were stirred for 2 h (TLC monitoring: AcOEt/MeOH, 
95:5) at room temperature. The reactions were quenched by addition of a 1 M solution of NH4Cl (1 
mL), diluted with AcOEt (10 mL) and extracted with brine (2 x 10 mL). The organic layers were 
separated, dried (Na2SO4), filtered and concentrated under evaporation. Compound 5a was purified  
as indicated for 4a-c, while compounds 5b-c were used for the next reaction step without further 
purification. 5a-c were dissolved CCl4 (0.5 mL) and then 
t
BuOOH (10 equiv.) was added in one 
portion. The systems were gently refluxed for 1 h (TLC monitoring: AcOEt/MeOH, 95:5) and then 
evaporated under reduced pressure. The crudes were purified by HPLC (system A for 6a-b, system 
B for 6c, see General Methods) affording compounds 6a-c.  
5-(E,Z)-Ethylideneamino-1-[2,3,5-tri-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3H-
imidazo-4-(E,Z)-propanoxime 5a (major isomer) 
Oil (7.8 mg, 0.012 mmol, 60%). Element. Anal. Calcd. for C31H62N4O5Si3 C, 56.84; H, 9.54; N, 
8.55; found C, 56.81; H, 9.57; N, 8.59; 
1
H-NMR (500 MHz; pyridine-d5): δ 12.80 (s, 1H, NOH), 
8.91 (q, J = 4.8 Hz, 1H, N=CHCH3), 8.31 (s, 1H, H-2), 6.25 (d, J = 5.0 Hz, 1H, H-1'), 4.81-4.77 (m, 
1H, H-2'), 4.56-4.52 (m, 1H, H-3'), 4.33-4.29 (m, 1H, H-4'), 4.07 (dd, J = 11.3, 4.1 Hz, 1H, H-5'a), 
3.91 (dd, J = 11.3, 2.7 Hz, 1H, H-5'b), 3.35 (q, J = 7.4 Hz, 2H, CH2CH3), 1.93 (d, J = 4.8 Hz, 3H, 
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N=CHCH3), 1.38 (t, J = 7.4 Hz, 3H, CH2CH3), 0.98 (s, 18H, 2 x C(CH3)3), 0.95 (s, 9H, C(CH3)3), 
0.19 (s, 3H, CH3), 0.18 (s, 3H, CH3), 0.17 (s, 3H, CH3), 0.16 (s, 3H, CH3), 0.13 (s, 3H, CH3), 0.06 
(s, 3H, CH3). 
13
C-NMR (175 MHz; pyridine-d5) ppm 168.0, 157.4, 139.5, 133.5, 125.9, 88.8, 85.6, 
77.2, 73.0, 63.6, 26.60 (two C), 26.58, 26.43 (four C), 26.38 (two C), 23.6, 21.3, 19.0, 18.8, 18.6, 
12.0, -3.8, -4.1, -4.2, -4.3, -4.89, -4.93. m/z 654.4032 (HRESIMS) ([M+Na]
+
, C31H62N4NaO5Si3, 
requires 654.4028). UV (MeOH) max 232 nm, shoulder 264 nm. 
 
8-Ethyl-5-methyl-3-[2,3,5-tri-O-(tert-butyldimethylsilyl)--D-ribofuranosyl]-3H-imidazo[4,5-
d][1,2,6]oxadiazepine 6a 
Amorphous white solid (7.1 mg, 0.011 mmol, 92%). Element. Anal. Calcd.  for C31H60N4O5Si3 C, 
57.01; H, 9.26; N, 8.58; found C, 57.02; H, 9.28; N, 8.60. []D -37.7 (c = 0.3 ,CH3OH). 
1
H-NMR 
(400 MHz, CD3OD) ppm 8.72 (s, 1H, H-2), 6.10 (d, J = 4.9 Hz, H-1’), 4.80-4.76 (m, 1H, H-2’), 
4.45-4.42 (m, 1H, H-3’), 4.19-4-14 (m, 1H, H-4’), 4.07 (dd, J = 11.9, 5.4 Hz, 1H, H-5’a), 3.86 (dd, J 
= 11.9, 2.6 Hz, 1H, H-5’b), 3.37 (q, J = 7.6 Hz, 2H, CH2CH3), 2.82 (s, 3H, CH3), 1.41 (t, J = 7.6 Hz, 
3H, CH2CH3), 0.97 (s, 9H, C(CH3)3), 0.95 (s, 9H, C(CH3)3), 0.82 (s, 9H, C(CH3)3), 0.17 (s, 3H, 
CH3), 0.15 (s, 9H, 3 x CH3), 0.019 (s, 3H, CH3), -0.20 (s, 3H, CH3). 
13
C-NMR (100 MHz, CD3OD) 
ppm 157.3, 156.2, 147.8, 143.7, 133.0, 90.3, 87.2, 77.4, 73.3, 63.7, 26.8, 26.6, 26.4, 21.3 (two C), 
19.6, 19.1, 18.9, 11.1, -3.8, -4.2, -4.6, -4.9, -5.1 . m/z 675.3764 (HRESIMS) ([M+Na]
+
, 
C31H60N4NaO5Si3, requires 675.3769). IR (neat)max 2923, 1470, 1251, 1119, 834, 773 cm
-1
. UV 
(MeOH) max 226, 324 nm. 
 
5-Ethyl-8-methyl-3-[2,3,5-tri-O-(tert-butyldimethylsilyl)--D-ribofuranosyl]-3H-imidazo[4,5-
d][1,2,6]oxadiazepine 6b 
Amorphous white solid (7.2 mg, 0.011 mmol, 55% over two steps). Element. Anal. Calcd. for 
C31H60N4O5Si3 C, 57.01; H, 9.26; N, 8.58; found C, 57.04; H, 9.29; N, 8.61. []D -40.2 (c = 0.1 
,CH3OH). 
1
H-NMR (400 MHz, CD3OD) ppm 8.74 (s, 1H, H-2), 6.12 (d, J = 5.4 Hz, H-1’), 4.86-
4.81 (m, 1H, H-2’), 4.44-4.39 (m, 1H, H-3’), 4.19-4-14 (m, 1H, H-4’), 4.06 (dd, J = 11.5, 5.3 Hz, 
1H, H-5
’
a), 3.87 (dd, J = 11.5, 3.0 Hz, 1H, H-5’b), 3.23 (q, J = 7.4 Hz, 2H, CH2CH3), 2.85 (s, 3H, 
CH3), 1.43 (t, J = 7.4 Hz, 3H, CH2CH3), 0.97 (s, 9H, C(CH3)3), 0.96 (s, 9H, C(CH3)3), 0.80 (s, 9H, 
C(CH3)3), 0.17 (s, 3H, CH3), 0.16 (s, 3H, CH3), 0.15 (s, 3H, CH3), 0.14 (s, 3H, CH3), 0.0040 (s, 3H, 
CH3), -0.23 (s, 3H, CH3). 
13
C-NMR (100 MHz, CD3OD) ppm 160.2, 151.6, 147.6, 143.1, 132.9, 
89.6, 86.9, 76.6, 73.2, 63.6, 27.1, 26.3, 26.2, 25.9, 19.1, 18.7, 18.5, 12.7, 10.4, -4.3, -4.5, -4.9, -5.3, 
-5.5. m/z (HRESIMS) 675.3760 ([M+Na]
+
, C31H60N4NaO5Si3, requires 675.3769). IR (neat) 2925, 
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1472, 1254, 1118, 835, 773max  cm
-1
. UV (MeOH) max 226, 320 nm 
 
5-Ethyl-8-phenyl-3-[2,3,5-tri-O-(tert-butyldimethylsilyl)--D-ribofuranosyl]-3H-imidazo[4,5-
d][1,2,6]oxadiazepine 6c 
Oil (7.7 mg, 0.011 mmol, 54% over two steps). Element. Anal. Calcd. for C36H62N4O5Si3 C, 60.46; 
H, 8.74; N, 7.83; found C, 60.48; H, 8.72; N, 7.81. []D -26.3 (c = 0.2 ,CH3OH). 
1
H-NMR (400 
MHz, CD3OD) ppm 8.73 (s, 1H, H-2), 8.08-8.04 (m, 2H, HPh), 7.63-7.59 (m, 3H, HPh), 6.17 (d, J 
= 5.3 Hz, H-1’), 4.87-4.84 (m, 1H, H-2’), 4.45-4.41 (m, 1H, H-3’), 4.20-4.16 (m, 1H, H-4’), 4.07 
(dd, J = 11.3, 4.9 Hz, 1H, H-5’a), 3.88 (dd, J = 11.3, 3.0 Hz, 1H, H-5’b), 3.27 (q, J = 7.4 Hz, 2H, 
CH2CH3), 1.47 (t, J = 7.4 Hz, 3H, CH2CH3), 0.98 (s, 9H, C(CH3)3), 0.95 (s, 9H, C(CH3)3), 0.82 (s, 
9H, C(CH3)3), 0.18 (s, 3H, CH3), 0.16 (s, 3H, CH3), 0.15 (s, 6H, 2 x CH3), 0.030 (s, 3H, CH3), -0.18 
(s, 3H, CH3). 
13
C-NMR (100 MHz, CD3OD) ppm 161.4, 149.5, 148.3, 144.4, 132.3 (two C), 132.1 
(two C), 129.2 (two C), 128.6, 89.8, 87.1, 76.9, 73.4, 63.7, 27.6, 26.5, 26.4, 26.2, 19.4, 18.9, 18.8, 
10.7, -4.1, -4.3, -4.7, -5.1, -5.2. m/z 737.3942 (HRESIMS) ([M+Na]
+
, C36H62N4NaO5Si3, requires 
737.3926). IR (neat)max 2955, 2931, 2858, 1255, 1160, 1124, 1075, 836, 777 cm
-1
.UV (MeOH) 
max 252, 296, shoulder 346 nm. 
General procedure for the desilylation of compounds 6a-c. Synthesis of 7a-c 
Compounds 6a-c (0.010 mmol) were dissolved in 1.0 mL of MeOH, and then NH4F (0.10 mmol) 
was added in one portion. The systems were refluxed for 5 h (TLC monitoring: AcOEt/MeOH, 7:3). 
The solvent was removed under reduced pressure and the crudes were dissolved in water, filtered 
and then purified by HPLC (system C, see General Methods) affording compounds 7a-c.  
8-Ethyl-5-methyl-3-(-D-ribofuranosyl)-3H-imidazo[4,5-d][1,2,6]oxadiazepine 7a 
Amorphous white solid (3.0 mg, 0.0097 mmol, 97%). Element. Anal. Calcd. for C13H18N4O5 C, 
50.32; H, 5.85; N, 18.06; found C, 50.30; H, 5.83; N, 18.05. []D -3.2 (c = 0.1 ,CH3OH). 
1
H-NMR 
(400 MHz, CD3OD) ppm 8.78 (s, 1H, H-2), 6.09 (d, J = 5.1 Hz, 1H, H-1’), 4.70-4.65 (m, 1H, H-2’), 
4.38-4.34 (m, 1H, H-3’), 4.17-4.11 (m, 1H, H-4’), 3.88 (dd, J = 12.2, 3.0 Hz, 1H, H-5’a), 3.77 (dd, J 
= 12.2, 3.4 Hz, 1H, H-5’b), 3.36 (q, J = 7.5 Hz, 2H, CH2CH3), 2.81 (s, 3H, CH3), 1.41 (t, J = 7.5 Hz, 
3H, CH2CH3). 
13
C-NMR (100 MHz, CD3OD) ppm 157.1, 155.8, 148.0, 143.7, 132.8, 90.4, 87.3, 
75.9, 71.8, 62.6, 21.0 (two C), 10.9. m/z 333.1170 (HRESIMS) ([M+Na]
+
, C13H18N4NaO5, requires 
333.1175). IR (neat)max  3329, 2917, 2848, 1245, 1117 cm
-1
. UV (MeOH) max 226, 325 nm. 
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5-Ethyl-8-methyl-3-(-D-ribofuranosyl)-3H-imidazo[4,5-d][1,2,6]oxadiazepine 7b 
Amorphous white solid (3.0 mg, 0.0096 mmol, 96%). Element. Anal. Calcd. for C13H18N4O5 C, 
50.32; H, 5.85; N, 18.06; found C, 50.33; H, 5.82; N, 18.04. []D -7.9 (c = 0.1, CH3OH). 
1
H-NMR 
(400 MHz, CD3OD) ppm 8.76 (s, 1H, H-2), 6.11 (d, J = 5.1 Hz, 1H, H-1’), 4.77-4.73 (m, 1H, H-2’), 
4.42-4.38 (m, 1H, H-3’), 4.15-4.11 (m, 1H, H-4’), 3.87 (dd, J = 12.2, 3.3 Hz, 1H, H-5’a), 3.77 (dd, J 
= 12.2, 3.9 Hz, 1H, H-5’b), 3.21 (q, J = 7.4 Hz, 2H, CH2CH3), 2.84 (s, 3H, CH3), 1.43 (t, J = 7.4 Hz, 
3H, CH2CH3). 
13
C-NMR (100 MHz, CD3OD) ppm 160.3, 151.7, 148.1, 143.5, 133.0, 90.3, 87.1, 
75.7, 71.8, 62.7, 27.2, 12.9, 10.3. m/z 333.1187 (HRESIMS) ([M+Na]
+
, C13H18N4NaO5, requires 
333.1175). IR (neat)max 3331, 2920, 2852, 1246, 1118 cm
-1
. UV (MeOH) max 225, 320 nm 
 
5-Ethyl-8-phenyl-3-(-D-ribofuranosyl)-3H-imidazo[4,5-d][1,2,6]oxadiazepine 7c 
Amorphous white solid (3.5 mg, 0.0094 mmol, 94%). Element. Anal. Calcd. for C18H20N4O5 C, 
58.06; H, 5.41; N, 15.05; found C, 58.03; H, 5.40; N, 15.07. []D = -10.4 (c = 0.1 ,CH3OH). 
1
H-
NMR (700 MHz, CD3OD) ppm 8.78 (s, 1H, H-2), 8.08-8.05 (m, 2H, HPh), 7.61-7.59 (m, 3H, HPh), 
6.16 (d, J = 5.0 Hz, 1H, H-1’), 4.80-4.77 (m, 1H, H-2’), 4.43-4.41 (m, 1H, H-3’), 4.16-4.13 (m, 1H, 
H-4’), 3.88 (dd, J = 12.1, 3.3 Hz, 1H, H-5’a), 3.79 (dd, J = 12.1, 3.8 Hz, 1H, H-5’b), 3.26 (q, J = 7.4 
Hz, 2H, CH2CH3), 1.47 (t, J = 7.4 Hz, 3H, CH2CH3). 
13
C-NMR (175 MHz, CD3OD) ppm 161.3, 
149.4, 148.7, 144.7, 132.3, 133.2, 132.1 (two C), 129.2 (two C), 128.8, 94.4, 87.1, 75.8, 71.9, 62.7, 
27.5, 10.4. m/z 395.1323 (HRESIMS) ([M+Na]
+
, C18H20N4NaO5, requires 395.1331). IR (neat)max 
3335, 2914, 2846, 1245, 1124 cm
-1
. UV (MeOH) max 252, 296, 342 nm. 
5.4.3 Experimental procedures for preparation of 2,6-disubstituted purine nucleosides 10a-f 
Compounds 2a-f – 4a-f have been prepared as described in § 5.4.2 for analogous compounds. 
3-bromopropanol was silylated according to a literature procedure
47 
to obtain 3-bromopropoxy-tert-
butyl-diphenylsilane. 
 
Preparation of 3-(tert-butyl-diphenyl-silanoxy)-propylmagnesium bromide 
To a mixture of Mg turnings (59.2 mg, 2.57 mmol, 1.3 eq.), iodine (catalytic amount) in 
anhydrous THF (5 mL) was slowly added (3-bromopropoxy)(tert-butyl)diphenylsilane (500 mg, 
1.98 mmol) in THF (5 mL) at room temperature under argon. After the reaction initiated, the speed 
of addition of (3-bromopropoxy)(tert-butyl)diphenylsilane solution was controlled to mantain the 
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temperature of the reaction mixture at 30-35 °C. After the addition was completed the resulting 
mixture was stirred at 40 °C for 1 h to afford a 0.9 M solution of 3-(tert-butyl-diphenyl-silanoxy)-
propylmagnesium bromide. The Grignard reagent was titrated according to a literature procedure
48
 
 
2’,3’,5’-Tri-O-(tert-butyldimethylsilyl)-6-(3-((tert-butyldiphenylsilyl)oxy)propyl) nebularine 
ossido 4e,f 
Oil (27.6 mg, 0.036 mmol, 60%). 
1
H NMR (400 MHz, CD3OD) δ = 8.97 (s, 1H, H-2), 8.82 (s, 1H, 
H-8), 7.62-7.59 (m, 4H, HPh), 7.43-7.34 (m, 6H, HPh), 6.09 (d, J = 4.6 Hz, 1H, H-1’), 4.70 (t, J = 
4.2 Hz, 1H, H-2’), 4.43 (t, J = 4.2 Hz, 1H, H-3’), 4.18 (dd, J = 6.7, 3.9 Hz, 1H, H-4’), 4.08 (dd, J = 
11.5, 4.1 Hz, 1H, H-5’ a), 3.87 (dd, J = 11.6, 2.7 Hz, 1H, H-5’b), 3.80 (t, J = 6.6 Hz, 2H, 
CH2CH2CH2OTBDPS), 3.47 (t, J = 6.6 Hz, 2H, CH2CH2CH2OTBDPS), 2.19 (quint, J = 6.6 Hz, 
2H, CH2CH2CH2OTBDPS), 0.97 (s, 9H, C(CH3)3), 0.96 (s, 9H, C(CH3)3), 0.94 (s, 9H, C(CH3)3), 
0.82 (s, 9H, C(CH3)3), 0.17 (s, 3H, CH3), 0.165 (s, 3H, CH3), 0.160 (s, 3H, CH3), 0.13 (s, 3H, CH3), 
0.02 (s, 3H, CH3), -0.19 (s, 3H, CH3). 
13
C NMR (100 MHz, CD3OD)  = 155.1, 148.3, 146.5, 144.2, 
136.6, 134.65, 134.60, 130.9, 128.8, 90.1, 87.0, 77.3, 73.0, 64.8, 63.4, 29.8, 27.3, 26.6, 26.4, 26.2, 
24.6, 19.9, 19.4, 19.0, 18.8, -4.0, -4.3, -4.7, -5.1, -5.2. ESI+/MS: 767 [M+H]
+
, 789 [M+Na]
+
, 805 
[M+K]
+
.
 
General procedure for the preparation of compounds 10a-f 
In a flamed round bottom flask charged with dry nitrogen, compound 4a-f (0.020 mmol), 
dissolved in dry THF (0.5 mL), was added via cannula. To the flask, fresh Grignard reagent (0.080 
mmol) was quickly added in one portion and the mixtures was stirred for 2 h (TLC monitoring: 
AcOEt/MeOH, 95:5) at room temperature. The reactions was quenched by addition of a 1 M 
solution of NH4Cl (1 mL), diluted with AcOEt (10 mL) and extracted with brine (2 x 10 mL). The 
organic layers were separated, dried (Na2SO4), filtered and concentrated under reduced pressure. 
Compound 5a-f was dissolved in a mixture of Ac2O-pyridine (6:4, v/v; 1 mL) and stirred at 50 °C 
for 16 and then evaporated under reduced pressure. The crude was purified over PLC plates (n-
hexane/AcOEt, 4:6). 
2’,3’,5’-Tri-O-(tert-butyldimethylsilyl)-6-ethyl-2-methyl- nebularine 10a 
Amorphous white solid (6.1 mg, 0.0096 mmol, 80% over four steps). 
1
H NMR (400 MHz, CD3OD) 
 = 8.57 (s, 1H, H-8), 6.11 (d, J = 5.0 Hz, 1H, H-1’), 4.92 (m, 1H, H-2’), 4.44 (dd, J = 4.1, 3.0 Hz, 
1H, H-3’), 4.17-4.14 (m, 1H, H-4’), 4.08 (dd, J = 11.3, 4.9 Hz, 1H, H-5’ a), 3.85 (dd, J = 11.3, 2.9 
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Hz, H-5’b), 3.14 (q, J = 7.3 Hz, 2H, CH2CH3), 2.74 (s, 3H, CH3), 1.38 (t, J = 7.3 Hz, 3H, CH2CH3), 
0.98 (s, 9H, C(CH3)3), 0.95 (s, 9H, C(CH3)3), 0.78 (s, 9H, C(CH3)3), 0.18 (s, 3H, CH3), 0.16 (s, 3H, 
CH3), 0.151 (s, 3H, CH3), 0.150 (s, 3H, CH3), -0.03 (s, 3H, CH3), -0.30 (s, 3H, CH3). 
13
C NMR 
(100 MHz, CD3OD)  = 164.9, 163.4, 152.5, 145.0, 131.3, 89.7, 87.4, 76.8, 73.8, 63.9, 27.25, 26.6, 
26.4, 26.2, 25.6, 19.4, 19.0, 18.8, 13.5, -4.1, -4.3, -5.0, -5.20, -5.25. ESI+/MS: 637 [M+H]
+
, 659 
[M+Na]
+
, 675 [M+K]
+
. 
 
2’,3’,5’-Tri-O-(tert-butyldimethylsilyl)-6-ethyl-2-phenyl nebularine 10b 
Amorphous white solid (6.3 mg, 0.009 mmol, 75% over four steps). 
1
H NMR (400 MHz, CD3OD) δ 
= 8.61 (s, 1H, H-8), 8.49 (m, 2H, HPh), 7.49 (m, 3H, HPh), 6.20 (d, J = 6.0 Hz, 1H, H-1’), 5.11 (dd, 
J = 5.9, 4.4 Hz, 1H, H-2’), 4.46 (dd, J = 4.1, 3.0 Hz, 1H, H-3’), 4.17 (m, 1H, H-4’), 4.09 (dd, J = 
11.0, 5.5 Hz, 1H, H-5’ a), 3.88 (dd, J = 11.1, 3.3 Hz, H-5’b), 3.24 (q, J = 7.6 Hz, 2H, CH2CH3), 1.48 
(t, J = 7.6 Hz, 3H, CH2CH3), 0.99 (s, 9H, C(CH3)3), 0.95 (s, 9H, C(CH3)3), 0.75 (s, 9H, C(CH3)3), 
0.19 (s, 3H, CH3), 0.17 (s, 3H, CH3), 0.14 (s, 3H, CH3), 0.13 (s, 3H, CH3), -0.05 (s, 3H, CH3), -0.31 
(s, 3H, CH3). 
13
C NMR (100 MHz, CD3OD)  = 164.8, 160.4, 152.6, 145.7, 139.3, 132.2, 131.3, 
129.5, 129.4, 89.8, 87.46, 76.3, 73.9, 64.1, 27.4, 26.5, 26.4, 26.2, 19.3, 19.0, 18.8, 12.9, -4.1, -4.2, -
4.3, -4.9, -5.1, -5.2. ESI+/MS: 699 [M+H]
+
, 721 [M+Na]
+
, 737 [M+K]
+
. 
 
2’,3’,5’-Tri-O-(tert-butyldimethylsilyl)-2-ethyl-6-methyl nebularine 10c 
Amorphous white solid (6.1 mg, 0.0096 mmol, 80% over four steps). 
1
H NMR (400 MHz, CD3OD) 
δ = 8.58 (s, 1H, H-8), 6.11 (d, J = 6.0 Hz, 1H, H-1’), 4.99 (dd, J = 4.4, 5.8 Hz, 1H, H-2’), 4.42 (dd, 
J = 4.4, 3.0 Hz, 1H, H-3’), 4.17-4.14 (m, 1H, H-4’), 4.10 (dd, J = 11.3, 5.4 Hz, 1H, H-5’ a), 3.85 
(dd, J = 11.1, 3.1 Hz, H-5’b), 3.01 (q, J = 7.6 Hz, 2H, CH2CH3), 2.79 (s, 3H, CH3), 1.39 (t, J = 7.6 
Hz, 3H, CH2CH3), 0.98 (s, 9H, C(CH3)3), 0.96 (s, 9H, C(CH3)3), 0.78 (s, 9H, C(CH3)3), 0.18 (s, 3H, 
CH3), 0.157 (s, 3H, CH3), 0.155 (s, 3H, CH3), 0.15 (s, 3H, CH3), -0.04 (s, 3H, CH3), -0.30 (s, 3H, 
CH3). 
13
C NMR (100 MHz, CD3OD)  = 167.6, 160.1, 152.4, 145.3, 132.3, 89.8, 87.4, 76.4, 73.9, 
64.0, 33.2, 26.5, 26.4, 26.2, 19.3, 19.05, 19.0, 18.8, 13.9, -4.1, -4.3, -4.9, -5.2, -5.3. ESI+/MS: 637 
[M+H]
+
, 659 [M+Na]
+
, 675 [M+K]
+
. 
 
2’,3’,5’-Tri-O-(tert-butyldimethylsilyl)-2,6-diphenyl nebularine 10d 
Amorphous white solid (7.5 mg, 0.010 mmol, 83% over four steps). 
1
H NMR (400 MHz, CD3OD) δ 
= 8.86 (dd, J = 8.0, 1.7 Hz, 2H, HPh), 8.65 (s, 1H, H-8), 8.61 (dd, J = 8.0, 1.8 Hz, 2H, HPh), 7.60 
(m, 3H, HPh), 7.52 (m, 3H, HPh), 6.26 (d, J = 6.0 Hz, 1H, H-1’), 5.13 (dd, J = 5.9, 4.4 Hz, 1H, H-
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2’), 4.48 (dd, J = 3.9, 2.8 Hz, 1H, H-3’), 4.18 (m, 1H, H-4’), 4.10 (dd, J = 11.0, 5.4 Hz, 1H, H-5’ a), 
3.90 (dd, J = 11.0, 3.2 Hz, H-5’b), 1.00 (s, 9H, C(CH3)3), 0.96 (s, 9H, C(CH3)3), 0.76 (s, 9H, 
C(CH3)3), 0.20 (s, 3H, CH3), 0.18 (s, 3H, CH3), 0.16 (s, 3H, CH3), 0.14 (s, 3H, CH3), -0.04 (s, 3H, 
CH3), -0.29 (s, 3H, CH3). 
13
C NMR (100 MHz, CD3OD)  = 160.0, 155.8, 154.6, 146.2, 139.4, 
137.2, 132.2, 131.4, 130.9, 129.6, 129.5, 129.4, 89.7, 87.4, 76.4, 74.0, 64.2, 26.6, 26.5, 26.2, 19.3, 
19.0, 18.8, -4.0, -4.2, -4.3, -4.8, -5.1, -5.2. ESI+/MS: 747 [M+H]
+
, 769 [M+Na]
+
, 785 [M+K]
+
. 
 
2’,3’,5’-Tri-O-(tert-butyldimethylsilyl)-6-(3-((tert-butyldiphenylsilyl)oxy)propyl)-2-phenyl 
nebularine 10e 
Amorphous white solid (6.0 mg, 0.0072 mmol, 60%). 
1
H NMR (400 MHz Acetone-d6) δ = 8.60 (s, 
1H, H-8), 8.59-8.56 (m, 2H, HPh), 7.69 (d, J = 4.6 Hz, 4H, HPh), 7.51-7.50 (m, 3H, HPh), 7.41-
7.34 (m, 6H, HPh), 6.24 (d, J = 5.2 Hz, 1H, H-1’), 5.14 (t, J = 3.7 Hz, 1H, H-2’), 4.58 (t, J = 3.6 Hz, 
1H, H-3’), 4.23-4.10(m, 2H, H-4’ e H-5’ a), 3.95 (dd, J = 10.4, 2.6 Hz, 1H, H-5’b), 3.87 (t, J = 6.6 
Hz, 2H, CH2CH2CH2OTBDPS), 3.39 (t, J = 6.6 Hz, 2H, CH2CH2CH2OTBDPS), 2.32 (quint, J = 
6.8 Hz, 2H, CH2CH2CH2OTBDPS), 1.03 (s, 9H, C(CH3)3), 1.00 (s, 9H, C(CH3)3), 0.96 (s, 9H, 
C(CH3)3), 0.80 (s, 9H, C(CH3)3), 0.22 (s, 3H, CH3), 0.19 (s, 3H, CH3), 0.16 (s, 3H, CH3), 0.15 (s, 
3H, CH3), 0.00 (s, 3H, CH3), -0.20 (s, 3H, CH3). 
13
C NMR (100 MHz, Acetone-d6)  = 162.9, 
159.0, 152.5, 144.9, 139.3, 136.3, 136.2, 134.6, 130.9, 130.5, 129.2, 129.1, 128.6, 89.3, 86.2, 75.8, 
73.1, 64.2, 63.6, 31.4, 27.2, 26.5, 26.3, 26.1, 19.8, 19.1, 18.7, 18.5, -4.0, -4.3, -4.7, -5.10, -5.15. 
ESI+/MS: 843 [M+H]
+
, 865 [M+Na]
+
, 881 [M+K]
+
. 
 
2’,3’,5’-Tri-O-(tert-butyldimethylsilyl)-2-ethil-6-(3-((tert-butyldiphenylsilyl)oxy)propyl) 
nebularine 10f 
Amorphous white solid (5.8 mg, 0.0073 mmol, 61%). 
1
H NMR (400 MHz Acetone-d6) δ = 8.48 (s, 
1H, H-8), 7.68 (d, J = 7.0 Hz, 4H, HPh), 7.47 – 7.35 (m, 6H, HPh), 6.11 (d, J = 5.4 Hz, 1H, H-1’), 
5.09 (t, J = 3.9 Hz, 1H, H-2’), 4.54 (t, J = 3.9 Hz, 1H, H-3’), 4.17-4.13 (m, 2H, H-4’ e H-5’ a), 3.89 
(dd, J = 13.2, 5.7 Hz, 1H, H-5’b), 3.82 (t, J = 6.6 Hz, 2H, CH2CH2CH2OTBDPS), 3.27 (t, J = 6.6 
Hz, 2H, CH2CH2CH2OTBDPS), 2.97 (q, J = 7.6 Hz, 2H, CH2CH3), 2.24 (quint, J = 6.6 Hz, 2H, 
CH2CH2CH2OTBDPS), 1.36 (t, J = 7.6 Hz, 3H, CH2CH3), 1.02 (s, 9H, C(CH3)3), 0.98 (s, 9H, 
C(CH3)3), 0.96 (s, 9H, C(CH3)3), 0.80 (s, 9H, C(CH3)3), 0.20 (s, 3H, CH3H), 0.17 (s, 3H, CH3), 0.15 
(s, 6H, 2CH3), -0.02 (s, 3H, CH3), -0.24 (s, 3H, CH3). 
13
C NMR (100 MHz, Acetone-d6)  = 166.4, 
162.7, 152.1, 144.0, 136.3, 134.7, 132.4, 130.5, 128.6, 89.3, 86.2, 75.6, 73.2, 64.2, 63.5, 33.3, 31.5, 
27.2, 26.4, 26.3, 26.1, 19.8, 19.1, 18.7, 18.5, 13.7, -4.1, -4.4, -4.8, -5.1, -5.2. ESI+/MS: 795 
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[M+H]
+
, 817 [M+Na]
+
, 833 [M+K]
+
. 
5.4.4 Procedures used for the MTS assays 
Cell viability was assessed by MTS assay as described elsewhere. Breast (MCF-7 cell line) and lung 
(A549 cell line) cancer cells were seeded at the concentration of 0.5 × 10
4
 cells per well on 96-well 
plate and maintained overnight under appropriate condition (1% sodium pyruvate MEM or DMEM, 
respectively, completed with 10% FCS, 2 mmol L-glutamine and 100 units/mL of penicillin. Cells 
in quadruplicated were than cultured in 5% FCS media containing different concentrations of tested 
compounds (0.1 µM, 1 µM, 10 µM and 100 µM) except for control wells that only received 5% 
FCS media. Every second day cells were washed with PBS and media were replaced. At the 
indicated time point cell viability was assessed reading the absorbance of treated and control cells at 
490 nm using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega), i.e., the 
3-(4,5,dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt (MTS) assay. 
 
5.4.5 Antitumor activity of compounds 7a-c  
MCF-7 breast cancer cell line and A549 lung cancer cell line were treated with different 
concentrations (0.1 μM, 1 μM, 10 μM and 100 µM) of novel RENs 7a-c. Cisplatin was used as 
control since its activity in these cell lines has been extensively studied.
27,28
 Cell viability was 
assessed by measuring the mitochondrial activity at day 1, 3 or 7 (MTS assay) in vitro.
26
 We found 
that all tested RENs increased significantly the mitochondrial activity of treated MCF-7 cells at day 
1 and 3, with the exception of 7b that resulted inactive at day 1 (Fig. S1, panels A and B). This 
phenomenon is often reported as “starving state” leading up to cell death at later time points and/or 
at higher concentrations. Accordingly, at day 7 RENs 7b and 7c increased the mitochondrial 
activity at concentrations up to 10 µM, while at 100 µM they showed 38% and 40% cell death, 
respectively (Figure 2, panel C in § 5.2.1). At the same time point 7a increased the mitochondrial 
activity at 0.1 µM and 1 µM, but showed 16% cell killing effect already at 10 µM and 55% cell 
death at 100 µM. It is noteworthy that at day 7 at 10 µM compound 7a proved to be as cytotoxic as 
cisplatin (16% and 15% cell death, respectively). 7a-c resulted less active in A549 cell line at 
almost all tested conditions (Figure 3, panels A-C in § 5.2.1) and, in agreement with the “starving 
state” hypothesis, we did not observe any increased mitochondrial activity at day 3 and 7. The most 
active compound in A549 cell line was 7a that showed 21% cell death at day 7 at 10 µM. All 
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together these data showed that the new synthesized compounds possess some degree of cytotoxic 
activity, whose manifestation in some cases was slower than the control. Further and more specific 
experiments would have to be performed in order to fully clarify the reason for such phenomenon. 
However, at this point we can speculate that only active metabolites formed around day 7 were 
capable to kill cells. 
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Chapter 6 
Preliminary experiments on the RuO4-catalyzed oxidative 
opening of acylated THF. An alternative method for the 
synthesis of bis--acyloxy 1,4-diketones 
6.1. Introduction 
Recently in our laboratory we have focused on the catalytic use of chlorochromatoperiodate 
(CCP for short), generated by the condensation of PCC and periodic acid,
1
 as a powerful reagent 
capable of oxidising THF-containing compounds of various structural complexity (for a deeper 
insight on PCC and CCP see § 1.3, and Chapter 2 and 3).
2-4
 In particular we have developed the first 
general synthesis of bis--acyloxy 1,4- and 1,5-diketones by a CCP-catalyzed oxidative opening of 
bis acylated THF and THP diols, in turn synthesized by osmium- or ruthenium-catalyzed oxidative 
cyclization of 1,5- and 1,6-dienes (Scheme 1, see also Chapter 3).
4
 Since -acyloxy ketones are 
important building blocks in organic synthesis,
5
 the presence in the same molecule of two of these 
structural subunits further increases the synthetic utility of bis--acyloxy diketones.  
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Scheme 1. Our general synthesis of bis--acyloxy diketones from dienes through CCP-catalyzed 
oxidative opening of bis acylated THF and THP diols.
4a
 
In order to extend this synthetic procedure to acid- or PCC- sensitive substrates, during the third 
year of my PhD programme some preliminary experiments have been carried out on mono-THF 
compounds using the systems RuO4 (cat.)/NaIO4 
6 
and RuO4 (cat.)/H5IO6
7
. Indeed, in 1980 Smith III 
and Scarborough used RuO4 to accomplish the transformation of unfunctionalised THF or THP ring 
mostly into lactones.
8
 In a single case, a 2,5-disubstituted THF was converted into a 1,4-diketone, 
but the process required long reaction times (typically 24) and there were no chiral centres adjacent 
to the reaction centres (Scheme 2). In this chapter we report our early experiments aimed at the 
development of a RuO4-catalyzed method for the synthesis of bis--acyloxy 1,4-diketones. 
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O
O
O
RuO4 (20 mol %)
NaIO4 (2.8 eq.)
CCl4/H2O (1/1)
    t. a. 24 h
 
Scheme 2. Oxidative THF opening under Smith III and Scarborough conditions.
8
 
6.2. Results and discussion 
Optimization of the oxidative protocol was carried out with THF 1 as model compound (Table 
1). In particular, two sets of conditions have been developed, one, employing NaIO4 as the 
stoichiometric oxidant, designed for acid-sensitive substrates, the other one, with H5IO6 as co-
oxidant. This would also allow to evaluate the effect of H5IO6 compared to NaIO4. Indeed, Tse
7a
 
and then Sharpless
7b
 reported the superiority of periodic acid over sodium periodate in the RuO4 
oxidations of organic compounds. 
As regards the conditions for acid-sensitive substrates, we initially tested the oxidation of 1 
(entry 1, Table 1) under Smith III and Scarborough conditions (20 mol% RuO2, 2.8 NaIO4, 
CCl4/H2O, 1:1). However, the process failed to go to completion under these conditions and after 24 
h the reaction stopped at a 60% conversion, indicating that new conditions had to be devised for 
more complex substrates. 
Then the process was accomplished varying the amounts of both oxidant and co-oxidant. In 
particular, two different solvent mixture, CCl4/CH3CN/H2O (2:2:3) (entries 2-4) and, 
t
BuOH/ H2O 
(7:3) (entries 5-7) were tested. Best results (complete conversion and 80% yield) were obtained 
using 10 mol % of RuCl3 and 10 equiv. of NaIO4 in CCl4/CH3CN/H2O, 2:2:3 at 40 °C (entry 4). In 
absence of water, using 5 mol % of RuCl3 as pre-catalist, 3 equiv. of SiO2-supported NaIO4 
9
 and 
CH3CN as solvent, a < 50% conversion was reached even after a week (entry 8). 
Regarding the oxidation with the system RuO4 (cat.)/H5IO6 (Entry 9-15), screening of different 
amounts of oxidant and co-oxidant and of various solvent systems was performed. In particular, 
using 15 mol % of RuCl3 and 13 equiv. of H5IO6 in CH3CN/H2O (9:1) the reaction went to 
completion in 48 h with a 70% yield (entry 9). Improved yields (90%) and reduced reaction times 
(16 h) were achieved using a mixture of 
t
BuOH/H2O (7:3) and 10 mol % of RuCl3 with 10 equiv. of 
H5IO6 (entry 12). When the process was carried out a larger scale (0.15 mmol compared to 0.03-
0.04 mmol used in all the others reactions) under the same conditions as in entry 12, the expected 
diketone in an improved 86% yield (entry 13), though in 26h. 
Eventually, using the biphasic mixture EtOAc/CH3CN/H2O (3:3:2) as the solvent, as reported for 
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others RuO4 (cat.)/H5IO6 oxidative processes,
7a,b
 the reaction did not proceed at all (<10% yield 6 
days, entry 15). 
Table 1. Optimization of the process on a model 2,5-disubstituted THF compound. 
O
HH OBzBzO O
O
OBz
BzO
RuO4 (cat.)
1 2  
Exp. 
Ox
 [a]
 
(mol%) 
       Co-Ox         eq Solvent Time 
Yield
[b]
 
(%) 
Conv.
[b]
 
(%) 
1 20  2.8 CCl4/H2O,  1:1 24 h  60 
2 5  4.2 CCl4/CH3CN/H2O,  2:2:3 6 d 80 90 
3 20  8 CCl4/CH3CN/H2O, 2:2:3 43 h  80 
4 10 NaIO4 10 CCl4/CH3CN/H2O, 2:2:3 7 h
[c]
 80 100 
5 10  8 
t
BuOH/ H2O, 7:3 13 h 66 90 
6 10  8 
t
BuOH/ H2O, 7:3 24 h 74 100 
7 5  8 
t
BuOH/ H2O, 7:3 48 h 75 100 
8 5 NaIO4/SiO2 3 CH3CN 7 d  <50 
9 15  13 CH3CN /H2O, 9:1 48 h 70 100 
10 10  15 CH3CN/H2O, 8:2 21 h  75 
11 5  10 CH3CN/H2O, 7:3 48 h  80 
12 10 H5IO6 10 
t
BuOH/ H2O, 7:3 16 h 90 100 
13
[d]
 10  10 
t
BuOH/ H2O, 7:3 26 86 90 
14 10  10 
t
BuOH/ H2O, 1:1 6 h
[c]
  72 
15 5  10 EtOAc/CH3CN/H2O, 3:3:2 6 d  <10 
[a] All the experiments, except entry 1, were carried out using RuCl3 as precursor of RuO4. Experiment 1 was 
performed using RuO2 as pre-catalyst, according to the Smith III and Scarborough procedure.
8
 [b] Estimated by 
1
H-
NMR of the crude mixture. Yields have been calculated only for reaction with good conversion (>90%). [c] Carried out 
at 40 °C. [d] reaction carried out on a 0.15 mmol scale (0.03-0.04 mmol were used in all the others reactions). 
Using non-acidic optimized condition a silylated mono-THF (3) has been oxidized (Scheme 3) to 
give the expected bis--acyloxy 1,4-diketone (4) with a 76% yield. It is to be noted that in this case 
the reaction went to completion within 2.5 hours, without needing to warm the system. It is likely 
that this is due to the electron withdrawing character of the benzoyl group, that unlike silyl, makes 
the substrate less susceptible to the attack of the oxidant. 
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O
HH OTBSO
O
O
OTBS
OTBS TBS
RuCl3 (10 mol %)
NaIO4 (10 eq.)
CCl4/CH3CN/H2O
(2/2/3), 2.5 h, r.t.
76%3 4
 
Scheme 3. Oxidation of a mono-THF substrate with RuO4 (cat.)/ NaIO4 conditions. 
Oxidation of mono-THF 5, one of the substrate previously oxidized with CCP (see § 3.2)
4a
, was 
then carried out using the optimized H5IO6 –conditions (Schema 4). In this case we obtained the 
expected bis--acyloxy 1,4-diketone with an improved 83% yield, using a 20 mol% of co-oxidant, 
whereas with CCP the yield was 74%. 
O
HH
OBzBzO
OBz
O
OOBz
OBz
OBz
BzO
BzO
A: RuCl3 (20 mol %)
      H5IO6 (10 eq.)
      t-BuOH/H2O (8/2)
      24 h r.t.
A: 83%
B: 74%
B: PCC (2 mol %)
     H5IO6 (3.2 eq.)
     CH3CN, 45min, r.t.
5 6
 
Scheme 4. Oxidation of a mono-THF substrate with RuO4 (cat.)/H5IO6 and with previously 
developed CCP conditions (§ 3.2).
4a 
6.3. Conclusions 
In conclusion, some preliminary experiments have been carried out to develop RuO4 conditions 
for the synthesis of bis--acyloxy 1,4-diketones, in order to extend the process to acid- or PCC- 
sensitive molecules. The procedure has been optimized using both NaIO4 and H5IO6 as co-oxidant 
and it has been used to oxidize two further mono-THF compounds. The first one, a silylated 
dimethanol THF that could not be cleaved using CCP, has been converted into the corresponding 
1,4-diketone with a good yield using the system RuO2/NaIO4. The second compound, a mono-THF 
previously oxidized with CCP (74% yield), has been transformed into the expected 1,4-diketone 
with an increased yield of 83%, using RuO4 (cat.)/H5IO6. These experiments show that the use of 
RuO4 might be a viable alternative to the previously developed CCP-mediated ether cleavage. 
Further experiments are currently ongoing. 
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6.4. Experimental section 
6.4.1 General methods 
All reagents and solvents were purchased (Aldrich and Fluka) at the highest commercial quality 
and used without further purification. Reactions were monitored by thin-layer chromatography 
carried out on precoated silica gel plates (Merck 60, F254, 0.25 mm thick). Merck silica gel 
(Kieselgel 40, particle size 0.063-0.200 mm) was used for column chromatography. NMR 
experiments were performed on Varian Unity Inova 700, Varian Unity Inova 500, Varian Mercury 
Plus 400 and Gemini 200 spectrometers in CDCl3 or CD3OD. Proton chemical shifts were 
referenced to the residual CHCl3 (7.26 ppm) signal. 
13
C-NMR chemical shifts were referenced to 
the solvents (CDCl3 77.0 ppm). Coupling constants, J, are given in Hz. Abbreviations for signal 
coupling are as follows: s=singlet, d=doublet, dd=double doublet, ddd=double double doublet, 
t=triplet, dt=double triplet, q=quartet, quin=quintet, m=multiplet, app=apparent, br=broad. 
6.4.2 Synthesis of Substrates  
The substrates 1,
10
 3, 5,
11
 were obtained by benzoylation and silylation of the corresponding THF 
polyols under standard conditions. 1
4b
 is a known compound. NMR spectroscopic data of 
compounds 2, 5 and 6 have been previously reported (§ 3.4.2).
4a 
3: Oil; 
1
H NMR (200 MHz, CDCl3) = 4.03-3.93 (m, 2H), 3.66-3.59 (dd, J = 10.3, 4.7 Hz, 2H), 
3.56-3.48 (dd, J = 10.3, 5.8 Hz, 2H), 1.97-1.82 (m, 2H), 1.81-1.67 (m, 2H), 0.89 (s, 18H), -0.51 (s, 
12H); 
13
C NMR (50 MHz, CDCl3) = 80.1 (2C), 65.8 (2C), 27.6 (2C), 25.9 (6C), 18.4 (2C), -5.3 
(4C); ESI+/MS: m/z 361 [M+H]
+
, 383 [M+Na]
+
 399 [M+K]
+
. 
6.4.3 Oxidative cleavage of substrates  
Procedure A. Oxidative cleavage with the system RuO4 (cat.)/ NaIO4 
NaIO4 (10 eq.) was dissolved in the biphasic mixture CCl4/CH3CN/H2O (2:2:3, 700 µL) at r.t., 
then RuCl3 (10 mol % from a 0.02 M stock solution in CH3CN) was added under vigorous stirring. 
After 5 min the THF compound (1 eq.) was added and the reaction mixture was warmed to 40 °C. 
After complete consumption of the starting material (TLC control), 
i
PrOH (excess) was added, and 
stirring continued until the colour of the solution turned from yellow to black (ca. 5 min). Then the 
Chapter 6 
 
147 
 
mixture was diluted with water (2 mL) and extracted with CH2Cl2 (3 x 3 mL). The combined 
organic phase was dried (Na2SO4) and evaporated in vacuo to give an oily product. Flash 
chromatography eluting with CHCl3/MeOH (100:0 to 9:1) gave the desired product. 
Benzoate-protected tetrahydrofuran 1 (10.5 mg, 0.031 mmol) was subjected to Procedure A to 
furnish compound 2 (8.8 mg, 0.025 mmol, 80 %) as a colorless solid. For experimental data see § 
3.4.3.
4a 
TBDMS-protected tetrahydrofuran 3 (10.0 mg, 0.028 mmol) was subjected to Procedure A to 
furnish compound 4 (7.9 mg, 0.021 mmol, 96 %) as an oil. 
 
4: Oil; 
1
H NMR (200 MHz, CDCl3) = 4.22 (s, 4H), 2.79 (s, 4H), 0.91 (s, 18H), 0.08 (s, 12H); 
13
C 
NMR (50 MHz, CDCl3) = 209.6 (2C), 69.2 (2C), 31.7 (2C), 25.8 (6C), 18.3 (2C), -5.5 (4C); 
ESI+/MS: m/z 375 [M+H]
+
, 397 [M+Na]
+
 413 [M+K]
+
. 
Procedure B. Oxidative cleavage with the system RuO4 (cat.)/ NaIO4 
To a solution of H5IO6 (10 eq.) in 
t
BuOH/ H2O (1mL, 7:3) at r.t. was added RuCl3 (10 mol % 
from a 0.02 M stock solution in 
t
BuOH) under vigorous stirring. After 5 min the THF compound (1 
eq.) was added. After complete consumption of the starting material (TLC control), 
i
PrOH (excess) 
was added and stirring continued until the colour of the solution turned from yellow to black (ca. 5 
min). Then the mixture was diluted with water (2 mL) and extracted with CH2Cl2 (3 x 3 mL). The 
combined organic phase was dried (Na2SO4) and evaporated in vacuo to give an oily product. Flash 
chromatography eluting with CHCl3/MeOH (100:0 to 9:1) gave the desired product. 
Benzoate-protected tetrahydrofuran 1 (15.0 mg, 0.044mmol) was subjected to General Procedure 
B to furnish compound 2 (14.0 mg, 0.04 mmol, 90 %) as a colorless solid. For experimental data 
see § 3.4.3.
4a
 The reaction has also been carried out on 50 mg (0.15 momol) of 1 with the same 
procedure to give compound 2 with a slightly diminished yiel (45.6 mg, 0.13 mmol, 86%). 
Benzoate-protected tetrahydrofuran 5 (20.9 mg, 0.031 mmol) was subjected to General 
Procedure B (20 mol % RuO4 was used) to furnish compound 6 (17.4 mg, 0.026 mmol, 83 %) as a 
white solid. For experimental data see § 3.4.3.
4a 
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Chapter 7 
Preliminary experiments on the OsO4-mediated  
oxidative bis-cyclization of farnesyl acetate 
7.1. Introduction 
Saturated ether rings of various sizes are part of the structure of a variety of natural and non-
natural substances displaying important biological properties. In particular, 2,5-disubstituted 
tetrahydrofurans are structural fragments commonly found in natural compounds such as polyether 
antibiotics, e.g. monensin A,
1
 squalene-derived metabolites such as glabrescol,
2
 and annonaceous 
acetogenins such as goniocin and mucocin,
 3
 just to mention some representative categories. Many 
research group have focused their efforts toward isolation, synthesis as well as structural 
modification of the basic backbone of these substances. Indeed, a variety of methods have been 
developed to produce or modify the oxacycle portions of these molecules, in order to obtain 
substances belonging to the above mentioned classes, but also to synthesize new analogues of these 
molecules to be used in biological assay or in structure activity relationship (SAR) studies. 
One of the method currently employed to synthesized THF rings features the oxidative 
cyclization of 1,5-dienes mediated by transition metal oxo-species. Initially, oxidative cyclization of 
polyenes was restricted to the reactivity of permanganate with 1,5-dienes,
4
 next it has been 
discovered that OsO4, RuO4, and MnO4
-
 share a common reactivity toward 1,5-dienes and all of 
them can be used to obtain mono-THF diol compounds.
5
 
Some of the findings in this field have been achieved in the laboratory where this PhD thesis has 
been carried out.
6,7
 In particular, besides studies focused on the oxidative mono-cyclization of 1,n-
dienes, some years ago, the same group has discovered a new RuO4-mediated stereoselective 
cascade process allowing the polycyclization of polyenes characterized by a repetitive 1,5-diene 
structural motif (Scheme 1).
7a
 Employing this procedure it is possible to prepare all-threo adjacently 
linked poly-THF compounds in a single step and a stereoselective manner. This process is useful in 
organic synthesis, since it can be used for the preparation of the poly-THF portion of natural and 
non-natural biological active substances containing one or more 2,5-disubstituted THF rings 
adjacently linked.
8
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OOOOO
OH OHH H H H H H
OAc
OH
OO OHH H
OAc
OAc
 HHHH
OH
OO OAc
OH
 
Squalene cis/cis/trans/trans/trans
RuO4(cat.)/NaIO4
(E,E)-Farnesil acetato
RuO4(cat.)/NaIO4
9
9
cis/cis
RuO4 (cat.)/NaIO4
1,5,9-triene lineare (tutto E) cis/cis  
Scheme 1. Representative examples of RuO4-catalyzed polycyclization of isoprenoid and linear 
polyenes developed by our own group. 
In continuing our studies in this field, during the last year of my PhD programme, some 
experiments have been carried out to assess the osmium ability to mediate the bis-cyclization of 
polyenes with a repetitive 1,5-diene structural motif. 
7.2. Results and discussion 
We envisaged that OsO4, like ruthenium tetroxide, could be successfully employed to induce the 
bis-cyclization of proper polyenes, to develop a new alternative and maybe more efficient method 
to that end. Therefore, farnesyl acetate (1) was used to test different reaction conditions. We found 
that the system K2OsO4/NaIO4 is able to induce the bis-cyclization process providing a 30% yield of 
bis-cyclised compounds. Best results were obtained using 5 mol % of K2OsO4, 4 equiv. of NaIO4 
and a mixture of EtOAc/MeCN/H2O (1/1/0.1) as the solvent (Scheme 2). In particular, the main 
product of the process is the mono-cyclized compound 2 (30%), whereas the product of bis-
cyclization 3 is obtained in a 25% yield along with a 5% amount of 4, a compound arising from the 
spiroketalizatin of 3. This process is similar to the RuO4-catalysed oxidative spiroketalization (see 
Chapter 4) that we have recently developed (Scheme 3). 
OAc
OO OHH H
OAcOH
OHOO
O
H
OAc
OH
O
H OH OAc
(E,E)-farnesyl acetate 1
K2OsO4 (5 mol %)
NaIO4 (4 eq.)
EtOAc/CH3CN/H2O 
      (1/1/0.1)
+
spiroketalization
2
3 4
 
Scheme 2. Reaction of farnesyl acetate with OsO4 (cat.)/NaIO4. 
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H OO H H
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O
H
O
O
H
O
(51%) 
Spiroketalization 
with retention at C-18
1818
RuCl3 (10 mol%)
NaIO4 (6 equiv.)
CH3CN/EtOAc/H2O
(1:1:1), t.a., 2.5 h
 
Scheme 3. RuO4-mediated spiroketalization. 
For what concerns the amount of water in the solvent mixture we found that larger quantities 
turned out to be detrimental for the process of bis-cyclization since water induces the hydrolysis of 
the osmate diester intermediate 7 (see later Scheme 5) interrupting the process after the mono-
cyclization. Once osmium has dissociated from the substrate it is no longer able to re-attack the 
mono-THF compound. Importantly, a certain amount of water is still required since it is needed to 
set osmium free at the end of the process in order to close the catalytic cycle. 
Therefore, we have demonstrated that the system K2OsO4/NaIO4 succeeded in the bis-cyclization 
process providing a 30% yield of bis-cyclised compounds. On the contrary, using K2OsO4 with 
pyridine N-oxide (PNO for short) as co-oxidant (PNO is a milder oxidant compared to NaIO4 and it 
is employed to avoid oxidation of Os(VI) to Os(VIII)), to cyclise the diol of farnesyl acetate (5, 
Scheme 3) in the conditions developed by Donohoe et al. for the mono-cyclization of 1,5-dienes, 
we only get the mono-cyclized product. This result suggests that possibly an Os
VIII 
 species is 
involved in the second cyclization. 
OAc
OH OH OH
O
H OH OAc
K2OsO4 (2-5%)
PNO (4 eq.),
citric acid (0.75 eq.),
Cu(OTf)2 (0.5 eq.),
CH3CN-H2O (6:4)5 2  
Scheme 4. Oxidative mono-cyclization using Donohoe’s conditions. 
A plausible mechanistic rationalisation for the formation the bis-cyclized product (Schema 5) is 
given in Scheme 5 in agreement with the known reactivity of OsO4 and related transition metal oxo-
species as well as the model developed for RuO4. It is likely that, after the formation of the first 
THF ring, an osmium species at a low-valent state is bonded to the newly formed diol system (7). 
At this point, if osmium is re-oxidized to Os
VIII
 forming intermediate 8, a second cycloaddition can 
occur and a new THF ring is formed, otherwise osmium ester 7 is hydrolyzed and the process stops 
leaving a mono-THF compound. It is also to be noted that both THF rings are cis because of the 
locked conformation adopted by the osmate ester in the intermediate 6 and 8. 
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Scheme 5. A plausible mechanistic explanation for the formation of compound 3. 
For what concerns the formation of the spiroketal moiety in 4, a mechanistic hypothesis is 
reported in Scheme 6. As we have seen for the analogue process mediated by RuO4 (see Chapter 6 
and Scheme 3), an oxo-osmium appendage tethered to the C2-OH could attack the C7-H bond 
leading to formation of the spiroketal. 
O
O
OH
H
OsO
OO
OAc
OH
OH OHOO
O
H
OAc
OO
OH H H OH
OAc
2 7
2 7
43
OsO4
 
Scheme 6. A plausible mechanistic hypothesis for the osmium-mediated spiroketalization. 
Overall, these results have a certain relevance since osmium ability to mediate the bis-cyclization 
of a 1,5,9-triene as well as the spiroketalization process have never been reported before and 
therefore these processes deserve further studies. 
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7.4. Experimental section 
Farnesyl acetate was obtained by acetylation of farnesol under classical condition. 
Farnesyl acetate (25.4 mg, 0.096 mmol) was was dissolved in the biphasic mixture 
EtOAc/CH3CN/H2O (1:1:0.1, 2.1 mL). NaIO4 (4 equiv., 0.385 mmol, 82.3 mg) and K2OsO4(5 mol 
%, 0.0043 mmol, 1.77 mg) were sequentially added under vigorous stirring. After 19 h excess 
Na2S2O5 was added and the mixture was stirred for further 10 min and then it was extracted with 
EtOAc (3 x 5mL). The combined organic phases were dried (Na2SO4) and evaporated in vacuo to 
give an oily product that was separated by HPLC (250 x 10 mm column, eluent: EtOAc-
cyclohexane, 6:4, flow 2.5 mL/min, 10 mg/injection) to give spiroketal 4 (1.6 mg, 0.0048 mmol, 5 
%, tR = 14.0 min), mono-THF 2 (9.0 mg, 0.029 mmol, 30 %, tR = 17.5 min) and bis-THF 3 (7.9 mg, 
0.024 mmol, 25 %, tR = 21.5 min). Spectral data of 3 are in agreement with those reported.
9
 
2: Oil; 
1
H NMR (500 MHz, CDCl3) = 5.38 (t, J = 7.0 Hz, 1H), 5.38 (t, J = 7.0 Hz, 1H), 4.59 (d, J 
= 7.0 Hz, 2H), 3.86 (t, J = 6.3 Hz, 1H), 3.41 – 3.35 (m, 1H), 2.34 (dd, J = 14.3, 7.1 Hz, 1H), 2.05, 
1.71, 1.25, 1.17, 1.13; ESI+/MS: m/z 315 [M+H]
+
, 337 [M+Na]
+
 353 [M+K]
+
. 
4: Oil; 
1
H NMR (500 MHz, CDCl3) = 4.59 (d, J = 6.9 Hz, 1H), 4.22 (dd, J = 11.8, 2.6 Hz, 1H), 
4.05 – 4.00 (m, 1H), 3.87 (d, J = 7.3 Hz, 1H), 3.65 (dd, J = 8.6, 2.7 Hz, 1H), 2.11 (s, 3H), 1.46 (s, 
3H), 1.33 (s, 3H), 1.32 (s, 3H), 1.03 (s, 3H); ESI+/MS: m/z 331 [M+H]
+
, 353 [M+Na]
+
 369 
[M+K]
+
.
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